Company,Year,Business,Risk Factor,Unresolved Staff Comments,Properties,Legal Proceedings,"Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities",Management’s Discussion and Analysis of Financial Condition and Results of Operations,Quantitative and Qualitative Disclosures About Market Risk,Financial Statements and Supplementary Data,Controls and Procedures
Meta,2021,"[(9.0, 'world closer together'), (9.0, 'involve matters central'), (4.0, 'work remotely'), (4.0, 'united states'), (4.0, 'time employees'), (4.0, 'regular basis'), (4.0, 'give people'), (4.0, 'build community'), (1.0, 'variety'), (1.0, 'subject'), (1.0, 'regulations'), (1.0, 'power'), (1.0, 'option'), (1.0, 'offer'), (1.0, 'mission'), (1.0, 'laws'), (1.0, 'full'), (1.0, 'facebook'), (1.0, 'business'), (1.0, 'bring'), (1.0, 'abroad')]","[(35.333333333333336, 'tax legislation provides preferential tax treatment'), (34.0, 'violates european union state aid rules'), (25.666666666666668, 'whether local country tax rulings'), (9.0, 'preventative measures implemented'), (9.0, 'multiple countries focusing'), (6.0, 'european commission'), (4.0, 'regulators regarding'), (4.0, 'receive formal'), (4.0, 'informal inquiries'), (4.0, 'help limit'), (4.0, 'government authorities'), (4.0, 'conducted investigations'), (1.0, 'spread'), (1.0, 'regulations'), (1.0, 'persistence'), (1.0, 'operate'), (1.0, 'laws'), (1.0, 'impacted'), (1.0, 'impact'), (1.0, 'illness'), (1.0, 'covid'), (1.0, 'continue'), (1.0, 'compliance'), (1.0, 'business'), (1.0, 'ability'), (1.0, '19')]","[(14.166666666666668, 'unresolved staff comments none'), (10.166666666666668, 'unresolved staff comments'), (9.666666666666668, 'unresolve staff comments'), (4.0, 'problem .""'), (4.0, 'item 1d'), (4.0, 'item 1c'), (4.0, 'item 1b'), (4.0, 'item 1b'), (4.0, 'item 1a'), (1.0, 'solution'), (1.0, 'satisfied'), (1.0, 'resolution'), (1.0, 'issue'), (1.0, 'happy'), (1.0, 'happy')]","[(36.0, 'leased approximately 10 million square feet'), (4.0, 'surrounding areas'), (4.0, 'menlo park'), (4.0, 'december 31'), (4.0, 'current needs'), (4.0, 'corporate headquarters'), (4.0, 'corporate headquarters'), (4.0, 'building space'), (1.0, 'owned'), (1.0, 'office'), (1.0, 'located'), (1.0, 'facilities'), (1.0, 'california'), (1.0, 'believe'), (1.0, 'adequate'), (1.0, '2021')]","[(16.0, 'proceedings involving law enforcement'), (9.0, 'modified consent order'), (9.0, 'meta platforms ireland'), (4.0, 'without merit'), (4.0, 'vigorously defending'), (4.0, 'took effect'), (4.0, 'required us'), (4.0, 'regulatory agencies'), (4.0, 'lawsuits described'), (4.0, 'ftc inquiry'), (4.0, 'april 2020'), (4.0, '0 billion'), (1.0, 'subject'), (1.0, 'settlement'), (1.0, 'resolve'), (1.0, 'penalty'), (1.0, 'pay'), (1.0, 'litigation'), (1.0, 'entered'), (1.0, 'believe'), (1.0, '5')]","[(15.0, 'nasdaq global select market'), (9.0, 'since may 18'), (9.0, 'shares repurchased depend'), (9.0, 'share repurchase program'), (5.0, 'market conditions'), (4.0, 'never declared'), (4.0, 'meta platforms'), (4.0, 'including price'), (4.0, 'common stock'), (4.0, 'common stock'), (4.0, 'cash dividend'), (4.0, 'actual number'), (1.0, 'variety'), (1.0, 'timing'), (1.0, 'symbol'), (1.0, 'paid'), (1.0, 'listed'), (1.0, 'inc'), (1.0, 'fb'), (1.0, 'factors'), (1.0, 'directors'), (1.0, 'class'), (1.0, 'board'), (1.0, 'authorized'), (1.0, '2012')]","[(9.0, 'remains highly uncertain'), (4.0, 'user growth'), (4.0, 'sales expenses'), (4.0, 'overall results'), (4.0, 'maus used'), (4.0, 'includes users'), (4.0, 'advertising services'), (4.0, '2021 increased'), (3.5, '2 billion'), (1.5, '2'), (1.0, 'well'), (1.0, 'pricing'), (1.0, 'pandemic'), (1.0, 'operations'), (1.0, 'number'), (1.0, 'messenger'), (1.0, 'mau'), (1.0, 'marketing'), (1.0, 'impact'), (1.0, 'facebook'), (1.0, 'engagement'), (1.0, 'described'), (1.0, 'demand'), (1.0, 'definition'), (1.0, 'calculation')]","[(49.0, 'held companies without readily determinable fair values'), (16.0, 'financial markets could result'), (9.0, 'material impairment charge'), (9.0, 'global economic climate'), (9.0, 'foreign currency losses'), (4.0, 'equity securities'), (4.0, '140 million'), (4.0, '129 million'), (4.0, '105 million'), (3.666666666666667, 'equity investments'), (3.666666666666667, 'equity investments'), (1.6666666666666667, 'investments'), (1.0, 'volatility'), (1.0, 'recognized'), (1.0, 'privately'), (1.0, '2021'), (1.0, '2020'), (1.0, '2019')]","[(8.0, 'reality labs revenue'), (4.0, 'see legal'), (4.0, 'related matters'), (4.0, 'note 11'), (4.0, 'apps revenue'), (2.0, 'revenue'), (1.0, 'operations'), (1.0, 'information'), (1.0, 'family'), (1.0, '986'), (1.0, '965'), (1.0, '946'), (1.0, '929'), (1.0, '85'), (1.0, '753'), (1.0, '70'), (1.0, '697'), (1.0, '671'), (1.0, '56'), (1.0, '489'), (1.0, '46'), (1.0, '39'), (1.0, '32'), (1.0, '294'), (1.0, '28'), (1.0, '23'), (1.0, '2019'), (1.0, '117')]","[(8.0, 'financial reporting identified'), (5.0, 'financial reporting'), (4.0, 'rules 13a'), (4.0, 'reasonably likely'), (4.0, 'materially affected'), (4.0, 'materially affect'), (4.0, 'internal controls'), (4.0, 'internal control'), (4.0, 'internal control'), (4.0, 'fourth quarter'), (4.0, 'exchange act'), (4.0, 'evaluation pursuant'), (4.0, 'december 31'), (3.5, 'management conducted'), (1.5, 'management'), (1.0, 'procedures'), (1.0, 'effectiveness'), (1.0, 'company'), (1.0, 'changes'), (1.0, 'assessment'), (1.0, '2021'), (1.0, '2021'), (1.0, '15d'), (1.0, '15'), (1.0, '15')]"
Meta,2020,"[(9.0, 'world closer together'), (9.0, 'impose different obligations'), (9.0, 'foreign data protection'), (8.0, 'currently working remotely'), (5.0, 'working remotely'), (4.0, 'vast majority'), (4.0, 'united states'), (4.0, 'long term'), (4.0, 'give people'), (4.0, 'build community'), (4.0, '19 pandemic'), (1.0, 'transition'), (1.0, 'result'), (1.0, 'restrictive'), (1.0, 'regulations'), (1.0, 'privacy'), (1.0, 'power'), (1.0, 'personnel'), (1.0, 'personnel'), (1.0, 'mission'), (1.0, 'laws'), (1.0, 'facebook'), (1.0, 'expect'), (1.0, 'covid'), (1.0, 'content'), (1.0, 'competition'), (1.0, 'bring')]","[(60.66666666666667, 'brazilian general data protection law recently took effect'), (25.0, 'multiple putative class action suits'), (10.666666666666668, 'user data practices'), (10.666666666666668, 'imposes data privacy'), (9.0, 'preventative measures implemented'), (4.0, 'services offered'), (4.0, 'related requirements'), (4.0, 'help limit'), (1.0, 'users'), (1.0, 'subject'), (1.0, 'spread'), (1.0, 'products'), (1.0, 'platform'), (1.0, 'persistence'), (1.0, 'operate'), (1.0, 'impacted'), (1.0, 'impact'), (1.0, 'illness'), (1.0, 'covid'), (1.0, 'continue'), (1.0, 'connection'), (1.0, 'business'), (1.0, 'brazil'), (1.0, 'ability'), (1.0, '19')]","[(14.166666666666668, 'unresolved staff comments none'), (10.166666666666668, 'unresolved staff comments'), (9.666666666666668, 'unresolve staff comments'), (4.0, 'problem .""'), (4.0, 'item 1d'), (4.0, 'item 1c'), (4.0, 'item 1b'), (4.0, 'item 1b'), (4.0, 'item 1a'), (1.0, 'solution'), (1.0, 'satisfied'), (1.0, 'resolution'), (1.0, 'issue'), (1.0, 'happy'), (1.0, 'happy')]","[(36.0, 'leased approximately 10 million square feet'), (23.5, '80 cities across north america'), (5.5, 'latin america'), (4.0, 'surrounding areas'), (4.0, 'middle east'), (4.0, 'december 31'), (4.0, 'corporate headquarters'), (4.0, 'building space'), (4.0, 'asia pacific'), (1.0, 'owned'), (1.0, 'offices'), (1.0, 'office'), (1.0, 'europe'), (1.0, 'africa'), (1.0, 'addition'), (1.0, '2020')]","[(25.0, 'facebook ireland challenged procedural aspects'), (15.0, 'federal trade commission act'), (9.0, 'judicial review commenced'), (9.0, 'irish high court'), (5.0, 'sherman act'), (4.0, 'september 2020'), (4.0, 'section 5'), (4.0, 'section 2'), (4.0, 'permanent injunction'), (4.0, 'idpc inquiry'), (4.0, 'attorneys general'), (4.0, 'antitrust laws'), (4.0, 'anticompetitive conduct'), (4.0, 'alleged violations'), (4.0, 'acquiring instagram'), (3.5, 'ftc filed'), (1.5, 'ftc'), (1.0, 'whatsapp'), (1.0, 'violation'), (1.0, 'us'), (1.0, 'u'), (1.0, 'seek'), (1.0, 'engaged'), (1.0, 'complaint'), (1.0, 'company'), (1.0, 'alleging'), (1.0, '2014'), (1.0, '2012')]","[(25.0, 'fiscal year ended december 31'), (9.0, 'last trading day'), (4.0, 'never declared'), (4.0, 'market close'), (4.0, 'january 2021'), (4.0, 'graph assumes'), (4.0, 'common stock'), (4.0, 'common stock'), (4.0, 'cash dividend'), (4.0, '25 billion'), (1.0, 'repurchases'), (1.0, 'program'), (1.0, 'paid'), (1.0, 'invested'), (1.0, 'inc'), (1.0, 'facebook'), (1.0, 'class'), (1.0, 'authorized'), (1.0, 'additional'), (1.0, '2015'), (1.0, '100')]","[(16.0, 'nongaap financial measures used'), (9.0, 'reliance industries limited'), (9.0, 'jio platforms limited'), (9.0, 'expect user growth'), (4.0, 'relatively lower'), (4.0, 'primarily concentrated'), (4.0, 'measure may'), (4.0, 'definitive agreement'), (4.0, 'comparison purposes'), (1.0, 'usefulness'), (1.0, 'subsidiary'), (1.0, 'regions'), (1.0, 'limiting'), (1.0, 'invest'), (1.0, 'future'), (1.0, 'entered'), (1.0, 'different'), (1.0, 'companies'), (1.0, 'arpu')]","[(16.0, 'financial markets could result'), (15.333333333333334, 'foreign currency exchange rates'), (14.0, 'interest rates relates primarily'), (9.0, 'material impairment charge'), (9.0, 'global economic climate'), (8.5, 'equity investment risk'), (6.0, 'interest rates'), (4.666666666666666, 'interest earned'), (4.5, 'equity investments'), (4.0, 'marketable securities'), (4.0, 'market value'), (4.0, 'market risks'), (3.5, 'including changes'), (3.5, 'cash equivalents'), (1.5, 'changes'), (1.5, 'cash'), (1.0, 'volatility'), (1.0, 'inflation'), (1.0, 'exposure'), (1.0, 'exposed')]","[(43.0, 'millions ): gross unrecognized tax benefits beginning'), (22.0, 'gross unrecognized tax benefits'), (16.0, 'following table reflects changes'), (16.0, '16 million shares reserved'), (15.0, 'issuance effective january 1'), (8.0, 'accounting standards update'), (5.0, '1 ).'), (4.0, 'directors approved'), (4.0, '2019 due'), (3.5, 'company changed'), (2.0, 'accounting'), (1.5, 'company'), (1.0, 'period'), (1.0, 'method'), (1.0, 'leases'), (1.0, 'increase'), (1.0, 'board'), (1.0, 'asu'), (1.0, 'adoption'), (1.0, '863'), (1.0, '7'), (1.0, '678'), (1.0, '4'), (1.0, '2021')]","[(8.0, 'financial reporting identified'), (5.0, 'financial reporting'), (4.0, 'rules 13a'), (4.0, 'reasonably likely'), (4.0, 'materially affected'), (4.0, 'materially affect'), (4.0, 'internal control'), (4.0, 'internal control'), (4.0, 'internal control'), (4.0, 'fourth quarter'), (4.0, 'exchange act'), (4.0, 'evaluation pursuant'), (3.5, 'management conducted'), (1.5, 'management'), (1.0, 'effectiveness'), (1.0, 'company'), (1.0, 'changes'), (1.0, 'assessment'), (1.0, '2020'), (1.0, '15d'), (1.0, '15'), (1.0, '15')]"
Meta,2019,"[(9.0, 'trade names appearing'), (9.0, 'involve matters central'), (9.0, 'common law trademarks'), (4.0, 'united states'), (4.0, 'service marks'), (4.0, 'like button'), (4.0, 'form 10'), (4.0, 'annual report'), (3.333333333333333, 'facebook logo'), (1.3333333333333333, 'facebook'), (1.3333333333333333, 'facebook'), (1.0, 'whatsapp'), (1.0, 'variety'), (1.0, 'subject'), (1.0, 'regulations'), (1.0, 'registered'), (1.0, 'property'), (1.0, 'oculus'), (1.0, 'laws'), (1.0, 'k'), (1.0, 'instagram'), (1.0, 'inc'), (1.0, 'fb'), (1.0, 'business'), (1.0, 'abroad')]","[(34.5, 'mobile devices depend upon effective operation'), (10.5, 'mobile operating systems'), (9.0, 'term stockholder value'), (4.0, 'user growth'), (4.0, 'risks inherent'), (4.0, 'fully consummated'), (4.0, 'enhance long'), (4.0, 'cannot guarantee'), (4.0, 'business internationally'), (1.0, 'variety'), (1.0, 'technologies'), (1.0, 'subject'), (1.0, 'standards'), (1.0, 'program'), (1.0, 'products'), (1.0, 'networks'), (1.0, 'monetization'), (1.0, 'engagement'), (1.0, 'control')]","[(14.166666666666668, 'unresolved staff comments none'), (10.166666666666668, 'unresolved staff comments'), (9.666666666666668, 'unresolve staff comments'), (4.0, 'problem .""'), (4.0, 'item 1d'), (4.0, 'item 1c'), (4.0, 'item 1b'), (4.0, 'item 1b'), (4.0, 'item 1a'), (1.0, 'solution'), (1.0, 'satisfied'), (1.0, 'resolution'), (1.0, 'issue'), (1.0, 'happy'), (1.0, 'happy')]","[(36.0, 'leased approximately nine million square feet'), (16.0, '15 data centers globally'), (4.0, 'surrounding areas'), (4.0, 'menlo park'), (4.0, 'december 31'), (4.0, 'current needs'), (4.0, 'corporate headquarters'), (4.0, 'corporate headquarters'), (4.0, 'building space'), (1.0, 'owned'), (1.0, 'office'), (1.0, 'located'), (1.0, 'facilities'), (1.0, 'california'), (1.0, 'believe'), (1.0, 'also'), (1.0, 'adequate'), (1.0, '2019')]","[(15.0, 'multiple putative class actions'), (5.0, 'derivative actions'), (4.0, 'without merit'), (4.0, 'vigorously defending'), (4.0, 'united states'), (4.0, 'remaining lawsuits'), (4.0, 'parties agreed'), (4.0, 'federal courts'), (4.0, '550 million'), (1.0, 'us'), (1.0, 'us'), (1.0, 'subject'), (1.0, 'state'), (1.0, 'settlement'), (1.0, 'resolve'), (1.0, 'require'), (1.0, 'principle'), (1.0, 'payment'), (1.0, 'officers'), (1.0, 'lawsuit'), (1.0, 'filed'), (1.0, 'elsewhere'), (1.0, 'directors'), (1.0, 'court'), (1.0, 'certain'), (1.0, 'believe'), (1.0, 'approval')]","[(9.0, 'shares repurchased depend'), (8.0, 'share repurchase program'), (4.0, 'market conditions'), (4.0, 'january 2017'), (4.0, 'investment opportunities'), (4.0, 'including price'), (4.0, 'general business'), (4.0, 'expiration date'), (4.0, 'december 31'), (4.0, 'common stock'), (4.0, 'actual number'), (4.0, '0 billion'), (2.0, 'program'), (1.0, 'variety'), (1.0, 'timing'), (1.0, 'repurchases'), (1.0, 'factors'), (1.0, 'directors'), (1.0, 'commenced'), (1.0, 'class'), (1.0, 'board'), (1.0, 'authorized'), (1.0, 'authorized'), (1.0, '4'), (1.0, '2019')]","[(16.0, 'nongaap financial measures used'), (14.5, 'average revenue per person'), (9.0, 'taxes paid related'), (9.0, 'net share settlement'), (4.0, 'operating margin'), (4.0, 'equity awards'), (4.0, 'comparison purposes'), (4.0, '67 billion'), (4.0, '42 billion'), (3.5, '34 billion'), (2.5, 'revenue'), (1.5, '34'), (1.0, 'usefulness'), (1.0, 'may'), (1.0, 'limiting'), (1.0, 'different'), (1.0, 'compared'), (1.0, 'companies'), (1.0, 'arpp'), (1.0, '70'), (1.0, '37'), (1.0, '2018'), (1.0, '1')]","[(9.0, 'foreign currency losses'), (8.0, 'interest rates affect'), (4.0, 'market value'), (4.0, 'interest earned'), (4.0, 'consolidated statements'), (4.0, '6 million'), (4.0, '213 million'), (4.0, '105 million'), (3.5, 'marketable securities'), (3.5, 'cash equivalents'), (2.0, 'interest'), (1.5, 'securities'), (1.5, 'cash'), (1.0, 'recognized'), (1.0, 'net'), (1.0, 'income'), (1.0, 'income'), (1.0, '2019'), (1.0, '2018'), (1.0, '2017')]","[(11.833333333333334, 'class b common stock'), (9.0, 'determine realized gains'), (8.0, 'specific identification method'), (8.0, 'accounting standards update'), (5.333333333333334, 'common stock'), (4.0, 'marketable securities'), (4.0, 'company changed'), (4.0, '2019 due'), (3.5, 'priority rights'), (2.5, 'class'), (2.3333333333333335, 'stock'), (2.0, 'method'), (2.0, 'accounting'), (1.5, 'rights'), (1.0, 'subject'), (1.0, 'sale'), (1.0, 'losses'), (1.0, 'leases'), (1.0, 'holders'), (1.0, 'holders'), (1.0, 'entitled'), (1.0, 'dividends'), (1.0, 'dividends'), (1.0, 'directors'), (1.0, 'declared'), (1.0, 'classes'), (1.0, 'board'), (1.0, 'asu'), (1.0, 'adoption'), (1.0, '2')]","[(13.333333333333332, 'maintaining adequate internal control'), (5.333333333333333, 'internal control'), (5.333333333333333, 'internal control'), (4.0, 'reasonably likely'), (4.0, 'materially affect'), (4.0, 'financial reporting'), (4.0, 'financial reporting'), (4.0, 'disclosure controls'), (4.0, 'december 31'), (3.666666666666667, 'management says'), (3.666666666666667, 'management evaluated'), (1.6666666666666667, 'management'), (1.0, 'responsible'), (1.0, 'procedures'), (1.0, 'establishing'), (1.0, 'effectiveness'), (1.0, 'changes'), (1.0, '2019')]"
Meta,2018,"[(9.0, 'world closer together'), (9.0, 'trade names appearing'), (9.0, 'common law trademarks'), (4.0, 'service marks'), (4.0, 'retain people'), (4.0, 'like button'), (4.0, 'give people'), (4.0, 'form 10'), (4.0, 'build community'), (4.0, 'annual report'), (3.333333333333333, 'facebook logo'), (1.3333333333333333, 'facebook'), (1.3333333333333333, 'facebook'), (1.0, 'whatsapp'), (1.0, 'use'), (1.0, 'registered'), (1.0, 'property'), (1.0, 'products'), (1.0, 'power'), (1.0, 'oculus'), (1.0, 'mission'), (1.0, 'k'), (1.0, 'instagram'), (1.0, 'inc'), (1.0, 'fb'), (1.0, 'engage'), (1.0, 'compete'), (1.0, 'bring'), (1.0, 'attract')]","[(34.5, 'mobile devices depend upon effective operation'), (10.5, 'mobile operating systems'), (9.0, 'term stockholder value'), (9.0, 'represented approximately 5'), (9.0, 'false accounts may'), (4.0, 'worldwide maus'), (4.0, 'user growth'), (4.0, 'fully consummated'), (4.0, 'enhance long'), (4.0, 'cannot guarantee'), (1.0, 'technologies'), (1.0, 'standards'), (1.0, 'program'), (1.0, 'products'), (1.0, 'networks'), (1.0, 'monetization'), (1.0, 'estimate'), (1.0, 'engagement'), (1.0, 'control')]","[(14.166666666666668, 'unresolved staff comments none'), (10.166666666666668, 'unresolved staff comments'), (9.666666666666668, 'unresolve staff comments'), (4.0, 'problem .""'), (4.0, 'item 1d'), (4.0, 'item 1c'), (4.0, 'item 1b'), (4.0, 'item 1b'), (4.0, 'item 1a'), (1.0, 'solution'), (1.0, 'satisfied'), (1.0, 'resolution'), (1.0, 'issue'), (1.0, 'happy'), (1.0, 'happy')]","[(36.0, 'leased approximately six million square feet'), (16.0, 'lease data centers throughout'), (9.0, 'various locations internationally'), (4.0, 'united states'), (4.0, 'surrounding areas'), (4.0, 'menlo park'), (4.0, 'december 31'), (4.0, 'corporate headquarters'), (4.0, 'corporate headquarters'), (4.0, 'building space'), (1.0, 'owned'), (1.0, 'office'), (1.0, 'located'), (1.0, 'california'), (1.0, 'also'), (1.0, '2018')]","[(16.0, 'two putative class actions'), (9.0, 'officers alleging violations'), (8.5, 'multiple legal grounds'), (4.5, 'legal proceedings'), (4.0, 'united states'), (4.0, 'securities laws'), (4.0, 'second quarter'), (4.0, 'government inquiries'), (4.0, 'federal court'), (4.0, 'earnings results'), (4.0, 'associated fines'), (4.0, 'also party'), (1.0, 'various'), (1.0, 'us'), (1.0, 'tax'), (1.0, 'satisfy'), (1.0, 'requests'), (1.0, 'regulatory'), (1.0, 'prevail'), (1.0, 'penalties'), (1.0, 'investigations'), (1.0, 'filed'), (1.0, 'disclosure'), (1.0, 'directors'), (1.0, 'connection'), (1.0, 'claims'), (1.0, 'certain'), (1.0, 'believe'), (1.0, '2018')]","[(11.733333333333333, 'future stock price performance'), (8.5, 'pay cash dividends'), (5.066666666666666, 'stock price'), (5.066666666666666, 'stock price'), (4.666666666666666, 'future earnings'), (4.666666666666666, 'foreseeable future'), (4.5, 'cash dividend'), (4.4, 'common stock'), (4.4, 'common stock'), (4.0, 'never declared'), (4.0, 'necessarily indicative'), (1.0, 'stockholders'), (1.0, 'shares'), (1.0, 'retain'), (1.0, 'paid'), (1.0, 'many'), (1.0, 'intend'), (1.0, 'institutions'), (1.0, 'held'), (1.0, 'expect'), (1.0, 'class'), (1.0, 'brokers'), (1.0, 'behalf')]","[(14.5, 'net unrecognized tax benefits'), (9.5, 'effective tax rate'), (5.0, 'net income'), (4.0, 'maus used'), (4.0, 'includes users'), (4.0, 'december 31'), (4.0, '9 billion'), (4.0, '597 million'), (4.0, '54 billion'), (1.0, 'number'), (1.0, 'messenger'), (1.0, 'mau'), (1.0, 'facebook'), (1.0, 'described'), (1.0, 'definition'), (1.0, 'decrease'), (1.0, 'calculation'), (1.0, '3'), (1.0, '3'), (1.0, '22'), (1.0, '2018'), (1.0, '2017'), (1.0, '13')]","[(16.0, 'effect hedging activities would'), (15.0, 'interest rates relates primarily'), (5.0, 'interest earned'), (4.0, 'marketable securities'), (4.0, 'market value'), (4.0, 'liquidity requirements'), (4.0, 'investment policy'), (3.5, 'cash equivalents'), (1.5, 'cash'), (1.0, 'supporting'), (1.0, 'strategy'), (1.0, 'results'), (1.0, 'preservation'), (1.0, 'predict'), (1.0, 'operations'), (1.0, 'focused'), (1.0, 'exposure'), (1.0, 'difficult'), (1.0, 'changes'), (1.0, 'capital')]","[(16.0, 'year ended december 31'), (16.0, 'companys financial statements based'), (9.0, 'stranded tax effects'), (9.0, 'deferred revenue balance'), (9.0, 'capital lease obligations'), (4.0, 'retained earnings'), (4.0, 'fully repaid'), (4.0, 'comprehensive loss'), (1.0, 'responsibility'), (1.0, 'reclassified'), (1.0, 'prepayments'), (1.0, 'opinion'), (1.0, 'material'), (1.0, 'marketers'), (1.0, 'increase'), (1.0, 'express'), (1.0, 'driven'), (1.0, 'audits'), (1.0, 'amount'), (1.0, 'accumulated'), (1.0, '2018'), (1.0, '2016')]","[(13.666666666666666, 'maintaining adequate internal control'), (9.0, 'financial reporting identified'), (5.666666666666666, 'internal control'), (4.666666666666666, 'internal controls'), (4.0, 'rules 13a'), (4.0, 'reasonably likely'), (4.0, 'materially affected'), (4.0, 'materially affect'), (4.0, 'fourth quarter'), (4.0, 'exchange act'), (4.0, 'evaluation pursuant'), (1.0, 'responsible'), (1.0, 'management'), (1.0, 'management'), (1.0, 'establishing'), (1.0, 'changes'), (1.0, '2018'), (1.0, '15d'), (1.0, '15'), (1.0, '15')]"
Meta,2017,"[(9.0, 'artificial intelligence research'), (4.0, 'virtual reality'), (4.0, 'top priority'), (4.0, 'term initiatives'), (4.0, 'retain people'), (4.0, 'retain marketers'), (4.0, 'personal computers'), (4.0, 'mobile devices'), (4.0, 'enable people'), (4.0, 'connectivity efforts'), (4.0, 'build useful'), (4.0, 'also investing'), (3.5, 'engaging products'), (1.5, 'products'), (1.0, 'use'), (1.0, 'surfaces'), (1.0, 'share'), (1.0, 'number'), (1.0, 'longer'), (1.0, 'friends'), (1.0, 'family'), (1.0, 'facebook'), (1.0, 'engage'), (1.0, 'connect'), (1.0, 'compete'), (1.0, 'augmented'), (1.0, 'attract'), (1.0, 'attract')]","[(9.0, 'government scrutiny applicable'), (4.0, 'unfavorable resolution'), (4.0, 'risks related'), (4.0, 'risks inherent'), (4.0, 'operations could'), (4.0, 'litigation referred'), (4.0, 'financial condition'), (4.0, 'economic instability'), (4.0, 'adversely affected'), (3.5, 'business internationally'), (1.5, 'business'), (1.0, 'variety'), (1.0, 'u'), (1.0, 'subject'), (1.0, 'social'), (1.0, 'results'), (1.0, 'result'), (1.0, 'regulatory'), (1.0, 'political'), (1.0, 'legal'), (1.0, 'including'), (1.0, 'disputes')]","[(14.166666666666668, 'unresolved staff comments none'), (10.166666666666668, 'unresolved staff comments'), (9.666666666666668, 'unresolve staff comments'), (4.0, 'problem .""'), (4.0, 'item 1d'), (4.0, 'item 1c'), (4.0, 'item 1b'), (4.0, 'item 1b'), (4.0, 'item 1a'), (1.0, 'solution'), (1.0, 'satisfied'), (1.0, 'resolution'), (1.0, 'issue'), (1.0, 'happy'), (1.0, 'happy')]","[(33.0, 'leased approximately three million square feet'), (16.0, 'lease data centers throughout'), (10.5, 'total leased space'), (10.5, 'excluded square footage'), (9.0, 'various locations internationally'), (4.0, 'united states'), (4.0, 'office buildings'), (4.0, 'december 31'), (4.0, 'corporate headquarters'), (3.5, 'owned properties'), (1.5, 'owned'), (1.0, 'disclosed'), (1.0, 'also'), (1.0, '2017')]","[(14.25, 'nasdaq stock market llc'), (14.166666666666666, 'multiple putative class actions'), (8.25, 'nasdaq omx group'), (7.5, 'multiple cases filed'), (4.666666666666666, 'individual actions'), (4.666666666666666, 'derivative actions'), (4.0, 'vast majority'), (4.0, 'united states'), (4.0, 'related errors'), (4.0, 'federal courts'), (4.0, 'collectively referred'), (4.0, 'alleging technical'), (2.25, 'nasdaq'), (2.25, 'nasdaq'), (2.0, 'filed'), (2.0, 'cases'), (1.0, 'us'), (1.0, 'u'), (1.0, 'trading'), (1.0, 'state'), (1.0, 'officers'), (1.0, 'jurisdictions'), (1.0, 'ipo'), (1.0, 'inc'), (1.0, 'herein'), (1.0, 'directors'), (1.0, 'connection'), (1.0, 'certain'), (1.0, 'along')]","[(16.0, 'nasdaq global select market'), (14.333333333333334, 'common stock commenced trading'), (12.833333333333334, 'class b common stock'), (9.0, 'share repurchase program'), (9.0, 'following graph shows'), (8.5, 'pay cash dividends'), (6.333333333333334, 'common stock'), (5.0, 'stock exchange'), (4.5, 'cash dividend'), (4.0, 'november 2016'), (4.0, 'never declared'), (4.0, 'may 18'), (4.0, 'future earnings'), (4.0, 'foreseeable future'), (4.0, 'directors authorized'), (4.0, 'december 31'), (4.0, '0 billion'), (2.5, 'class'), (1.0, 'traded'), (1.0, 'retain'), (1.0, 'paid'), (1.0, 'listed'), (1.0, 'intend'), (1.0, 'expect'), (1.0, 'date'), (1.0, 'comparison'), (1.0, 'board'), (1.0, '6'), (1.0, '2017'), (1.0, '2012')]","[(16.0, 'year ended december 31'), (16.0, 'worldwide daus increased 14'), (4.0, 'user growth'), (4.0, 'relatively lower'), (4.0, 'primarily concentrated'), (4.0, 'maus used'), (4.0, 'includes users'), (4.0, '12 billion'), (1.0, 'regions'), (1.0, 'number'), (1.0, 'messenger'), (1.0, 'mau'), (1.0, 'future'), (1.0, 'facebook'), (1.0, 'expect'), (1.0, 'described'), (1.0, 'definition'), (1.0, 'calculation'), (1.0, 'arpu'), (1.0, '2017'), (1.0, '1')]","[(16.0, 'foreign currency risks related'), (15.0, 'interest rates relates primarily'), (9.0, 'operating expenses denominated'), (5.0, 'interest earned'), (4.0, 'marketable securities'), (4.0, 'market value'), (4.0, 'liquidity requirements'), (4.0, 'investment policy'), (3.5, 'cash equivalents'), (1.5, 'cash'), (1.0, 'u'), (1.0, 'supporting'), (1.0, 'strategy'), (1.0, 'revenue'), (1.0, 'preservation'), (1.0, 'focused'), (1.0, 'exposure'), (1.0, 'dollar'), (1.0, 'currencies'), (1.0, 'changes'), (1.0, 'capital')]","[(16.0, 'companys financial statements based'), (8.666666666666666, 'including development costs'), (8.666666666666666, 'capitalize costs associated'), (4.666666666666666, 'direct costs'), (4.0, 'original programming'), (4.0, 'eps calculation'), (4.0, 'dilutive effect'), (1.0, 'rsus'), (1.0, 'responsibility'), (1.0, 'recoverable'), (1.0, 'production'), (1.0, 'opinion'), (1.0, 'material'), (1.0, 'express'), (1.0, 'excluded'), (1.0, 'audits'), (1.0, 'anti'), (1.0, 'amounts')]","[(9.0, 'financial reporting based'), (9.0, 'criteria set forth'), (8.5, 'integrated framework issued'), (8.25, 'internal financial reporting'), (4.5, '2013 framework'), (4.25, 'internal control'), (4.25, 'internal control'), (4.25, 'internal control'), (4.0, 'treadway commission'), (4.0, 'sponsoring organizations'), (4.0, 'reasonably likely'), (4.0, 'materially affected'), (4.0, 'materially affect'), (4.0, 'management conducted'), (4.0, 'fourth quarter'), (1.0, 'effectiveness'), (1.0, 'committee'), (1.0, 'changes'), (1.0, 'assessment'), (1.0, '2017')]"
Merck & Co.,2021,"[(9.0, 'local agencies around'), (9.0, 'independent grantmaking organization'), (9.0, 'improving global health'), (9.0, 'determining drug safety'), (4.0, 'world focused'), (4.0, 'provided funds'), (4.0, 'pharmaceutical industry'), (4.0, 'organizations dedicated'), (4.0, 'also subject'), (3.5, 'merck foundation'), (1.5, 'merck'), (1.0, 'variety'), (1.0, 'state'), (1.0, 'standards'), (1.0, 'regulation'), (1.0, 'regional'), (1.0, 'processes'), (1.0, 'partnered'), (1.0, 'effectiveness'), (1.0, 'country')]","[(9.0, 'product liability insurance'), (9.0, 'health care industry'), (8.0, 'new government laws'), (8.0, 'could become subject'), (5.0, 'government laws'), (4.0, 'products may'), (4.0, 'legal action'), (4.0, 'increasing regulation'), (4.0, 'currently subject'), (4.0, 'cost prohibitive'), (3.5, 'company believes'), (2.0, 'subject'), (1.5, 'company'), (1.0, 'well'), (1.0, 'unavailable'), (1.0, 'regulations'), (1.0, 'political'), (1.0, 'number'), (1.0, 'limited'), (1.0, 'future'), (1.0, 'continue')]","[(9.0, 'unresolved staff comments'), (9.0, 'unresolve staff comments'), (4.0, 'item 1d'), (3.5, 'item 2'), (3.5, 'item 1c'), (3.5, 'item 1b'), (3.5, 'item 1b'), (3.5, 'item 1a'), (3.2, '1 .""'), (1.5, '2'), (1.5, '1c'), (1.5, '1b'), (1.5, '1b'), (1.5, '1a'), (1.2, '1'), (1.2, '1'), (1.2, '1'), (1.2, '1'), (1.0, '4'), (1.0, '3')]","[(9.0, 'mercks manufacturing operations'), (9.0, 'human health products'), (4.0, 'whitehouse station'), (4.0, 'seven locations'), (4.0, 'puerto rico'), (4.0, 'production facilities'), (4.0, 'new jersey'), (4.0, 'currently headquartered'), (4.0, 'capital expenditures'), (4.0, '8 billion'), (3.666666666666667, '4 billion'), (3.666666666666667, '4 billion'), (1.6666666666666667, '4'), (1.0, 'u'), (1.0, 'transferred'), (1.0, 'spin'), (1.0, 'properties'), (1.0, 'organon'), (1.0, 'number'), (1.0, '3'), (1.0, '2021'), (1.0, '2021'), (1.0, '2020'), (1.0, '1')]","[(4.0, 'supplementary data'), (4.0, 'note 11'), (4.0, 'legal proceedings'), (4.0, 'financial statements'), (4.0, 'environmental liabilities'), (3.6, 'item 8'), (3.6, 'item 8'), (3.6, 'item 3'), (3.5, 'information called'), (3.333333333333333, 'incorporated herein'), (1.6, 'item'), (1.6, 'item'), (1.5, 'information'), (1.3333333333333333, 'incorporated'), (1.3333333333333333, 'incorporated'), (1.0, 'reference'), (1.0, 'reference'), (1.0, 'reference'), (1.0, 'contingencies')]","[(9.0, 'sp 500 index'), (9.0, 'following graph assumes'), (9.0, 'composite peer group'), (9.0, 'companys common stock'), (8.5, 'merck common stock'), (4.5, 'merck shares'), (4.0, 'shares purchased'), (4.0, 'pharmaceutical companies'), (4.0, 'major u'), (4.0, 'january 31'), (4.0, 'december 31'), (4.0, 'approximately 99'), (4.0, '932 shareholders'), (4.0, '100 investment'), (4.0, '10 billion'), (1.0, 'treasury'), (1.0, 'reinvestment'), (1.0, 'record'), (1.0, 'purchase'), (1.0, 'plan'), (1.0, 'period'), (1.0, 'part'), (1.0, 'made'), (1.0, 'dividends'), (1.0, '2022'), (1.0, '2016')]","[(49.0, 'publicly traded company named organon organon co'), (16.0, 'federal income tax purposes'), (9.0, 'merck completed spin'), (9.0, 'f contents disease'), (9.0, 'established brands businesses'), (4.0, 'von hippel'), (4.0, 'oral hypoxia'), (4.0, 'inducible factor'), (4.0, 'gross margin'), (4.0, 'drug administration'), (4.0, 'belzutifan ),'), (4.0, 'approved welireg'), (4.0, 'adult patients'), (3.5, '2 alpha'), (1.5, '2'), (1.0, 'vhl'), (1.0, 'u'), (1.0, 'treatment'), (1.0, 'table'), (1.0, 'new'), (1.0, 'lindau'), (1.0, 'inhibitor'), (1.0, 'independent'), (1.0, 'hif'), (1.0, 'health'), (1.0, 'food'), (1.0, 'fda'), (1.0, '67'), (1.0, '0')]","[(23.0, 'financial instruments market risk disclosures'), (5.0, 'financial condition'), (5.0, 'financial condition'), (4.0, 'information required'), (4.0, 'f contents'), (3.75, 'item includes'), (3.75, 'item 7a'), (3.75, 'item 7'), (3.333333333333333, 'managements discussion'), (1.75, 'item'), (1.3333333333333333, 'discussion'), (1.3333333333333333, 'discussion'), (1.0, 'table'), (1.0, 'results'), (1.0, 'results'), (1.0, 'reference'), (1.0, 'operations'), (1.0, 'operations'), (1.0, 'incorporated'), (1.0, 'analysis'), (1.0, 'analysis')]","[(22.5, 'certain additional matters including governmental'), (16.0, 'merck incurred separation costs'), (10.0, 'including product liability'), (9.0, 'nature considered normal'), (5.5, 'environmental matters'), (4.0, 'various claims'), (4.0, 'legal proceedings'), (4.0, 'intellectual property'), (4.0, 'commercial litigation'), (4.0, '743 million'), (4.0, '556 million'), (1.0, 'well'), (1.0, 'spin'), (1.0, 'result'), (1.0, 'organon'), (1.0, 'involved'), (1.0, 'company'), (1.0, 'business'), (1.0, '2021'), (1.0, '2020')]","[(25.0, 'independent registered public accounting firm'), (8.333333333333334, 'financial statements report'), (7.666666666666668, 'companys internal control'), (4.666666666666667, 'internal control'), (4.666666666666667, 'internal control'), (4.333333333333334, 'financial reporting'), (4.333333333333334, 'financial reporting'), (4.0, 'reasonably likely'), (4.0, 'pricewaterhousecoopers llp'), (4.0, 'materially affected'), (4.0, 'materially affect'), (4.0, 'managements stewardship'), (4.0, 'fourth quarter'), (4.0, 'company assets'), (1.0, 'performed'), (1.0, 'effectiveness'), (1.0, 'changes'), (1.0, 'assessment'), (1.0, '2021')]"
Merck & Co.,2020,"[(25.0, 'orally administered soluble guanylate cyclase'), (9.0, 'local agencies around'), (9.0, 'independent grantmaking organization'), (9.0, 'improving global health'), (8.5, 'also provided funds'), (4.5, 'also subject'), (4.0, 'pharmaceutical industry'), (4.0, 'organizations dedicated'), (3.5, 'merck foundation'), (1.5, 'merck'), (1.0, 'world'), (1.0, 'vericiguat'), (1.0, 'variety'), (1.0, 'stimulator'), (1.0, 'state'), (1.0, 'sgc'), (1.0, 'review'), (1.0, 'regulation'), (1.0, 'regional'), (1.0, 'partnered'), (1.0, 'mk'), (1.0, 'japan'), (1.0, 'eu'), (1.0, 'country'), (1.0, '1242')]","[(9.0, 'product liability insurance'), (9.0, 'health care industry'), (9.0, 'complex tax laws'), (4.0, 'united states'), (4.0, 'products may'), (4.0, 'political action'), (4.0, 'may result'), (4.0, 'increasing regulation'), (4.0, 'global covid'), (4.0, 'cost prohibitive'), (4.0, 'companys business'), (4.0, 'adverse impact'), (4.0, 'additional liabilities'), (4.0, '19 pandemic'), (1.0, 'unavailable'), (1.0, 'subject'), (1.0, 'subject'), (1.0, 'limited'), (1.0, 'evolving'), (1.0, 'continue'), (1.0, 'company')]","[(9.0, 'unresolved staff comments'), (9.0, 'unresolve staff comments'), (4.0, 'item 1d'), (3.5, 'item 2'), (3.5, 'item 1c'), (3.5, 'item 1b'), (3.5, 'item 1b'), (3.5, 'item 1a'), (3.2, '1 .""'), (1.5, '2'), (1.5, '1c'), (1.5, '1b'), (1.5, '1b'), (1.5, '1a'), (1.2, '1'), (1.2, '1'), (1.2, '1'), (1.2, '1'), (1.0, '4'), (1.0, '3')]","[(9.0, 'mercks manufacturing operations'), (9.0, 'human health products'), (4.0, 'whitehouse station'), (4.0, 'united states'), (4.0, 'production facilities'), (4.0, 'nine locations'), (4.0, 'new jersey'), (4.0, 'currently headquartered'), (4.0, 'capital expenditures'), (4.0, '6 billion'), (1.0, 'transferred'), (1.0, 'spin'), (1.0, 'properties'), (1.0, 'organon'), (1.0, 'number'), (1.0, 'companys'), (1.0, '4'), (1.0, '2018')]","[(4.0, 'supplementary data'), (4.0, 'supplementary data'), (4.0, 'note 10'), (4.0, 'legal proceedings'), (4.0, 'information called'), (4.0, 'financial statements'), (4.0, 'financial statements'), (4.0, 'environmental liabilities'), (3.333333333333333, 'incorporated herein'), (3.25, 'item 8'), (1.3333333333333333, 'incorporated'), (1.3333333333333333, 'incorporated'), (1.25, 'item'), (1.25, 'item'), (1.25, 'item'), (1.0, 'reference'), (1.0, 'reference'), (1.0, 'contingencies')]","[(25.0, 'three months ended december 31'), (15.5, 'new york stock exchange'), (9.5, 'companys common stock'), (4.0, 'symbol mrk'), (4.0, 'principal market'), (4.0, 'plan approved'), (4.0, 'october 2018'), (4.0, '10 billion'), (3.5, 'merck shares'), (1.5, 'shares'), (1.0, 'treasury'), (1.0, 'trading'), (1.0, 'purchase'), (1.0, 'purchase'), (1.0, 'nyse'), (1.0, 'directors'), (1.0, 'company'), (1.0, 'board'), (1.0, '2020')]","[(25.0, 'pharmaceutical segment profits grew 5'), (25.0, 'cscc ), metastatic microsatellite instability'), (16.0, 'cutaneous squamous cell carcinoma'), (9.0, 'mismatch repair deficient'), (9.0, 'keytruda received approval'), (9.0, 'hpv types covered'), (9.0, 'girls nine years'), (9.0, 'genital warts caused'), (9.0, '2019 driven primarily'), (4.0, 'vulvar precancers'), (4.0, 'united states'), (4.0, 'therapeutic areas'), (4.0, 'promotional costs'), (4.0, 'lower selling'), (4.0, 'higher sales'), (4.0, 'gardasil 9'), (4.0, 'colorectal cancer'), (4.0, 'cervical cancer'), (4.0, 'certain cervical'), (4.0, '2020 compared'), (1.0, 'women'), (1.0, 'well'), (1.0, 'vaginal'), (1.0, 'vaccine'), (1.0, 'use'), (1.0, 'prevention'), (1.0, 'pmda'), (1.0, 'older'), (1.0, 'msi'), (1.0, 'monotherapy'), (1.0, 'japan'), (1.0, 'high'), (1.0, 'h'), (1.0, 'dmmr'), (1.0, 'colore'), (1.0, 'approved')]","[(20.5, 'financial instruments market risk disclosures'), (7.0, 'market risk'), (5.5, 'financial condition'), (4.0, 'qualitative disclifications'), (4.0, 'information required'), (3.75, 'item 7a'), (3.75, 'item 7'), (3.75, 'item 7'), (3.5, 'managements discussion'), (1.75, 'item'), (1.5, 'discussion'), (1.0, 'results'), (1.0, 'reference'), (1.0, 'quantitative'), (1.0, 'operations'), (1.0, 'incorporated'), (1.0, 'analysis')]","[(22.5, 'certain additional matters including governmental'), (10.0, 'including product liability'), (9.0, 'nature considered normal'), (9.0, 'employee separation expense'), (8.0, 'cumulative pretax costs'), (5.5, 'environmental matters'), (4.0, 'various claims'), (4.0, 'primarily related'), (4.0, 'legal proceedings'), (4.0, 'intellectual property'), (4.0, 'facility shut'), (4.0, 'company estimates'), (4.0, 'commercial litigation'), (4.0, 'cash outlays'), (4.0, 'approximately 70'), (2.0, 'costs'), (1.0, 'well'), (1.0, 'result'), (1.0, 'merck'), (1.0, 'involved'), (1.0, 'business')]","[(25.0, 'independent registered public accounting firm'), (9.0, 'financial statements report'), (9.0, 'financial reporting based'), (8.0, 'internal control integrated'), (5.0, 'internal control'), (4.0, 'treadway commission'), (4.0, 'sponsoring organizations'), (4.0, 'pricewaterhousecoopers llp'), (4.0, 'managements stewardship'), (4.0, 'management conducted'), (4.0, 'company assets'), (3.5, 'framework issued'), (1.5, 'framework'), (1.0, 'performed'), (1.0, 'evaluation'), (1.0, 'effectiveness'), (1.0, 'committee'), (1.0, 'assessment'), (1.0, '2013')]"
Merck & Co.,2019,"[(36.0, 'fast track designation provides pharmaceutical manufacturers'), (9.0, 'independent grantmaking organization'), (9.0, 'improving global health'), (4.0, 'provided funds'), (4.0, 'products development'), (4.0, 'organizations dedicated'), (4.0, 'frequent interactions'), (4.0, 'first half'), (4.0, 'fda reviewers'), (4.0, 'certain conditions'), (3.5, 'merck foundation'), (1.5, 'merck'), (1.0, 'variety'), (1.0, 'subject'), (1.0, 'spin'), (1.0, 'partnered'), (1.0, 'opportunities'), (1.0, 'market'), (1.0, 'expected'), (1.0, 'completed'), (1.0, '2021')]","[(16.0, 'vaccines carry unique risks'), (9.0, 'product liability insurance'), (9.0, 'material adverse effect'), (9.0, 'companys future results'), (9.0, 'company cannot state'), (9.0, 'company anticipates sales'), (4.0, 'patent expiries'), (4.0, 'decline substantially'), (4.0, 'cost prohibitive'), (3.5, 'products may'), (1.5, 'products'), (1.0, 'whether'), (1.0, 'uncertainties'), (1.0, 'unavailable'), (1.0, 'operations'), (1.0, 'markets'), (1.0, 'limited'), (1.0, 'launched'), (1.0, 'januvia'), (1.0, 'janumet'), (1.0, 'development'), (1.0, 'could'), (1.0, 'certainty'), (1.0, 'biologics'), (1.0, 'approved')]","[(9.0, 'unresolved staff comments'), (9.0, 'unresolve staff comments'), (4.0, 'item 1d'), (3.5, 'item 2'), (3.5, 'item 1c'), (3.5, 'item 1b'), (3.5, 'item 1b'), (3.5, 'item 1a'), (3.2, '1 .""'), (1.5, '2'), (1.5, '1c'), (1.5, '1b'), (1.5, '1b'), (1.5, '1a'), (1.2, '1'), (1.2, '1'), (1.2, '1'), (1.2, '1'), (1.0, '4'), (1.0, '3')]","[(16.0, 'disclosed capital expansion projects'), (9.0, 'mercks manufacturing operations'), (8.0, 'human health products'), (4.0, 'whitehouse station'), (4.0, 'united states'), (4.0, 'puerto rico'), (4.0, 'projected needs'), (4.0, 'production facilities'), (4.0, 'nine locations'), (4.0, 'new jersey'), (4.0, 'intended purposes'), (4.0, 'including previously'), (4.0, 'company believes'), (3.5, 'projected capacities'), (2.0, 'products'), (1.5, 'capacities'), (1.0, 'suitable'), (1.0, 'plants'), (1.0, 'manufacture'), (1.0, 'headquartered'), (1.0, 'current'), (1.0, 'adequate')]","[(4.0, 'supplementary data'), (4.0, 'supplementary data'), (4.0, 'note 10'), (4.0, 'legal proceedings'), (4.0, 'information called'), (4.0, 'financial statements'), (4.0, 'financial statements'), (4.0, 'environmental liabilities'), (3.333333333333333, 'incorporated herein'), (3.25, 'item 8'), (1.3333333333333333, 'incorporated'), (1.3333333333333333, 'incorporated'), (1.25, 'item'), (1.25, 'item'), (1.25, 'item'), (1.0, 'reference'), (1.0, 'reference'), (1.0, 'contingencies')]","[(9.0, 'performance graph assumes'), (9.0, 'composite peer group'), (9.0, 'companys common shares'), (9.0, 'companion common stock'), (8.5, 'sp 500 index'), (4.5, '500 shareholders'), (4.0, 'pharmaceutical companies'), (4.0, 'major u'), (4.0, 'january 31'), (4.0, 'december 31'), (4.0, 'approximately 109'), (4.0, '100 investment'), (1.0, 'reinvestment'), (1.0, 'record'), (1.0, 'dividends'), (1.0, '2020'), (1.0, '2014')]","[(45.0, 'isentress hd also partially offset revenue growth'), (16.0, 'worldwide clinical development collaboration'), (15.0, 'help prevent certain cancers'), (11.0, 'hiv products isentress'), (10.5, 'rotateq also grew'), (9.0, 'vytorin declined 35'), (9.0, 'pulmonary arterial hypertension'), (9.0, 'diabetes products januvia'), (9.0, 'asia pacific region'), (8.0, '2019 driven primarily'), (5.0, 'certain types'), (4.5, 'grew 19'), (4.0, 'united states'), (4.0, 'lower sales'), (4.0, 'higher demand'), (4.0, 'diseases caused'), (4.0, 'countries outside'), (4.0, 'cardiovascular drug'), (3.5, 'gardasil 9'), (2.0, '2019'), (1.5, 'gardasil'), (1.0, 'zetia'), (1.0, 'varivax'), (1.0, 'vaccines'), (1.0, 'treatment'), (1.0, 'particularly'), (1.0, 'part'), (1.0, 'marketed'), (1.0, 'janumet'), (1.0, 'hpv'), (1.0, 'ezetrol'), (1.0, 'china'), (1.0, 'adempas')]","[(22.166666666666664, 'financial instruments market risk disclosures'), (17.166666666666664, 'financial instruments market risk'), (5.666666666666666, 'financial condition'), (3.75, 'item 7a'), (3.75, 'item 7'), (3.75, 'item 7'), (3.5, 'information required'), (3.333333333333333, 'managements discussion'), (1.75, 'item'), (1.5, 'information'), (1.3333333333333333, 'discussion'), (1.3333333333333333, 'discussion'), (1.0, 'results'), (1.0, 'reference'), (1.0, 'reference'), (1.0, 'operations'), (1.0, 'incorporated'), (1.0, 'incorporated'), (1.0, 'analysis')]","[(16.0, 'projected future cash flows'), (16.0, 'including revenue hedging activities'), (9.0, 'party manufacturing sales'), (9.0, 'miscellaneous corporate revenues'), (9.0, 'estimated useful life'), (4.0, 'upfront payment'), (4.0, 'primarily comprised'), (4.0, 'merck made'), (4.0, 'impairment testing'), (4.0, '4 billion'), (1.0, 'well'), (1.0, 'third'), (1.0, 'supported'), (1.0, 'subject'), (1.0, 'part'), (1.0, 'astrazeneca'), (1.0, 'amount'), (1.0, 'amortized'), (1.0, 'agreement'), (1.0, '2026'), (1.0, '1')]","[(16.0, 'maintaining adequate internal control'), (8.5, 'financial statements report'), (8.0, 'securities exchange act'), (4.5, 'financial reporting'), (4.0, 'rule 13a'), (4.0, 'managements stewardship'), (4.0, 'company assets'), (2.0, 'act'), (1.0, 'term'), (1.0, 'responsible'), (1.0, 'management'), (1.0, 'f'), (1.0, 'establishing'), (1.0, 'defined'), (1.0, 'amended'), (1.0, '1934'), (1.0, '15')]"
Merck & Co.,2018,"[(33.5, 'fast track designation provides pharmaceutical manufacturers'), (23.5, 'august 2018 fda approved delstrigo'), (14.5, 'prior antiretroviral treatment experience'), (9.0, 'received breakthrough drug'), (9.0, 'company also recognizes'), (5.5, 'fda reviewers'), (4.0, 'improve access'), (4.0, 'important role'), (4.0, 'frequent interactions'), (4.0, 'cosmetic therapy'), (4.0, 'adult patients'), (4.0, '1 infection'), (3.5, 'products development'), (3.5, 'designation'), (2.5, 'treatment'), (1.5, 'products'), (1.0, 'qidp'), (1.0, 'play'), (1.0, 'opportunities'), (1.0, 'keytruda'), (1.0, 'hiv'), (1.0, 'helping')]","[(13.333333333333334, 'party patents may prevent'), (9.0, 'particular geographic area'), (9.0, 'health authorities appear'), (9.0, 'diseased tissue samples'), (5.0, 'companys patents'), (4.333333333333334, 'may deprive'), (4.0, 'viral strains'), (4.0, 'unique risks'), (4.0, 'patent litigation'), (4.0, 'new products'), (4.0, 'market exclusivity'), (4.0, 'making decisions'), (4.0, 'limited access'), (4.0, 'cell lines'), (4.0, 'biological materials'), (3.5, 'patented product'), (2.3333333333333335, 'may'), (1.5, 'product'), (1.0, 'vaccines'), (1.0, 'unpredictable'), (1.0, 'uncertainties'), (1.0, 'third'), (1.0, 'supply'), (1.0, 'selling'), (1.0, 'pathogens'), (1.0, 'normal'), (1.0, 'marketing'), (1.0, 'including'), (1.0, 'costly'), (1.0, 'company'), (1.0, 'company'), (1.0, 'challenges'), (1.0, 'cautious'), (1.0, 'cases'), (1.0, 'biologics'), (1.0, 'become'), (1.0, 'bacteria'), (1.0, 'approvability')]","[(9.0, 'unresolved staff comments'), (9.0, 'unresolve staff comments'), (4.0, 'item 1d'), (3.5, 'item 2'), (3.5, 'item 1c'), (3.5, 'item 1b'), (3.5, 'item 1b'), (3.5, 'item 1a'), (3.2, '1 .""'), (1.5, '2'), (1.5, '1c'), (1.5, '1b'), (1.5, '1b'), (1.5, '1a'), (1.2, '1'), (1.2, '1'), (1.2, '1'), (1.2, '1'), (1.0, '4'), (1.0, '3')]","[(9.0, 'mercks manufacturing operations'), (8.5, 'new capital projects'), (4.5, 'new jersey'), (4.0, 'whitehouse station'), (4.0, 'united states'), (4.0, 'invest approximately'), (4.0, 'company announced'), (4.0, '5 billion'), (4.0, '16 billion'), (3.333333333333333, 'october 2018'), (1.3333333333333333, '2018'), (1.3333333333333333, '2018'), (1.0, 'plans'), (1.0, 'headquartered'), (1.0, 'amounted'), (1.0, '2022'), (1.0, '1')]","[(4.0, 'supplementary data'), (4.0, 'note 11'), (4.0, 'legal proceedings'), (4.0, 'financial statements'), (4.0, 'environmental liabilities'), (3.6, 'item 8'), (3.6, 'item 8'), (3.6, 'item 3'), (3.5, 'information called'), (3.333333333333333, 'incorporated herein'), (1.6, 'item'), (1.6, 'item'), (1.5, 'information'), (1.3333333333333333, 'incorporated'), (1.3333333333333333, 'incorporated'), (1.0, 'reference'), (1.0, 'reference'), (1.0, 'reference'), (1.0, 'contingencies')]","[(9.0, 'roche holding ag'), (9.0, 'mercks common stock'), (9.0, '70 peer grp'), (4.0, 'sanofi sa'), (4.0, 'plan approved'), (4.0, 'november 2017'), (4.0, '10 billion'), (3.5, 'merck shares'), (3.5, 'amgen inc'), (1.5, 'shares'), (1.5, 'amgen'), (1.0, 'treasury'), (1.0, 'purchased'), (1.0, 'purchase'), (1.0, 'part'), (1.0, 'directors'), (1.0, 'board'), (1.0, 'approximated')]","[(9.0, 'primary peritoneal cancer'), (9.0, 'help prevent shingles'), (9.0, 'fda approved lynparza'), (9.0, 'estimated fair value'), (9.0, 'contingent consideration related'), (9.0, 'adults 50 years'), (4.0, 'somatic brca'), (4.0, 'net reduction'), (4.0, 'mutated advanced'), (4.0, 'maintenance treatment'), (4.0, 'herpes zoster'), (4.0, 'fallopian tube'), (4.0, 'company recorded'), (4.0, 'certain programs'), (4.0, 'adult patients'), (4.0, '54 million'), (4.0, '402 million'), (4.0, '217 million'), (3.5, 'december 2018'), (1.5, '2018'), (1.0, 'zostavax'), (1.0, 'vaccine'), (1.0, 'use'), (1.0, 'sales'), (1.0, 'ovarian'), (1.0, 'older'), (1.0, 'liabilities'), (1.0, 'germline'), (1.0, 'expenses'), (1.0, 'discontinuation'), (1.0, 'deleterious'), (1.0, 'delay'), (1.0, 'decrease'), (1.0, 'decline'), (1.0, 'compared'), (1.0, 'age'), (1.0, '68'), (1.0, '2017')]","[(22.166666666666664, 'financial instruments market risk disclosures'), (17.166666666666664, 'financial instruments market risk'), (5.666666666666666, 'financial condition'), (3.75, 'item 7a'), (3.75, 'item 7'), (3.75, 'item 7'), (3.5, 'information required'), (3.333333333333333, 'managements discussion'), (1.75, 'item'), (1.5, 'information'), (1.3333333333333333, 'discussion'), (1.3333333333333333, 'discussion'), (1.0, 'results'), (1.0, 'reference'), (1.0, 'reference'), (1.0, 'operations'), (1.0, 'incorporated'), (1.0, 'incorporated'), (1.0, 'analysis')]","[(16.0, 'projected future cash flows'), (16.0, 'including revenue hedging activities'), (9.0, 'party manufacturing sales'), (9.0, 'miscellaneous corporate revenues'), (9.0, 'estimated useful life'), (4.0, 'primarily comprised'), (4.0, 'impairment testing'), (4.0, 'fair value'), (4.0, 'contingent consideration'), (4.0, 'company determined'), (4.0, 'acquisition date'), (4.0, '223 million'), (1.0, 'well'), (1.0, 'third'), (1.0, 'supported'), (1.0, 'subject'), (1.0, 'amount'), (1.0, 'amortized'), (1.0, '2026')]","[(25.0, 'independent registered public accounting firm'), (15.0, 'maintaining adequate internal control'), (10.0, 'companys internal control'), (9.0, 'securities exchange act'), (8.5, 'financial statements report'), (4.5, 'financial reporting'), (4.0, 'rule 13a'), (4.0, 'pricewaterhousecoopers llp'), (4.0, 'managements stewardship'), (4.0, 'company assets'), (1.0, 'term'), (1.0, 'responsible'), (1.0, 'performed'), (1.0, 'management'), (1.0, 'f'), (1.0, 'establishing'), (1.0, 'effectiveness'), (1.0, 'defined'), (1.0, 'assessment'), (1.0, '1934'), (1.0, '15')]"
Merck & Co.,2017,"[(16.0, 'large scale phase 2'), (16.0, 'activated protein kinasek pathway'), (9.0, 'multiple cancer types'), (9.0, '3 clinical trials'), (4.0, 'vaccine candidate'), (4.0, 'selective inhibitor'), (4.0, 'investigational rvsv'), (1.0, 'zebov'), (1.0, 'vaxelis'), (1.0, 'v920'), (1.0, 'v419'), (1.0, 'studied'), (1.0, 'selumetinib'), (1.0, 'potent'), (1.0, 'part'), (1.0, 'oral'), (1.0, 'mk'), (1.0, 'mitogen'), (1.0, 'mek'), (1.0, 'marketed'), (1.0, 'eu'), (1.0, 'ebola'), (1.0, 'developed'), (1.0, '5618')]","[(9.0, 'harmful side effects'), (8.0, 'animal health vaccines'), (7.5, 'development may fail'), (4.5, 'successful development'), (4.0, 'uncertain process'), (4.0, 'superior safety'), (4.0, 'particularly human'), (4.0, 'numerous reasons'), (4.0, 'appear promising'), (3.5, 'competing products'), (3.0, 'clinical testing'), (2.0, 'vaccines'), (2.0, 'fail'), (1.5, 'testing'), (1.5, 'products'), (1.5, 'clinical'), (1.0, 'succeed'), (1.0, 'reach'), (1.0, 'pre'), (1.0, 'market'), (1.0, 'manufacturing'), (1.0, 'long'), (1.0, 'ineffectiveness'), (1.0, 'including'), (1.0, 'following'), (1.0, 'findings'), (1.0, 'expensive'), (1.0, 'efficacy'), (1.0, 'commercialization'), (1.0, 'biologics')]","[(9.0, 'unresolved staff comments'), (9.0, 'unresolve staff comments'), (4.0, 'item 1d'), (3.5, 'item 2'), (3.5, 'item 1c'), (3.5, 'item 1b'), (3.5, 'item 1b'), (3.5, 'item 1a'), (3.2, '1 .""'), (1.5, '2'), (1.5, '1c'), (1.5, '1b'), (1.5, '1b'), (1.5, '1a'), (1.2, '1'), (1.2, '1'), (1.2, '1'), (1.2, '1'), (1.0, '4'), (1.0, '3')]","[(24.0, 'mercks animal health global headquarters'), (10.0, 'human health products'), (4.0, 'united states'), (4.0, 'puerto rico'), (4.0, 'production facilities'), (4.0, 'principal facilities'), (4.0, 'nine locations'), (4.0, 'new jersey'), (4.0, 'manufacturing plants'), (4.0, 'companys u'), (4.0, 'company also'), (1.0, 'titles'), (1.0, 'subsidiaries'), (1.0, 'satisfactory'), (1.0, 'madison'), (1.0, 'located'), (1.0, 'consider')]","[(4.0, 'supplementary data'), (4.0, 'note 11'), (4.0, 'legal proceedings'), (4.0, 'financial statements'), (4.0, 'environmental liabilities'), (3.6, 'item 8'), (3.6, 'item 8'), (3.6, 'item 3'), (3.5, 'information called'), (3.333333333333333, 'incorporated herein'), (1.6, 'item'), (1.6, 'item'), (1.5, 'information'), (1.3333333333333333, 'incorporated'), (1.3333333333333333, 'incorporated'), (1.0, 'reference'), (1.0, 'reference'), (1.0, 'reference'), (1.0, 'contingencies')]","[(16.0, 'directors authorized additional purchases'), (14.833333333333334, 'new york stock exchange'), (9.333333333333334, 'mercks common stock'), (9.333333333333334, 'companys common stock'), (9.0, 'company specifically requests'), (8.5, 'securities exchange act'), (8.5, 'following graph assumes'), (5.0, 'securities act'), (4.5, 'performance graph'), (4.0, 'symbol mrk'), (4.0, 'soliciting material'), (4.0, 'principal market'), (4.0, 'november 2017'), (4.0, 'december 31'), (4.0, '100 investment'), (4.0, '10 billion'), (1.0, 'treated'), (1.0, 'treasury'), (1.0, 'trading'), (1.0, 'reinvestment'), (1.0, 'reference'), (1.0, 'nyse'), (1.0, 'information'), (1.0, 'incorporated'), (1.0, 'filing'), (1.0, 'extent'), (1.0, 'except'), (1.0, 'dividends'), (1.0, 'deemed'), (1.0, 'board'), (1.0, '2012'), (1.0, '1934'), (1.0, '1933')]","[(9.0, 'united states reflecting'), (9.0, 'public sector purchasing'), (9.0, 'companys common stock'), (9.0, '48 per share'), (4.0, 'second quarter'), (4.0, 'sales growth'), (4.0, 'partially offset'), (4.0, 'lower demand'), (4.0, 'higher sales'), (4.0, 'higher pricing'), (4.0, 'driven primarily'), (4.0, 'company purchased'), (4.0, 'april 2018'), (4.0, '2018 payable'), (1.0, 'effects'), (1.0, 'compared'), (1.0, '87'), (1.0, '4'), (1.0, '2016'), (1.0, '2015'), (1.0, '1')]","[(22.166666666666664, 'financial instruments market risk disclosures'), (17.166666666666664, 'financial instruments market risk'), (5.666666666666666, 'financial condition'), (3.75, 'item 7a'), (3.75, 'item 7'), (3.75, 'item 7'), (3.5, 'information required'), (3.333333333333333, 'managements discussion'), (1.75, 'item'), (1.5, 'information'), (1.3333333333333333, 'discussion'), (1.3333333333333333, 'discussion'), (1.0, 'results'), (1.0, 'reference'), (1.0, 'reference'), (1.0, 'operations'), (1.0, 'incorporated'), (1.0, 'incorporated'), (1.0, 'analysis')]","[(25.0, 'company may recognize additional non'), (9.0, 'nature considered normal'), (9.0, 'including product liability'), (9.0, 'fair value determination'), (8.5, 'cash impairment charges'), (4.5, 'charges could'), (4.0, 'various claims'), (4.0, 'pipeline programs'), (4.0, 'marketed products'), (4.0, 'legal proceedings'), (4.0, 'intellectual property'), (4.0, 'future related'), (4.0, 'credit risk'), (4.0, 'credit risk'), (4.0, 'commercial litigation'), (3.5, 'derivatives includes'), (1.5, 'derivatives'), (1.0, 'significant'), (1.0, 'merck'), (1.0, 'material'), (1.0, 'involved'), (1.0, 'impact'), (1.0, 'effects'), (1.0, 'counterparties'), (1.0, 'companys'), (1.0, 'business')]","[(25.0, 'independent registered public accounting firm'), (15.0, 'maintaining adequate internal control'), (10.0, 'companys internal control'), (8.5, 'financial statements report'), (4.5, 'financial reporting'), (4.0, 'pricewaterhousecoopers llp'), (4.0, 'managements stewardship'), (4.0, 'company assets'), (1.0, 'responsible'), (1.0, 'performed'), (1.0, 'management'), (1.0, 'establishing'), (1.0, 'effectiveness'), (1.0, 'assessment')]"
Alphabet Inc.,2021,"[(16.0, 'features like data migration'), (9.0, 'systems every year'), (9.0, 'see significant opportunity'), (9.0, 'ready cloud services'), (9.0, 'modern development environments'), (9.0, 'machine learning tools'), (9.0, 'helping businesses utilize'), (9.0, 'best advertising experiences'), (4.0, 'removing billions'), (4.0, 'provide enterprise'), (4.0, 'many ways'), (4.0, 'invalid traffic'), (4.0, 'including filtering'), (4.0, 'core values'), (4.0, 'bad ads'), (3.5, 'build sustainability'), (1.5, 'sustainability'), (1.0, 'users'), (1.0, 'strive'), (1.0, 'strengths'), (1.0, 'one'), (1.0, 'google'), (1.0, 'focus'), (1.0, 'everything'), (1.0, 'creating'), (1.0, 'advertisers')]","[(36.0, 'marketable equity securities may differ significantly'), (9.0, 'fair value remeasurements'), (8.5, 'data localization laws'), (4.5, 'data collected'), (4.0, 'ultimately experience'), (4.0, 'provide hardware'), (4.0, 'processed within'), (4.0, 'generally mandate'), (4.0, 'competes effectively'), (4.0, 'certain types'), (3.5, 'unrealized gains'), (3.5, 'particular country'), (1.5, 'gains'), (1.5, 'country'), (1.0, 'stored'), (1.0, 'record'), (1.0, 'non'), (1.0, 'losses'), (1.0, 'losses'), (1.0, 'investments'), (1.0, 'assurance'), (1.0, 'able')]","[(9.0, 'unresolved staff comments'), (4.0, 'please submit'), (3.5, 'item 1b'), (1.5, 'item'), (1.0, 'unresolvement'), (1.0, 'resolved'), (1.0, 'issues'), (1.0, 'issues'), (1.0, 'end'), (1.0, 'editor'), (1.0, 'comment'), (1.0, 'article'), (1.0, 'applicable'), (1.0, 'applicable'), (1.0, 'applicable')]","[(9.0, 'rd sites around'), (4.0, 'south america'), (4.0, 'mountain view'), (4.0, 'lease office'), (4.0, 'good condition'), (4.0, 'existing facilities'), (4.0, 'building space'), (1.0, 'world'), (1.0, 'suitable'), (1.0, 'owned'), (1.0, 'located'), (1.0, 'leased'), (1.0, 'headquarters'), (1.0, 'europe'), (1.0, 'conduct'), (1.0, 'california'), (1.0, 'business'), (1.0, 'believe'), (1.0, 'asia')]","[(16.0, 'consolidated financial statements included'), (15.0, 'material pending legal proceedings'), (8.5, 'see legal matters'), (5.5, 'legal matters'), (4.0, 'part ii'), (4.0, 'note 10'), (4.0, 'note 10'), (4.0, 'item 8'), (4.0, 'item 10'), (4.0, 'incorporated herein'), (4.0, 'form 10'), (4.0, 'annual report'), (4.0, 'annual report'), (1.0, 'year'), (1.0, 'results'), (1.0, 'reference'), (1.0, 'notes'), (1.0, 'k'), (1.0, 'description')]","[(9.0, 'suggest future performance'), (4.0, 'term growth'), (4.0, 'returns shown'), (4.0, 'regularly evaluates'), (4.0, 'primary use'), (4.0, 'market conditions'), (4.0, 'historical results'), (4.0, 'capital structure'), (4.0, 'capital return'), (4.0, 'capital continues'), (4.0, 'alphabet inc'), (3.5, 'general business'), (1.5, 'business'), (1.0, 'time'), (1.0, 'time'), (1.0, 'subject'), (1.0, 'stockholders'), (1.0, 'size'), (1.0, 'repurchases'), (1.0, 'pace'), (1.0, 'long'), (1.0, 'invest'), (1.0, 'intended'), (1.0, 'including'), (1.0, 'form'), (1.0, 'executed'), (1.0, 'cash'), (1.0, 'based')]","[(9.0, 'google cloud revenues'), (9.0, '2021 primarily driven'), (8.0, 'google cloud platform'), (8.0, 'expense ), net'), (4.0, 'partially offset'), (4.0, 'includes fees'), (4.0, 'impressions related'), (3.5, 'impressions increased'), (2.0, 'platform'), (2.0, 'net'), (1.5, 'increased'), (1.0, 'services'), (1.0, 'infrastructure'), (1.0, 'income'), (1.0, 'growth'), (1.0, 'following'), (1.0, 'decline'), (1.0, 'comprised'), (1.0, 'adsense'), (1.0, 'admob'), (1.0, '5'), (1.0, '3'), (1.0, '2020')]","[(25.0, 'foreign currency exchange rate change'), (9.0, 'total monetary assets'), (9.0, 'marketable equity securities'), (9.0, 'balance sheet date'), (4.0, 'measurement alternative'), (4.0, 'december 31'), (4.0, 'commitments denominated'), (4.0, 'carrying value'), (4.0, 'approxima tely'), (4.0, 'adverse effect'), (4.0, 'adverse 10'), (4.0, '497 million'), (4.0, '4 billion'), (4.0, '285 million'), (4.0, '0 billion'), (3.5, 'income taxes'), (3.5, 'functional currencies'), (1.5, 'income'), (1.5, 'currencies'), (1.0, 'would'), (1.0, 'resulted'), (1.0, 'non'), (1.0, 'liabilities'), (1.0, 'applied'), (1.0, 'accounted'), (1.0, '2021'), (1.0, '2020'), (1.0, '18'), (1.0, '1')]","[(25.0, 'following table presents revenues disaggregated'), (16.0, 'average remaining useful lives'), (14.5, 'companys financial statements based'), (8.0, 'income tax audits'), (4.0, 'trade names'), (4.0, 'developed technology'), (4.0, 'customer relationships'), (4.0, '7 billion'), (4.0, '4 billion'), (2.5, 'based'), (2.0, 'audits'), (1.0, 'weighted'), (1.0, 'responsibility'), (1.0, 'recognized'), (1.0, 'patents'), (1.0, 'opinion'), (1.0, 'non'), (1.0, 'geography'), (1.0, 'express'), (1.0, 'customers'), (1.0, 'charge'), (1.0, 'alphabet'), (1.0, 'addresses'), (1.0, '2'), (1.0, '0')]","[(15.0, 'quarter ended december 31'), (9.0, 'global workforce continued'), (5.0, 'second quarter'), (4.0, 'operate primarily'), (4.0, 'internal controls'), (4.0, 'included changes'), (4.0, 'home environment'), (4.0, 'financial reporting'), (1.0, 'years'), (1.0, 'work'), (1.0, 'subledgers'), (1.0, 'result'), (1.0, 'processes'), (1.0, 'procedures'), (1.0, 'phases'), (1.0, 'next'), (1.0, 'implementation'), (1.0, 'expected'), (1.0, 'covid'), (1.0, 'continue'), (1.0, 'certain'), (1.0, '2021'), (1.0, '2021'), (1.0, '19')]"
Alphabet Inc.,2020,"[(16.0, 'grow revenues beyond advertising'), (14.25, 'google comprises two segments'), (9.0, 'key manufacturing regions'), (9.0, 'free energy across'), (9.0, 'enable 5 gw'), (4.25, 'google services'), (4.25, 'google cloud'), (4.0, 'term investments'), (4.0, 'new carbon'), (4.0, 'making long'), (4.0, 'helps people'), (4.0, 'build technology'), (2.25, 'google'), (1.0, 'planet'), (1.0, 'investment'), (1.0, 'intend'), (1.0, '2030')]","[(23.0, 'may also experience downward pressure'), (9.0, 'operating margin resulting'), (4.0, 'third parties'), (4.0, 'subscription products'), (4.0, 'providing access'), (4.0, 'new fields'), (4.0, 'google cloud'), (4.0, 'content created'), (4.0, 'competes effectively'), (4.0, 'alphabet inc'), (3.5, 'provide hardware'), (3.0, 'may'), (1.5, 'hardware'), (1.0, 'virtue'), (1.0, 'transmitting'), (1.0, 'subject'), (1.0, 'marketing'), (1.0, 'involvement'), (1.0, 'hosting'), (1.0, 'expansion'), (1.0, 'claims'), (1.0, 'business'), (1.0, 'branding'), (1.0, 'assurance'), (1.0, 'able')]","[(9.0, 'unresolved staff comments'), (4.0, 'parent company'), (3.2, 'alphabet inc'), (1.2, 'alphabet'), (1.2, 'alphabet'), (1.2, 'alphabet'), (1.2, 'alphabet'), (1.0, 'youtube'), (1.0, 'unresolvement'), (1.0, 'result'), (1.0, 'required'), (1.0, 'google'), (1.0, 'facebook'), (1.0, 'dispute'), (1.0, 'article'), (1.0, 'applicable'), (1.0, 'applicable'), (1.0, 'apple')]","[(9.0, 'development sites around'), (4.0, 'south america'), (4.0, 'mountain view'), (4.0, 'lease office'), (4.0, 'good condition'), (4.0, 'existing facilities'), (4.0, 'building space'), (1.0, 'world'), (1.0, 'suitable'), (1.0, 'research'), (1.0, 'owned'), (1.0, 'located'), (1.0, 'leased'), (1.0, 'headquarters'), (1.0, 'europe'), (1.0, 'conduct'), (1.0, 'california'), (1.0, 'business'), (1.0, 'believe'), (1.0, 'asia')]","[(16.0, 'consolidated financial statements included'), (15.333333333333334, 'material pending legal proceedings'), (14.333333333333334, 'please see legal matters'), (6.333333333333334, 'legal matters'), (4.0, 'part ii'), (4.0, 'note 10'), (4.0, 'note 10'), (4.0, 'item 8'), (4.0, 'item 8'), (4.0, 'incorporated herein'), (4.0, 'form 10'), (4.0, 'annual report'), (1.0, 'reference'), (1.0, 'notes'), (1.0, 'k'), (1.0, 'description')]","[(25.0, 'symbol goog since august 19'), (16.0, 'nasdaq global select market'), (8.0, 'suggest future performance'), (4.0, 'returns shown'), (4.0, 'historical results'), (4.0, 'graph tracks'), (4.0, 'common stock'), (4.0, 'common stock'), (4.0, '100 investment'), (2.0, 'performance'), (1.0, 'reinvestment'), (1.0, 'listed'), (1.0, 'intended'), (1.0, 'index'), (1.0, 'dividends'), (1.0, 'class'), (1.0, 'based'), (1.0, 'alphabet'), (1.0, '2004')]","[(34.5, 'search partners infringed european competition law'), (15.0, '554 million charge recognized'), (10.5, 'european commission fines'), (9.0, 'certain contractual provisions'), (8.0, 'google network members'), (5.0, '543 million'), (4.0, 'revenues increased'), (4.0, 'partially offset'), (4.0, 'legal settlement'), (4.0, 'ec announced'), (3.666666666666667, 'march 2019'), (3.666666666666667, '2019 relating'), (2.0, 'google'), (1.6666666666666667, '2019'), (1.0, 'properties'), (1.0, 'increase'), (1.0, 'decision'), (1.0, 'agreements'), (1.0, 'adsense'), (1.0, '2020'), (1.0, '1')]","[(36.0, 'impairment assessment requires significant judgment due'), (25.0, 'risk ("" var "") analysis'), (9.0, 'marketable debt securities'), (4.0, 'uncertainty around'), (4.0, 'typically dependent'), (4.0, 'realize appreciation'), (4.0, 'private company'), (4.0, 'interest rates'), (4.0, 'interest rates'), (4.0, 'estimated one'), (4.0, 'december 31'), (4.0, 'day loss'), (3.5, 'use value'), (3.5, 'potential effect'), (3.5, 'fair value'), (1.5, 'value'), (1.5, 'value'), (1.5, 'effect'), (1.0, 'success'), (1.0, 'shown'), (1.0, 'severity'), (1.0, 'likelihood'), (1.0, 'investment'), (1.0, 'impact'), (1.0, 'fluctuations'), (1.0, 'duration'), (1.0, 'determine'), (1.0, 'covid'), (1.0, 'ability'), (1.0, '2020'), (1.0, '2019'), (1.0, '19')]","[(23.333333333333336, 'income tax audits primarily arises'), (9.333333333333334, 'tax rate applied'), (9.0, 'tested relevant controls'), (9.0, 'identified risks associated'), (5.333333333333334, 'tax treatment'), (4.0, 'term debt'), (4.0, 'subject matter'), (4.0, 'managements accounting'), (4.0, 'august 2020'), (4.0, 'alphabet issued'), (4.0, '4 billion'), (1.0, 'services'), (1.0, 'sale'), (1.0, 'products'), (1.0, 'non'), (1.0, 'matters'), (1.0, 'long'), (1.0, 'jurisdictions'), (1.0, 'disputes'), (1.0, 'disclosure'), (1.0, '10')]","[(25.0, 'independent registered public accounting firm'), (9.0, 'procedures must reflect'), (9.0, 'ernst young llp'), (8.5, 'possible controls relative'), (4.5, 'disclosure controls'), (4.0, 'resource constraints'), (4.0, 'internal control'), (4.0, 'financial reporting'), (4.0, 'december 31'), (1.0, 'required'), (1.0, 'management'), (1.0, 'judgment'), (1.0, 'fact'), (1.0, 'evaluating'), (1.0, 'effectiveness'), (1.0, 'design'), (1.0, 'costs'), (1.0, 'benefits'), (1.0, 'audited'), (1.0, 'apply'), (1.0, '2020')]"
Alphabet Inc.,2019,"[(16.0, 'operating efficient data centers'), (9.0, 'responsible supply chain'), (9.0, 'propelling new ideas'), (9.0, 'creating sustainable workplaces'), (9.0, 'building better devices'), (4.0, 'powerful equalizers'), (4.0, 'people forward'), (4.0, 'free energy'), (4.0, 'empowering users'), (4.0, 'build sustainability'), (4.0, 'advancing carbon'), (1.0, 'world'), (1.0, 'technology'), (1.0, 'strive'), (1.0, 'services'), (1.0, 'one'), (1.0, 'internet'), (1.0, 'everything'), (1.0, 'enabling'), (1.0, 'designing'), (1.0, 'capable')]","[(15.0, 'digital millennium copyright act'), (9.0, 'statutory safe harbors'), (5.0, 'copyright liability'), (4.0, 'various linking'), (4.0, 'valuable role'), (4.0, 'united states'), (4.0, 'truly useful'), (4.0, 'technology leader'), (4.0, 'set forth'), (4.0, 'provide high'), (4.0, 'innovative products'), (4.0, 'hosting activities'), (4.0, 'depend largely'), (4.0, 'commerce directive'), (1.0, 'success'), (1.0, 'settings'), (1.0, 'services'), (1.0, 'remain'), (1.0, 'rely'), (1.0, 'range'), (1.0, 'quality'), (1.0, 'play'), (1.0, 'europe'), (1.0, 'e'), (1.0, 'continue'), (1.0, 'caching'), (1.0, 'ability')]","[(9.0, 'unresolved staff comments'), (4.0, 'please submit'), (3.5, 'item 1b'), (1.5, 'item'), (1.0, 'unresolvement'), (1.0, 'resolved'), (1.0, 'issues'), (1.0, 'issues'), (1.0, 'end'), (1.0, 'editor'), (1.0, 'comment'), (1.0, 'article'), (1.0, 'applicable'), (1.0, 'applicable'), (1.0, 'applicable')]","[(9.0, 'development sites around'), (4.0, 'south america'), (4.0, 'mountain view'), (4.0, 'lease office'), (4.0, 'good condition'), (4.0, 'existing facilities'), (4.0, 'building space'), (1.0, 'world'), (1.0, 'suitable'), (1.0, 'research'), (1.0, 'owned'), (1.0, 'located'), (1.0, 'leased'), (1.0, 'headquarters'), (1.0, 'europe'), (1.0, 'conduct'), (1.0, 'california'), (1.0, 'business'), (1.0, 'believe'), (1.0, 'asia')]","[(23.5, 'please see note 10 commitments'), (14.5, 'material pending legal proceedings'), (14.5, 'consolidated financial statements included'), (5.5, 'form 10'), (4.5, 'legal matters'), (4.5, 'legal matters'), (4.5, 'legal matters'), (4.0, 'item 8'), (4.0, 'item 3'), (4.0, 'incorporated herein'), (4.0, 'annual report'), (4.0, 'annual report'), (2.5, 'included'), (1.0, 'summary'), (1.0, 'reference'), (1.0, 'notes'), (1.0, 'k'), (1.0, 'description'), (1.0, 'contingencies')]","[(15.5, 'year total shareholder return'), (15.0, ""matches alphabet inc .'""), (15.0, 'class c capital stock'), (14.833333333333334, 'rdg internet composite index'), (9.833333333333334, 'nasdaq composite index'), (9.333333333333334, 'sp 500 index'), (9.0, 'suggest future performance'), (8.0, 'cumulative total returns'), (5.0, 'common stock'), (5.0, 'alphabet authorized'), (4.5, 'cumulative 5'), (4.0, 'historical results'), (4.0, '5 billion'), (4.0, '0 billion'), (2.0, 'returns'), (1.0, 'repurchase'), (1.0, 'intended'), (1.0, 'graph'), (1.0, 'directors'), (1.0, 'company'), (1.0, 'board'), (1.0, 'based'), (1.0, 'additional'), (1.0, '25'), (1.0, '12')]","[(16.0, 'corporate legal entity structure'), (9.0, 'license intellectual property'), (8.5, 'marketable equity securities'), (4.5, 'equity method'), (4.0, 'youtube subscriptions'), (4.0, 'put pressure'), (4.0, 'primarily driven'), (4.0, 'overall margins'), (4.0, 'measurement alternative'), (4.0, 'google play'), (4.0, 'fair value'), (4.0, 'december 31'), (4.0, 'carried either'), (1.0, 'u'), (1.0, 'trends'), (1.0, 'simplified'), (1.0, 'non'), (1.0, 'growth'), (1.0, 'expect'), (1.0, 'continue'), (1.0, 'accounted'), (1.0, '2019')]","[(15.333333333333332, 'foreign currency gains related'), (13.333333333333332, 'use foreign currency forwards'), (9.833333333333332, 'foreign currency collars'), (9.0, 'debt security portfolio'), (8.5, 'option strategy comprised'), (5.0, 'forwards offset'), (4.5, 'use value'), (4.5, 'option contracts'), (4.5, 'including collars'), (4.0, 'written options'), (4.0, 'potential effect'), (4.0, 'interest rates'), (3.5, 'forecasted u'), (3.5, 'dollar weakens'), (1.5, 'value'), (1.5, 'u'), (1.5, 'dollar'), (1.0, 'var'), (1.0, 'risk'), (1.0, 'purchased'), (1.0, 'protect'), (1.0, 'losses'), (1.0, 'fluctuations'), (1.0, 'earnings'), (1.0, 'determine'), (1.0, 'combination'), (1.0, 'analysis')]","[(23.333333333333336, 'income tax audits primarily arises'), (9.333333333333334, 'tax rate applied'), (9.0, 'bring new discoveries'), (8.666666666666666, 'clinical development support'), (8.5, 'abbvie provides scientific'), (8.166666666666666, 'early drug development'), (5.333333333333334, 'tax treatment'), (4.666666666666666, 'development facility'), (4.5, 'scientific expertise'), (4.5, 'drug discovery'), (4.0, 'subject matter'), (4.0, 'commercial expertise'), (4.0, 'class research'), (1.0, 'world'), (1.0, 'used'), (1.0, 'services'), (1.0, 'sale'), (1.0, 'products'), (1.0, 'non'), (1.0, 'market'), (1.0, 'jurisdictions'), (1.0, 'focus'), (1.0, 'establish'), (1.0, 'disputes'), (1.0, 'calico')]","[(16.0, 'quarter ended december 31'), (16.0, 'new erp system continues'), (9.0, 'evaluate quarterly whether'), (4.0, 'reasonably likely'), (4.0, 'phased implementation'), (4.0, 'materially affected'), (4.0, 'materially affect'), (4.0, 'financial reporting'), (4.0, 'financial reporting'), (4.0, 'could result'), (3.3333333333333335, 'internal control'), (3.3333333333333335, 'internal control'), (3.25, 'changes occur'), (1.6666666666666667, 'internal'), (1.6666666666666667, 'control'), (1.25, 'changes'), (1.25, 'changes'), (1.25, 'changes'), (1.0, 'turn'), (1.0, 'processes'), (1.0, 'procedures'), (1.0, 'change'), (1.0, '2019')]"
Alphabet Inc.,2018,"[(9.0, 'propelling new ideas'), (4.0, 'various stages'), (4.0, 'term success'), (4.0, 'shy away'), (4.0, 'reward projects'), (4.0, 'powerful equalizers'), (4.0, 'people forward'), (4.0, 'google ceo'), (4.0, 'emerging businesses'), (4.0, 'beginning stages'), (3.5, 'development phase'), (1.5, 'development'), (1.0, 'worlds'), (1.0, 'risk'), (1.0, 'research'), (1.0, 'ranging'), (1.0, 'one'), (1.0, 'long'), (1.0, 'key'), (1.0, 'internet'), (1.0, 'high'), (1.0, 'high'), (1.0, 'commercialization'), (1.0, 'capable'), (1.0, 'bets'), (1.0, 'believe')]","[(43.5, 'class c capital stock may fluctuate widely'), (6.5, 'common stock'), (4.0, 'various risks'), (4.0, 'various factors'), (4.0, 'trading price'), (4.0, 'financial results'), (4.0, 'exchange rates'), (4.0, 'class'), (3.5, 'including fluctuations'), (1.5, 'including'), (1.0, 'uncertainties'), (1.0, 'subject'), (1.0, 'response'), (1.0, 'regulations'), (1.0, 'operations'), (1.0, 'limited'), (1.0, 'likely'), (1.0, 'laws'), (1.0, 'increase'), (1.0, 'high'), (1.0, 'future'), (1.0, 'described'), (1.0, 'costs'), (1.0, 'compliance')]","[(9.0, 'unresolved staff comments'), (4.0, 'please submit'), (3.5, 'item 1b'), (1.5, 'item'), (1.0, 'unresolvement'), (1.0, 'resolved'), (1.0, 'issues'), (1.0, 'issues'), (1.0, 'end'), (1.0, 'editor'), (1.0, 'comment'), (1.0, 'article'), (1.0, 'applicable'), (1.0, 'applicable'), (1.0, 'applicable')]","[(9.0, 'leases data centers'), (9.0, 'development sites around'), (4.0, 'south america'), (4.0, 'north america'), (4.0, 'mountain view'), (4.0, 'lease office'), (4.0, 'good condition'), (4.0, 'existing facilities'), (4.0, 'company owns'), (4.0, 'building space'), (1.0, 'world'), (1.0, 'suitable'), (1.0, 'research'), (1.0, 'owned'), (1.0, 'located'), (1.0, 'leased'), (1.0, 'headquarters'), (1.0, 'europe'), (1.0, 'conduct'), (1.0, 'california'), (1.0, 'business'), (1.0, 'believe'), (1.0, 'asia')]","[(25.0, 'please see note 9 commitments'), (14.666666666666666, 'material pending legal proceedings'), (14.5, 'consolidated financial statements included'), (7.833333333333333, 'form form 10'), (5.166666666666666, 'form 10'), (4.666666666666666, 'legal matters'), (4.666666666666666, 'legal matters'), (4.0, 'item 8'), (4.0, 'item 8'), (4.0, 'item 3'), (4.0, 'incorporated herein'), (3.666666666666667, 'annual report'), (3.666666666666667, 'annual report'), (2.5, 'included'), (1.6666666666666667, 'report'), (1.0, 'reference'), (1.0, 'notes'), (1.0, 'k'), (1.0, 'k'), (1.0, 'description'), (1.0, 'contingencies')]","[(16.0, 'class c capital stock'), (9.0, 'suggest future performance'), (9.0, 'privately negotiated transactions'), (8.5, 'open market purchases'), (4.5, 'market conditions'), (4.0, 'returns shown'), (4.0, 'january 2018'), (4.0, 'investment opportunities'), (4.0, 'historical results'), (4.0, 'general business'), (4.0, 'alphabet authorized'), (4.0, '6 billion'), (1.0, 'time'), (1.0, 'time'), (1.0, 'subject'), (1.0, 'repurchases'), (1.0, 'repurchase'), (1.0, 'intended'), (1.0, 'executed'), (1.0, 'directors'), (1.0, 'company'), (1.0, 'board'), (1.0, 'based'), (1.0, '8')]","[(15.0, 'accrued performance fees related'), (9.0, 'traditional adsense businesses'), (9.0, 'programmatic advertising buying'), (5.0, 'related costs'), (4.0, 'primarily due'), (4.0, 'largely resulting'), (4.0, 'including sbc'), (4.0, 'equity securities'), (4.0, 'compensation expenses'), (4.0, '660 million'), (1.0, 'strength'), (1.0, 'offset'), (1.0, 'increase'), (1.0, 'increase'), (1.0, 'growth'), (1.0, 'gains'), (1.0, 'facilities'), (1.0, 'driven'), (1.0, 'decline'), (1.0, 'admob'), (1.0, '1')]","[(23.0, 'foreign currency spot rate changes'), (16.0, 'readily determinable market values'), (15.0, 'use foreign currency forwards'), (14.5, 'foreign currency gains related'), (10.5, 'foreign currency collars'), (9.0, 'fair value based'), (8.5, 'option strategy comprised'), (8.5, 'marketable equity securities'), (5.0, 'forwards offset'), (4.5, 'option contracts'), (4.5, 'including collars'), (4.5, 'equity method'), (4.0, 'written options'), (4.0, 'alphabet inc'), (3.5, 'forecasted u'), (3.5, 'dollar weakens'), (2.5, 'gains'), (1.5, 'u'), (1.5, 'dollar'), (1.0, 'reflects'), (1.0, 'record'), (1.0, 'purchased'), (1.0, 'protect'), (1.0, 'losses'), (1.0, 'losses'), (1.0, 'k'), (1.0, 'earnings'), (1.0, 'component'), (1.0, 'combination'), (1.0, 'aoci'), (1.0, 'accounted')]","[(25.0, 'state net operating loss carryforwards'), (15.5, 'cash flow hedge included'), (9.5, 'hedge effective assessment'), (9.0, 'income tax purposes'), (9.0, 'bring new discoveries'), (8.666666666666666, 'clinical development support'), (8.5, 'abbvie provides scientific'), (8.333333333333334, '9 billion respectively'), (8.166666666666666, 'early drug development'), (4.666666666666666, 'development facility'), (4.5, 'scientific expertise'), (4.5, 'drug discovery'), (4.333333333333334, '5 billion'), (4.0, 'december 31'), (4.0, 'commercial expertise'), (4.0, 'class research'), (3.8333333333333335, '3 billion'), (1.5, '3'), (1.0, 'world'), (1.0, 'used'), (1.0, 'reflect'), (1.0, 'market'), (1.0, 'losses'), (1.0, 'gains'), (1.0, 'focus'), (1.0, 'federal'), (1.0, 'establish'), (1.0, 'component'), (1.0, 'calico'), (1.0, 'approximately'), (1.0, 'aoci'), (1.0, '2018'), (1.0, '2'), (1.0, '1')]","[(16.0, 'quarter ended december 31'), (12.666666666666668, 'maintaining adequate internal control'), (4.666666666666667, 'internal control'), (4.0, 'rule 13a'), (4.0, 'reasonably likely'), (4.0, 'materially affected'), (4.0, 'materially affect'), (4.0, 'financial reporting'), (4.0, 'financial reporting'), (4.0, 'financial reporting'), (4.0, 'exchange act'), (2.3333333333333335, 'internal'), (2.3333333333333335, 'control'), (1.0, 'responsible'), (1.0, 'occurred'), (1.0, 'management'), (1.0, 'f'), (1.0, 'establishing'), (1.0, 'defined'), (1.0, 'changes'), (1.0, '2018'), (1.0, '15')]"
Microsoft Corporation,2021,"[(23.0, 'worlds largest corporate research organizations'), (9.0, 'top universities around'), (9.0, 'third party relating'), (9.0, 'chief executive officer'), (5.0, 'microsoft research'), (5.0, 'continuing research'), (4.0, 'single license'), (4.0, 'satya nadella'), (4.0, 'materially dependent'), (4.0, 'computer science'), (4.0, 'close collaboration'), (4.0, 'broad range'), (3.5, 'product development'), (1.5, 'development'), (1.0, 'world'), (1.0, 'works'), (1.0, 'state'), (1.0, 'products'), (1.0, 'one'), (1.0, 'disciplines'), (1.0, 'chairman'), (1.0, 'board'), (1.0, 'believe'), (1.0, 'art'), (1.0, 'agreement'), (1.0, 'advance')]","[(25.0, 'companies like us whose business'), (15.5, 'competition rules may limit'), (9.5, 'ai may result'), (9.0, 'regulatory activity relating'), (8.0, 'providing technology products'), (4.0, 'significant challenge'), (4.0, 'security threats'), (4.0, 'reputational harm'), (4.0, 'government litigation'), (2.0, 'products'), (1.0, 'use'), (1.0, 'services'), (1.0, 'others'), (1.0, 'market'), (1.0, 'liability'), (1.0, 'issues'), (1.0, 'development'), (1.0, 'design')]","[(61.0, 'written comments regarding sec reports issued 180 days'), (8.333333333333332, 'last fiscal year'), (8.333333333333332, 'fiscal year 2022'), (7.0, 'sec since'), (5.333333333333333, 'fiscal year'), (4.0, 'unresolved issues'), (4.0, 'remain unresolved'), (4.0, 'exchange commission'), (1.0, 'staff'), (1.0, 'securities'), (1.0, 'responded'), (1.0, 'made'), (1.0, 'end'), (1.0, 'end'), (1.0, 'comment')]","[(23.5, 'largest owned properties include space'), (5.5, 'facilities owned'), (4.0, 'square footage'), (4.0, 'leased domestically'), (4.0, 'june 30'), (4.0, 'following locations'), (4.0, 'corporate headquarters'), (1.0, 'washington'), (1.0, 'table'), (1.0, 'summary'), (1.0, 'singapore'), (1.0, 'shows'), (1.0, 'redmond'), (1.0, 'office'), (1.0, 'netherlands'), (1.0, 'located'), (1.0, 'ireland'), (1.0, 'internationally'), (1.0, 'india'), (1.0, 'datacenter'), (1.0, 'china'), (1.0, '2022')]","[(13.333333333333332, 'information regarding legal proceedings'), (9.0, 'note 15 contingencies'), (5.333333333333333, 'legal proceedings'), (5.333333333333333, 'legal proceedings'), (4.0, 'part ii'), (4.0, 'item 8'), (4.0, 'form 10'), (4.0, 'financial statements'), (1.0, 'referred'), (1.0, 'refer'), (1.0, 'notes'), (1.0, 'k'), (1.0, 'involved'), (1.0, 'involved'), (1.0, 'company')]","[(25.0, 'settle employee tax withholding related'), (14.5, 'table excludes shares repurchased'), (9.5, 'following table includes'), (9.0, 'publicly announced plans'), (9.0, 'fiscal year 2022'), (5.0, 'shares purchased'), (4.0, 'stock awards'), (4.0, 'share repurchases'), (4.0, 'fourth quarter'), (4.0, 'company returned'), (4.0, '4 billion'), (1.0, 'vesting'), (1.0, 'shareholders'), (1.0, 'programs'), (1.0, 'part'), (1.0, 'number'), (1.0, 'form'), (1.0, 'dividends'), (1.0, '12')]","[(22.0, 'cloud services revenue increased 11'), (11.0, 'surface revenue increased'), (10.0, 'intelligent cloud segment'), (9.0, 'windows commercial products'), (8.0, 'fiscal year 2022'), (4.0, 'third quarter'), (4.0, 'june 30'), (4.0, '226 million'), (3.666666666666667, 'microsoft completed'), (3.666666666666667, 'microsoft 365'), (2.0, '2022'), (1.6666666666666667, 'microsoft'), (1.0, 'respectively'), (1.0, 'reported'), (1.0, 'part'), (1.0, 'nuance'), (1.0, 'nuance'), (1.0, 'driven'), (1.0, 'demand'), (1.0, 'acquisition'), (1.0, '3'), (1.0, '2021')]","[(16.0, 'following table sets forth'), (9.0, 'including associated derivatives'), (8.666666666666666, 'relevant market rates'), (8.666666666666666, 'foreign exchange rates'), (8.333333333333334, 'risk categories include'), (4.666666666666666, 'interest rates'), (4.333333333333334, 'economic risk'), (4.333333333333334, 'credit risk'), (4.0, 'potential loss'), (4.0, 'japanese yen'), (4.0, 'hypothetical changes'), (4.0, 'future earnings'), (4.0, 'fair values'), (4.0, 'canadian dollar'), (4.0, 'british pound'), (4.0, 'australian dollar'), (3.5, 'equity prices'), (1.5, 'prices'), (1.0, 'resulting'), (1.0, 'millions'), (1.0, 'exposed'), (1.0, 'euro')]","[(16.0, 'employees may purchase shares'), (9.0, 'intelligent cloud segment'), (9.0, 'fiscal years 2022'), (4.0, 'primarily attributed'), (4.0, 'offering period'), (4.0, 'material impairments'), (4.0, 'intangible assets'), (4.0, 'increased synergies'), (4.0, 'gross compensation'), (4.0, 'exceeding 15'), (1.0, 'value'), (1.0, 'nuance'), (1.0, 'integration'), (1.0, 'identified'), (1.0, 'goodwill'), (1.0, 'expected'), (1.0, 'assigned'), (1.0, 'achieved'), (1.0, '2021'), (1.0, '2020')]","[(25.0, 'provide reasonable assurance regarding reliability'), (16.0, 'year ended june 30'), (16.0, 'report dated july 28'), (16.0, 'del touche touche llp'), (11.833333333333332, 'internal control integrated framework'), (8.5, 'consolidated financial statements'), (7.833333333333334, 'financial reporting based'), (5.333333333333333, 'internal control'), (5.333333333333333, 'internal control'), (4.833333333333334, 'financial reporting'), (4.833333333333334, 'financial reporting'), (4.0, 'sponsoring organizations'), (4.0, 'process designed'), (4.0, 'management conducted'), (2.5, 'framework'), (1.0, 'microsoft'), (1.0, 'issued'), (1.0, 'evaluation'), (1.0, 'effectiveness'), (1.0, 'company'), (1.0, 'committee'), (1.0, 'audited'), (1.0, '2022'), (1.0, '2022'), (1.0, '2013')]"
Microsoft Corporation,2020,"[(23.5, 'worlds largest corporate research organizations'), (12.5, 'appointed executive vice president'), (6.0, 'executive vice'), (5.0, 'microsoft research'), (4.0, 'top universities'), (4.0, 'november 2014'), (4.0, 'mr hogan'), (4.0, 'human resources'), (4.0, 'general counsel'), (4.0, 'close collaboration'), (2.5, 'president'), (1.5, 'microsoft'), (1.0, 'works'), (1.0, 'well'), (1.0, 'supporting'), (1.0, 'served'), (1.0, 'secretary'), (1.0, 'safety'), (1.0, 'one'), (1.0, 'employees'), (1.0, 'committed'), (1.0, '2015'), (1.0, '2011')]","[(16.0, 'events could negatively impact'), (15.5, 'competition rules may limit'), (9.5, 'regulators may assert'), (9.0, 'regulatory activity relating'), (4.0, 'financial condition'), (1.0, 'use'), (1.0, 'results'), (1.0, 'reputation'), (1.0, 'regulations'), (1.0, 'products'), (1.0, 'operations'), (1.0, 'market'), (1.0, 'management'), (1.0, 'legal'), (1.0, 'laws'), (1.0, 'inconsistent'), (1.0, 'design'), (1.0, 'data'), (1.0, 'customer'), (1.0, 'collection')]","[(29.333333333333332, 'written comments regarding reports issued 180 days'), (9.0, 'written comments'), (9.0, 'fiscal year 2021'), (9.0, 'fiscal year 2019'), (7.833333333333334, 'issued 180'), (6.5, 'sec regarding'), (4.0, 'reports'), (4.0, 'remain unresolved'), (4.0, 'exchange commission'), (4.0, 'days'), (3.3333333333333335, 'issued'), (1.0, 'staff'), (1.0, 'staff'), (1.0, 'securities'), (1.0, 'responded'), (1.0, 'prior'), (1.0, 'issues'), (1.0, 'end'), (1.0, 'end')]","[(24.0, 'largest owned properties include space'), (10.0, 'datacenter facilities owned'), (8.0, 'lease facilities internationally'), (4.0, 'square footage'), (4.0, 'south korea'), (4.0, 'leased domestically'), (4.0, 'june 30'), (4.0, 'following locations'), (4.0, 'corporate headquarters'), (2.0, 'internationally'), (1.0, 'washington'), (1.0, 'table'), (1.0, 'summary'), (1.0, 'singapore'), (1.0, 'shows'), (1.0, 'research'), (1.0, 'redmond'), (1.0, 'operations'), (1.0, 'office'), (1.0, 'netherlands'), (1.0, 'located'), (1.0, 'ireland'), (1.0, 'india'), (1.0, 'development'), (1.0, 'datacenters'), (1.0, 'china'), (1.0, 'also'), (1.0, '2021')]","[(16.0, 'companys antitrust compliance office'), (15.0, 'united states district court'), (9.0, 'make annual reports'), (9.0, 'ballmer et al'), (7.666666666666667, 'final order expired'), (5.0, 'western district'), (4.666666666666667, 'final order'), (4.666666666666667, 'final order'), (4.0, 'general activities'), (4.0, 'barovic v'), (1.0, 'washington'), (1.0, 'required'), (1.0, 'required'), (1.0, 'judgment'), (1.0, 'company'), (1.0, 'april'), (1.0, '2021')]","[(25.0, 'settle employee tax withholding related'), (16.0, 'table excludes shares repurchased'), (9.0, 'fiscal year 2021'), (8.333333333333334, 'nasdaq stock market'), (4.333333333333334, 'stock awards'), (4.333333333333334, 'common stock'), (4.0, 'symbol msft'), (4.0, 'share repurchases'), (4.0, 'microsoft returned'), (4.0, 'fourth quarter'), (4.0, '4 billion'), (1.0, 'vesting'), (1.0, 'traded'), (1.0, 'shareholders'), (1.0, 'form'), (1.0, 'dividends'), (1.0, '10')]","[(21.5, 'microsoft 365 consumer subscription revenue'), (16.0, 'cloud services revenue increased'), (15.5, 'strong prior year comparable'), (10.0, 'office consumer products'), (10.0, 'internal revenue service'), (9.5, 'fiscal year 2011'), (9.0, 'tax years 2004'), (9.0, 'acquire nuance communications'), (5.5, 'microsoft settled'), (4.0, 'transactional strength'), (4.0, 'definitive agreement'), (4.0, 'april 11'), (4.0, '474 million'), (4.0, '0 billion'), (1.0, 'portion'), (1.0, 'japan'), (1.0, 'irs'), (1.0, 'inc'), (1.0, 'entered'), (1.0, 'driven'), (1.0, 'benefited'), (1.0, 'audit'), (1.0, '2021'), (1.0, '2006'), (1.0, '13'), (1.0, '10')]","[(16.0, 'following table sets forth'), (14.666666666666666, 'risk categorieshypothetical changejune 30'), (9.0, 'including associated derivatives'), (8.666666666666666, 'relevant market rates'), (8.666666666666666, 'foreign exchange rates'), (4.666666666666666, 'interest rates'), (4.666666666666666, 'economic risk'), (4.666666666666666, 'credit risk'), (4.0, 'potential loss'), (4.0, 'hypothetical changes'), (4.0, 'future earnings'), (4.0, 'fair values'), (3.5, 'equity prices'), (1.5, 'prices'), (1.0, 'resulting'), (1.0, 'millions'), (1.0, 'impact'), (1.0, 'exposed')]","[(16.0, 'filed supplemental expert evidence'), (13.666666666666666, 'consolidated financial statements since'), (5.666666666666666, 'financial statements'), (4.666666666666666, 'financial results'), (1.0, 'strike'), (1.0, 'resolution'), (1.0, 'portions'), (1.0, 'plaintiffs'), (1.0, 'moved'), (1.0, 'material'), (1.0, 'included'), (1.0, 'github'), (1.0, 'expected'), (1.0, 'defendants'), (1.0, 'date'), (1.0, 'audits'), (1.0, 'acquisition')]","[(13.5, 'maintaining effective internal control'), (13.5, 'internal control integrated framework'), (9.0, 'deloitte touche llp'), (8.0, 'financial reporting based'), (5.5, 'internal control'), (5.0, 'financial reporting'), (4.0, 'treadway commission'), (4.0, 'sponsoring organizations'), (4.0, 'june 30'), (4.0, 'item 9a'), (4.0, 'criteria established'), (3.5, 'management conducted'), (2.75, 'internal'), (2.75, 'control'), (1.5, 'management'), (1.0, 'responsible'), (1.0, 'report'), (1.0, 'issued'), (1.0, 'included'), (1.0, 'evaluation'), (1.0, 'effectiveness'), (1.0, 'company'), (1.0, 'committee'), (1.0, 'audited'), (1.0, '2021'), (1.0, '2013')]"
Microsoft Corporation,2019,"[(23.0, 'worlds largest corporate research organizations'), (9.0, 'top universities around'), (5.0, 'microsoft research'), (5.0, 'continuing research'), (4.0, 'single license'), (4.0, 'party retailers'), (4.0, 'materially dependent'), (4.0, 'computer science'), (4.0, 'close collaboration'), (4.0, 'broad range'), (4.0, 'agreement relating'), (3.5, 'product development'), (1.5, 'development'), (1.0, 'world'), (1.0, 'works'), (1.0, 'third'), (1.0, 'state'), (1.0, 'products'), (1.0, 'one'), (1.0, 'distribute'), (1.0, 'disciplines'), (1.0, 'devices'), (1.0, 'believe'), (1.0, 'art'), (1.0, 'advance')]","[(25.0, 'reduced future cash flow estimates'), (16.0, 'services contain valuable information'), (15.0, 'amortizable intangible assets may'), (9.0, 'slower growth rates'), (5.0, 'may indicate'), (4.0, 'technical measures'), (4.0, 'stock price'), (4.0, 'recoverable include'), (4.0, 'microsoft products'), (4.0, 'market capitalization'), (4.0, 'industry segments'), (4.0, 'contractual restrictions'), (4.0, 'content protected'), (4.0, 'carrying value'), (1.0, 'participate'), (1.0, 'goodwill'), (1.0, 'factors'), (1.0, 'decline')]","[(29.333333333333332, 'written comments regarding reports issued 180 days'), (9.0, 'written comments'), (8.0, 'fiscal year 2020'), (7.833333333333334, 'issued 180'), (6.5, 'sec regarding'), (5.0, 'fiscal year'), (4.0, 'reports'), (4.0, 'remain unresolved'), (4.0, 'exchange commission'), (4.0, 'days'), (3.3333333333333335, 'issued'), (1.0, 'staff'), (1.0, 'staff'), (1.0, 'securities'), (1.0, 'responded'), (1.0, 'prior'), (1.0, 'issues'), (1.0, 'end'), (1.0, 'end')]","[(15.0, 'largest owned properties include'), (5.0, 'facilities owned'), (4.0, 'square footage'), (4.0, 'leased domestically'), (4.0, 'june 30'), (4.0, 'development centers'), (1.0, 'table'), (1.0, 'summary'), (1.0, 'singapore'), (1.0, 'shows'), (1.0, 'retail'), (1.0, 'research'), (1.0, 'office'), (1.0, 'netherlands'), (1.0, 'ireland'), (1.0, 'internationally'), (1.0, 'india'), (1.0, 'datacenters'), (1.0, 'datacenter'), (1.0, 'china'), (1.0, '2020')]","[(16.0, 'information regarding legal proceedings'), (16.0, 'companys antitrust compliance office'), (15.0, 'united states district court'), (9.0, 'note 15 contingencies'), (9.0, 'following annual report'), (9.0, 'ballmer et al'), (5.0, 'western district'), (4.0, 'part ii'), (4.0, 'item 8'), (4.0, 'general activities'), (4.0, 'form 10'), (4.0, 'financial statements'), (4.0, 'final order'), (4.0, 'final order'), (4.0, 'company makes'), (4.0, 'barovic v'), (1.0, 'washington'), (1.0, 'required'), (1.0, 'refer'), (1.0, 'notes'), (1.0, 'k'), (1.0, 'judgment'), (1.0, 'involved')]","[(8.0, 'fiscal year 2020'), (4.0, 'share repurchases'), (4.0, 'june 17'), (4.0, 'fourth quarter'), (4.0, 'directors declared'), (4.0, '9 billion'), (4.0, '2020september 10'), (4.0, '2020august 20'), (3.5, 'following dividends'), (2.0, '2020'), (1.5, 'dividends'), (1.0, 'shareholders'), (1.0, 'returned'), (1.0, 'form'), (1.0, 'board'), (1.0, '861'), (1.0, '8'), (1.0, '51'), (1.0, '3'), (1.0, '0')]","[(59.0, 'xbox hardware revenue declined 31 %, primarily due'), (11.5, '15 %, driven'), (10.5, 'microsoft revenue increased'), (9.0, 'consolidated financial statements'), (4.0, 'office commercial'), (4.0, 'net income'), (4.0, 'microsoft paid'), (4.0, 'income taxes'), (4.0, 'consoles sold'), (4.0, '5 billion'), (4.0, '1 billion'), (4.0, '0 billion'), (3.5, '2 billion'), (2.0, 'microsoft'), (1.5, '2'), (1.0, 'volume'), (1.0, 'resolution'), (1.0, 'purchase'), (1.0, 'price'), (1.0, 'material'), (1.0, 'linkedin'), (1.0, 'investing'), (1.0, 'growth'), (1.0, 'facilitate'), (1.0, 'expected'), (1.0, 'decrease'), (1.0, 'components'), (1.0, 'audits'), (1.0, '7'), (1.0, '24'), (1.0, '133')]","[(16.0, 'following table sets forth'), (14.666666666666666, 'risk categorieshypothetical changejune 30'), (9.0, 'including associated derivatives'), (8.666666666666666, 'relevant market rates'), (8.666666666666666, 'foreign exchange rates'), (4.666666666666666, 'interest rates'), (4.666666666666666, 'economic risk'), (4.666666666666666, 'credit risk'), (4.0, 'potential loss'), (4.0, 'hypothetical changes'), (4.0, 'future earnings'), (4.0, 'fair values'), (3.5, 'equity prices'), (1.5, 'prices'), (1.0, 'resulting'), (1.0, 'millions'), (1.0, 'impact'), (1.0, 'exposed')]","[(15.0, 'consolidated financial statements since'), (9.0, 'record receivable related'), (9.0, 'amortization period would'), (5.0, 'financial results'), (4.0, 'revenue recognized'), (4.0, 'premises licenses'), (4.0, 'practical expedient'), (3.5, 'one year'), (3.5, 'expense costs'), (1.5, 'year'), (1.5, 'costs'), (1.0, 'obtain'), (1.0, 'multi'), (1.0, 'less'), (1.0, 'incurred'), (1.0, 'included'), (1.0, 'github'), (1.0, 'date'), (1.0, 'customer'), (1.0, 'contract'), (1.0, 'apply'), (1.0, 'acquisition')]","[(15.5, 'deloite touches llp believes'), (13.666666666666666, 'maintaining effective internal control'), (9.5, 'deloitte touche llp'), (5.666666666666666, 'internal control'), (4.666666666666666, 'internal controls'), (4.0, 'reasonable basis'), (4.0, 'june 30'), (4.0, 'item 9a'), (4.0, 'financial reporting'), (4.0, 'audit provides'), (3.5, 'management conducted'), (1.5, 'management'), (1.0, 'responsible'), (1.0, 'report'), (1.0, 'procedures'), (1.0, 'opinion'), (1.0, 'included'), (1.0, 'evaluation'), (1.0, 'effectiveness'), (1.0, 'company'), (1.0, 'audited'), (1.0, '2020')]"
Microsoft Corporation,2018,"[(23.0, 'worlds largest corporate research organizations'), (9.0, 'top universities around'), (8.5, 'microsoft research works'), (5.5, 'microsoft research'), (5.0, 'continuing research'), (4.0, 'single license'), (4.0, 'party retailers'), (4.0, 'materially dependent'), (4.0, 'computer science'), (4.0, 'close collaboration'), (4.0, 'broad range'), (4.0, 'agreement relating'), (3.5, 'product development'), (1.5, 'development'), (1.0, 'world'), (1.0, 'third'), (1.0, 'state'), (1.0, 'products'), (1.0, 'one'), (1.0, 'distribute'), (1.0, 'disciplines'), (1.0, 'devices'), (1.0, 'believe'), (1.0, 'art'), (1.0, 'advance')]","[(23.5, 'catastrophic event could cause delays'), (14.5, 'amortizable intangible assets may'), (5.5, 'weather event'), (4.0, 'various risks'), (4.0, 'terrorist attack'), (4.0, 'stock price'), (4.0, 'market capitalization'), (4.0, 'major earthquake'), (4.0, 'financial results'), (4.0, 'completing sales'), (4.0, 'carrying value'), (2.5, 'may'), (1.0, 'uncertainties'), (1.0, 'systems'), (1.0, 'subject'), (1.0, 'recoverable'), (1.0, 'operations'), (1.0, 'operations'), (1.0, 'indicating'), (1.0, 'including'), (1.0, 'include'), (1.0, 'goodwill'), (1.0, 'failure'), (1.0, 'factors'), (1.0, 'disruption'), (1.0, 'described'), (1.0, 'decline'), (1.0, 'cyberattack'), (1.0, 'circumstances'), (1.0, 'change')]","[(38.166666666666664, 'written comments regarding reports issued 180 days'), (9.666666666666668, 'sec staff regarding'), (9.0, 'fiscal year 2019'), (8.166666666666666, 'written comments'), (5.666666666666666, 'written comment'), (4.0, 'remain unresolved'), (4.0, 'issued'), (4.0, 'exchange commission'), (3.5, 'unresolved issues'), (1.6666666666666667, 'staff'), (1.6666666666666667, 'staff'), (1.5, 'issues'), (1.0, 'securities'), (1.0, 'received'), (1.0, 'prior'), (1.0, 'end'), (1.0, 'commented')]","[(7.5, 'lease facilities internationally'), (4.5, 'facilities owned'), (4.0, 'united kingdom'), (4.0, 'square footage'), (4.0, 'leased domestically'), (4.0, 'june 30'), (4.0, 'include space'), (2.0, 'internationally'), (1.0, 'table'), (1.0, 'summary'), (1.0, 'shows'), (1.0, 'retail'), (1.0, 'office'), (1.0, 'japan'), (1.0, 'india'), (1.0, 'germany'), (1.0, 'datacenter'), (1.0, 'china'), (1.0, 'canada'), (1.0, 'australia'), (1.0, 'also'), (1.0, '2019')]","[(16.0, 'companys antitrust compliance office'), (15.0, 'united states district court'), (9.0, 'ballmer et al'), (8.5, 'following annual report'), (5.0, 'western district'), (4.5, 'annual reports'), (4.0, 'general activities'), (4.0, 'final order'), (4.0, 'final order'), (4.0, 'company makes'), (4.0, 'barovic v'), (1.0, 'washington'), (1.0, 'required'), (1.0, 'judgment'), (1.0, 'continue'), (1.0, '2020')]","[(25.0, 'settle employee tax withholding related'), (16.0, 'table excludes shares repurchased'), (9.0, 'fiscal year 2019'), (8.333333333333334, 'nasdaq stock market'), (4.333333333333334, 'stock awards'), (4.333333333333334, 'common stock'), (4.0, 'symbol msft'), (4.0, 'share repurchases'), (4.0, 'microsoft returned'), (4.0, 'fourth quarter'), (3.5, '7 billion'), (1.5, '7'), (1.0, 'vesting'), (1.0, 'traded'), (1.0, 'shareholders'), (1.0, 'form'), (1.0, 'dividends')]","[(19.666666666666668, 'linkedin revenue increased 28 %,'), (16.0, 'business processes revenue increased'), (10.0, 'linkedin expenses increased'), (9.666666666666666, '20 %, mainly'), (9.666666666666666, '15 %, driven'), (9.333333333333334, 'services revenue growth'), (9.0, 'party title strength'), (8.333333333333334, 'linkedin sessions growth'), (4.0, 'xbox software'), (4.0, 'record levels'), (4.0, 'office commercial'), (4.0, 'engagement highlighted'), (4.0, '9 billion'), (4.0, '762 million'), (4.0, '27 %.'), (3.5, '1 billion'), (3.0, 'linkedin'), (2.3333333333333335, 'growth'), (1.5, '1'), (1.0, 'third'), (1.0, 'productivity'), (1.0, '6')]","[(16.0, 'following table sets forth'), (9.0, 'use derivatives instruments'), (9.0, 'may still impact'), (9.0, 'fair values resulting'), (9.0, 'consolidated financial statements'), (8.666666666666666, 'relevant market rates'), (8.666666666666666, 'foreign exchange rates'), (4.666666666666666, 'interest rates'), (4.0, 'potential loss'), (4.0, 'hypothetical changes'), (4.0, 'future earnings'), (4.0, 'economic risk'), (4.0, 'credit risk'), (3.5, 'equity prices'), (1.5, 'prices'), (1.0, 'risks'), (1.0, 'manage'), (1.0, 'however'), (1.0, 'exposed')]","[(13.666666666666666, 'consolidated financial statements since'), (8.5, 'deferred tax assets'), (5.666666666666666, 'financial statements'), (4.666666666666666, 'financial results'), (4.5, 'tax benefit'), (4.0, 'valuation allowance'), (4.0, 'reported net'), (4.0, 'eligible employees'), (1.0, 'resolution'), (1.0, 'realized'), (1.0, 'material'), (1.0, 'likely'), (1.0, 'included'), (1.0, 'github'), (1.0, 'github'), (1.0, 'expected'), (1.0, 'espp'), (1.0, 'date'), (1.0, 'audits'), (1.0, 'acquisition')]","[(16.0, 'accounting principles generally accepted'), (15.0, 'provide reasonable assurance regarding'), (13.5, 'consolidated financial statements would'), (10.0, 'provide absolute assurance'), (9.0, 'deloitte touche llp'), (5.5, 'financial statements'), (4.5, 'financial reporting'), (4.5, 'financial reporting'), (4.0, 'united states'), (4.0, 'june 30'), (4.0, 'internal control'), (4.0, 'internal control'), (4.0, 'internal control'), (4.0, 'external purposes'), (1.0, 'reliability'), (1.0, 'prevented'), (1.0, 'preparation'), (1.0, 'misstatement'), (1.0, 'intended'), (1.0, 'detected'), (1.0, 'designed'), (1.0, 'company'), (1.0, 'audited'), (1.0, 'america'), (1.0, 'accordance'), (1.0, '2019')]"
Microsoft Corporation,2017,"[(23.0, 'worlds largest corporate research organizations'), (9.0, 'top universities around'), (8.5, 'microsoft research works'), (5.5, 'microsoft research'), (5.0, 'continuing research'), (4.0, 'single license'), (4.0, 'party retailers'), (4.0, 'materially dependent'), (4.0, 'computer science'), (4.0, 'close collaboration'), (4.0, 'broad range'), (4.0, 'agreement relating'), (3.5, 'product development'), (1.5, 'development'), (1.0, 'world'), (1.0, 'third'), (1.0, 'state'), (1.0, 'products'), (1.0, 'one'), (1.0, 'distribute'), (1.0, 'disciplines'), (1.0, 'devices'), (1.0, 'believe'), (1.0, 'art'), (1.0, 'advance')]","[(23.5, 'catastrophic event could cause delays'), (14.5, 'amortizable intangible assets may'), (5.5, 'weather event'), (4.0, 'various risks'), (4.0, 'terrorist attack'), (4.0, 'stock price'), (4.0, 'market capitalization'), (4.0, 'major earthquake'), (4.0, 'financial results'), (4.0, 'completing sales'), (4.0, 'carrying value'), (2.5, 'may'), (1.0, 'uncertainties'), (1.0, 'systems'), (1.0, 'subject'), (1.0, 'recoverable'), (1.0, 'operations'), (1.0, 'operations'), (1.0, 'indicating'), (1.0, 'including'), (1.0, 'include'), (1.0, 'goodwill'), (1.0, 'failure'), (1.0, 'factors'), (1.0, 'disruption'), (1.0, 'described'), (1.0, 'decline'), (1.0, 'cyberattack'), (1.0, 'circumstances'), (1.0, 'change')]","[(38.166666666666664, 'written comments regarding reports issued 180 days'), (9.666666666666668, 'sec staff regarding'), (9.0, 'fiscal year 2019'), (8.166666666666666, 'written comments'), (5.666666666666666, 'written comment'), (4.0, 'remain unresolved'), (4.0, 'issued'), (4.0, 'exchange commission'), (3.5, 'unresolved issues'), (1.6666666666666667, 'staff'), (1.6666666666666667, 'staff'), (1.5, 'issues'), (1.0, 'securities'), (1.0, 'received'), (1.0, 'prior'), (1.0, 'end'), (1.0, 'commented')]","[(7.5, 'lease facilities internationally'), (4.5, 'facilities owned'), (4.0, 'united kingdom'), (4.0, 'square footage'), (4.0, 'leased domestically'), (4.0, 'june 30'), (4.0, 'include space'), (2.0, 'internationally'), (1.0, 'table'), (1.0, 'summary'), (1.0, 'shows'), (1.0, 'retail'), (1.0, 'office'), (1.0, 'japan'), (1.0, 'india'), (1.0, 'germany'), (1.0, 'datacenter'), (1.0, 'china'), (1.0, 'canada'), (1.0, 'australia'), (1.0, 'also'), (1.0, '2019')]","[(16.0, 'companys antitrust compliance office'), (15.0, 'united states district court'), (9.0, 'ballmer et al'), (8.5, 'following annual report'), (5.0, 'western district'), (4.5, 'annual reports'), (4.0, 'general activities'), (4.0, 'final order'), (4.0, 'final order'), (4.0, 'company makes'), (4.0, 'barovic v'), (1.0, 'washington'), (1.0, 'required'), (1.0, 'judgment'), (1.0, 'continue'), (1.0, '2020')]","[(25.0, 'settle employee tax withholding related'), (16.0, 'table excludes shares repurchased'), (9.0, 'fiscal year 2019'), (8.333333333333334, 'nasdaq stock market'), (4.333333333333334, 'stock awards'), (4.333333333333334, 'common stock'), (4.0, 'symbol msft'), (4.0, 'share repurchases'), (4.0, 'microsoft returned'), (4.0, 'fourth quarter'), (3.5, '7 billion'), (1.5, '7'), (1.0, 'vesting'), (1.0, 'traded'), (1.0, 'shareholders'), (1.0, 'form'), (1.0, 'dividends')]","[(19.666666666666668, 'linkedin revenue increased 28 %,'), (16.0, 'business processes revenue increased'), (10.0, 'linkedin expenses increased'), (9.666666666666666, '20 %, mainly'), (9.666666666666666, '15 %, driven'), (9.333333333333334, 'services revenue growth'), (9.0, 'party title strength'), (8.333333333333334, 'linkedin sessions growth'), (4.0, 'xbox software'), (4.0, 'record levels'), (4.0, 'office commercial'), (4.0, 'engagement highlighted'), (4.0, '9 billion'), (4.0, '762 million'), (4.0, '27 %.'), (3.5, '1 billion'), (3.0, 'linkedin'), (2.3333333333333335, 'growth'), (1.5, '1'), (1.0, 'third'), (1.0, 'productivity'), (1.0, '6')]","[(16.0, 'following table sets forth'), (9.0, 'use derivatives instruments'), (9.0, 'may still impact'), (9.0, 'fair values resulting'), (9.0, 'consolidated financial statements'), (8.666666666666666, 'relevant market rates'), (8.666666666666666, 'foreign exchange rates'), (4.666666666666666, 'interest rates'), (4.0, 'potential loss'), (4.0, 'hypothetical changes'), (4.0, 'future earnings'), (4.0, 'economic risk'), (4.0, 'credit risk'), (3.5, 'equity prices'), (1.5, 'prices'), (1.0, 'risks'), (1.0, 'manage'), (1.0, 'however'), (1.0, 'exposed')]","[(13.666666666666666, 'consolidated financial statements since'), (8.5, 'deferred tax assets'), (5.666666666666666, 'financial statements'), (4.666666666666666, 'financial results'), (4.5, 'tax benefit'), (4.0, 'valuation allowance'), (4.0, 'reported net'), (4.0, 'eligible employees'), (1.0, 'resolution'), (1.0, 'realized'), (1.0, 'material'), (1.0, 'likely'), (1.0, 'included'), (1.0, 'github'), (1.0, 'github'), (1.0, 'expected'), (1.0, 'espp'), (1.0, 'date'), (1.0, 'audits'), (1.0, 'acquisition')]","[(16.0, 'accounting principles generally accepted'), (15.0, 'provide reasonable assurance regarding'), (13.5, 'consolidated financial statements would'), (10.0, 'provide absolute assurance'), (9.0, 'deloitte touche llp'), (5.5, 'financial statements'), (4.5, 'financial reporting'), (4.5, 'financial reporting'), (4.0, 'united states'), (4.0, 'june 30'), (4.0, 'internal control'), (4.0, 'internal control'), (4.0, 'internal control'), (4.0, 'external purposes'), (1.0, 'reliability'), (1.0, 'prevented'), (1.0, 'preparation'), (1.0, 'misstatement'), (1.0, 'intended'), (1.0, 'detected'), (1.0, 'designed'), (1.0, 'company'), (1.0, 'audited'), (1.0, 'america'), (1.0, 'accordance'), (1.0, '2019')]"
Costco,2021,"[(36.0, 'business members may add additional cardholders'), (9.0, 'annual fee applies'), (8.0, 'company operates e'), (4.0, 'information statements'), (4.0, 'file electronically'), (4.0, 'contains reports'), (4.0, 'commerce websites'), (4.0, 'affiliates ),'), (3.5, 'sec maintains'), (2.0, 'company'), (1.5, 'sec'), (1.0, 'www'), (1.0, 'u'), (1.0, 'site'), (1.0, 'proxy'), (1.0, 'org'), (1.0, 'issuers'), (1.0, 'gov'), (1.0, 'costco')]","[(33.5, 'backup systems would require significant investments'), (25.0, 'senior management could negatively impact'), (25.0, 'brand recognition could adversely affect'), (9.0, 'maintain membership growth'), (4.0, 'succession plan'), (3.5, 'systems'), (3.5, 'data centers'), (1.5, 'data'), (1.0, 'variety'), (1.0, 'u'), (1.0, 'subject'), (1.0, 'store'), (1.0, 'services'), (1.0, 'results'), (1.0, 'restore'), (1.0, 'resources'), (1.0, 'process'), (1.0, 'operations'), (1.0, 'loyalty'), (1.0, 'implement'), (1.0, 'identify'), (1.0, 'failure'), (1.0, 'failure'), (1.0, 'failure'), (1.0, 'factors'), (1.0, 'critical'), (1.0, 'collect'), (1.0, 'business')]","[(9.0, 'unresolved staff comments'), (9.0, 'unresolve staff comments'), (4.0, 'status quo'), (3.857142857142857, 'item 2b'), (3.857142857142857, 'item 1e'), (3.857142857142857, 'item 1d'), (3.857142857142857, 'item 1c'), (3.857142857142857, 'item 1b'), (3.857142857142857, 'item 1a'), (3.333333333333333, 'make changes'), (1.8571428571428572, 'item'), (1.3333333333333333, 'make'), (1.3333333333333333, 'make'), (1.0, 'happy'), (1.0, 'going'), (1.0, 'decision'), (1.0, 'clarify'), (1.0, 'change')]","[(16.0, 'total square feet associated'), (15.0, 'warehouses contained approximately 118'), (13.5, '9 million square feet'), (9.0, 'operating floor space'), (5.5, '9 million'), (5.0, 'approximately 31'), (4.5, '8 million'), (4.5, '4 million'), (4.0, 'logistics facilities'), (4.0, 'costco owns'), (3.5, '171 leases'), (1.5, 'leases'), (1.0, 'land'), (1.0, 'international'), (1.0, 'end'), (1.0, 'distribution'), (1.0, 'canada'), (1.0, 'building'), (1.0, '83'), (1.0, '2021'), (1.0, '20'), (1.0, '121')]","[(16.0, 'consolidated financial statements included'), (13.0, 'legal proceedings see discussion'), (12.566666666666666, 'item 8 includes discussion'), (5.0, 'legal proceedings'), (5.0, 'legal proceedings'), (5.0, 'legal proceedings'), (4.566666666666666, 'item 8'), (4.566666666666666, 'item 8'), (4.566666666666666, 'item 8'), (4.566666666666666, 'item 8'), (4.166666666666666, 'item 9'), (4.166666666666666, 'item 9'), (4.166666666666666, 'item 7'), (4.166666666666666, 'item 3'), (4.166666666666666, 'item 3'), (4.166666666666666, 'item 11'), (4.166666666666666, 'item 10'), (4.0, 'note 11'), (1.0, 'report')]","[(81.0, 'following graph provides information concerning average sales per warehouse'), (9.0, '10 year period'), (9.0, '000 authorization approved'), (4.0, 'september 28'), (4.0, 'repurchase program'), (4.0, 'april 2023'), (4.0, 'april 2019'), (4.0, '958 stockholders'), (1.0, 'record'), (1.0, 'expires'), (1.0, 'directors'), (1.0, 'conducted'), (1.0, 'board'), (1.0, '9'), (1.0, '4'), (1.0, '2021')]","[(16.0, 'core merchandise categories increased'), (14.0, 'payroll leveraging increased sales'), (9.0, '24 basis points'), (8.0, 'operating cash flows'), (8.0, 'insurance liabilities claims'), (4.0, 'workers compensation'), (4.0, 'warehouse operations'), (4.0, 'property damage'), (4.0, 'property damage'), (4.0, 'particularly strong'), (4.0, 'management believes'), (4.0, 'largely attributable'), (4.0, 'investment position'), (4.0, 'general liability'), (4.0, 'funded predominantly'), (4.0, 'foreseeable future'), (4.0, 'employee health'), (4.0, 'care benefits'), (4.0, 'capital requirements'), (2.0, 'sales'), (2.0, 'sales'), (2.0, 'insurance'), (2.0, 'cash'), (1.0, 'sufficient'), (1.0, 'self'), (1.0, 'self'), (1.0, 'non'), (1.0, 'meet'), (1.0, 'lower'), (1.0, 'liquidity'), (1.0, 'insurers'), (1.0, 'foods'), (1.0, 'businesses')]","[(16.0, 'known future expenditures denominated'), (16.0, 'financial market risk results'), (12.833333333333334, 'foreign currency exchange rates'), (9.833333333333334, 'functional foreign currency'), (9.333333333333334, 'use forward foreign'), (5.0, 'interest rates'), (5.0, 'exchange contracts'), (4.0, 'particularly electricity'), (4.0, 'natural gas'), (4.0, 'manufacturing operations'), (4.0, 'economically hedge'), (4.0, 'commodities used'), (1.0, 'retail'), (1.0, 'prices'), (1.0, 'non'), (1.0, 'impact'), (1.0, 'fluctuations'), (1.0, 'fluctuations'), (1.0, 'fluctuations'), (1.0, 'exposure'), (1.0, 'exposed'), (1.0, 'energy')]","[(24.5, 'former temporary staffing employee filed'), (16.0, 'product tax audit resulting'), (15.25, 'staffing company alleging violations'), (14.75, 'company acquired innovel solutions'), (14.5, '999 using existing cash'), (9.0, 'pay minimum wages'), (9.0, 'california labor code'), (4.75, 'company reached'), (4.0, 'rest breaks'), (4.0, 'provide meal'), (4.0, 'plaintiff agreed'), (4.0, 'june 2021'), (4.0, 'july 2021'), (4.0, 'fourth quarter'), (4.0, 'class action'), (2.75, 'company'), (2.5, 'cash'), (1.0, 'failure'), (1.0, 'dismiss'), (1.0, 'claims'), (1.0, 'benefit'), (1.0, 'agreement'), (1.0, '84'), (1.0, '2020')]","[(14.0, 'maintaining adequate internal control'), (9.0, 'internal control may'), (6.0, 'internal control'), (4.0, 'rule 13a'), (4.0, 'inherent limitations'), (4.0, 'fourth quarter'), (4.0, 'financial reporting'), (4.0, 'exchange act'), (4.0, 'detect misstatements'), (1.0, 'responsible'), (1.0, 'prevent'), (1.0, 'occurred'), (1.0, 'management'), (1.0, 'f'), (1.0, 'establishing'), (1.0, 'defined'), (1.0, 'changes'), (1.0, '2021'), (1.0, '15')]"
Costco,2020,"[(36.0, 'week fiscal years ended august 30'), (16.0, 'senior financial officers pursuant'), (4.0, 'september 2'), (4.0, 'september 1'), (4.0, 'section 406'), (4.0, 'oxley act'), (4.0, 'costco wholesale'), (3.5, '2018 relate'), (1.5, '2018'), (1.0, 'sarbanes'), (1.0, 'respectively'), (1.0, 'references'), (1.0, 'ethics'), (1.0, 'code'), (1.0, 'adopted'), (1.0, '52'), (1.0, '2020'), (1.0, '2020'), (1.0, '2019'), (1.0, '2019')]","[(23.333333333333332, 'senior management could negatively impact'), (23.333333333333332, 'brand recognition could adversely affect'), (15.0, 'including active shooter situations'), (12.333333333333332, 'could negatively affect'), (9.0, 'public health issues'), (9.0, 'maintain membership growth'), (9.0, 'extreme weather conditions'), (5.0, 'including pandemics'), (4.0, 'succession plan'), (4.0, 'natural disasters'), (1.0, 'violence'), (1.0, 'typhoons'), (1.0, 'terrorism'), (1.0, 'results'), (1.0, 'quarantines'), (1.0, 'operations'), (1.0, 'operations'), (1.0, 'loyalty'), (1.0, 'implement'), (1.0, 'identify'), (1.0, 'hurricanes'), (1.0, 'floods'), (1.0, 'failure'), (1.0, 'failure'), (1.0, 'earthquakes'), (1.0, 'business'), (1.0, 'acts')]","[(9.0, 'unresolved staff comments'), (9.0, 'unresolve staff comments'), (4.0, 'status quo'), (3.857142857142857, 'item 2b'), (3.857142857142857, 'item 1e'), (3.857142857142857, 'item 1d'), (3.857142857142857, 'item 1c'), (3.857142857142857, 'item 1b'), (3.857142857142857, 'item 1a'), (3.333333333333333, 'make changes'), (1.8571428571428572, 'item'), (1.3333333333333333, 'make'), (1.3333333333333333, 'make'), (1.0, 'happy'), (1.0, 'going'), (1.0, 'decision'), (1.0, 'clarify'), (1.0, 'change')]","[(16.0, 'warehouses contained approximately 116'), (14.666666666666666, '1 million square feet'), (9.0, 'operating floor space'), (4.666666666666666, '4 million'), (4.666666666666666, '3 million'), (4.0, 'puerto rico'), (4.0, 'costco owns'), (3.5, '166 leases'), (1.5, 'leases'), (1.0, 'u'), (1.0, 'land'), (1.0, 'end'), (1.0, 'canada'), (1.0, 'building'), (1.0, '81'), (1.0, '2020'), (1.0, '20'), (1.0, '119')]","[(16.0, 'consolidated financial statements included'), (13.0, 'legal proceedings see discussion'), (12.566666666666666, 'item 8 includes discussion'), (5.0, 'legal proceedings'), (5.0, 'legal proceedings'), (5.0, 'legal proceedings'), (4.566666666666666, 'item 8'), (4.566666666666666, 'item 8'), (4.566666666666666, 'item 8'), (4.566666666666666, 'item 8'), (4.166666666666666, 'item 9'), (4.166666666666666, 'item 9'), (4.166666666666666, 'item 7'), (4.166666666666666, 'item 3'), (4.166666666666666, 'item 3'), (4.166666666666666, 'item 11'), (4.166666666666666, 'item 10'), (4.0, 'note 11'), (1.0, 'report')]","[(16.0, 'cumulative total shareholder return'), (14.5, 'sp 500 retail index'), (10.5, 'sp 500 index'), (9.0, 'stock price appreciation'), (9.0, 'following graph compares'), (9.0, 'costco common stock'), (9.0, '000 authorization approved'), (4.0, 'repurchase program'), (4.0, 'five years'), (4.0, 'april 2023'), (4.0, 'april 2019'), (1.0, 'reinvestment'), (1.0, 'investment'), (1.0, 'expires'), (1.0, 'dividends'), (1.0, 'directors'), (1.0, 'conducted'), (1.0, 'board'), (1.0, '4'), (1.0, '100')]","[(25.0, 'lower gross margin percentage relative'), (25.0, 'dollar positively impacted sga expenses'), (9.0, 'cash flow provided'), (8.5, 'commerce business growth'), (4.5, 'warehouse business'), (4.0, 'primarily derived'), (4.0, 'membership fees'), (4.0, 'also increased'), (3.5, 'net sales'), (1.5, 'sales'), (1.0, 'u'), (1.0, 'operations'), (1.0, 'internationally'), (1.0, 'generally'), (1.0, 'e'), (1.0, 'domestically'), (1.0, 'approximately'), (1.0, '58')]","[(16.0, 'financial market risk results'), (15.0, 'foreign currency exchange rates'), (8.5, 'fixed interest rates'), (5.5, 'interest rates'), (4.0, 'term debt'), (4.0, 'particularly electricity'), (4.0, 'natural gas'), (4.0, 'manufacturing operations'), (4.0, 'commodities used'), (1.0, 'retail'), (1.0, 'prices'), (1.0, 'long'), (1.0, 'fluctuations'), (1.0, 'fluctuations'), (1.0, 'exposure'), (1.0, 'exposed'), (1.0, 'energy'), (1.0, 'end'), (1.0, '7'), (1.0, '657'), (1.0, '2020')]","[(16.0, 'produce high sales volumes'), (16.0, 'operates membership warehouses based'), (16.0, 'offering members low prices'), (9.0, 'rapid inventory turnover'), (9.0, 'impairment charges recognized'), (8.0, 'costco wholesale corporation'), (4.0, 'wide range'), (4.0, 'merchandise categories'), (4.0, 'limited selection'), (4.0, 'label products'), (2.0, 'costco'), (1.0, 'private'), (1.0, 'nationally'), (1.0, 'concept'), (1.0, 'company'), (1.0, 'branded'), (1.0, '2020'), (1.0, '2019'), (1.0, '2018')]","[(16.0, 'provide reasonable assurance regarding'), (14.0, 'maintaining adequate internal control'), (6.0, 'internal control'), (4.0, 'rule 13a'), (4.0, 'financial statements'), (4.0, 'financial reporting'), (4.0, 'financial reporting'), (4.0, 'external purposes'), (4.0, 'exchange act'), (1.0, 'u'), (1.0, 'responsible'), (1.0, 'reliability'), (1.0, 'preparation'), (1.0, 'management'), (1.0, 'gaap'), (1.0, 'f'), (1.0, 'establishing'), (1.0, 'designed'), (1.0, 'defined'), (1.0, 'accordance'), (1.0, '15')]"
Costco,2019,"[(25.0, '700 active stock keeping units'), (9.0, 'costco operated 782'), (9.0, '741 warehouses worldwide'), (8.5, 'core warehouse business'), (4.5, 'per warehouse'), (4.0, 'significantly less'), (4.0, 'september 3'), (4.0, 'september 2'), (4.0, 'september 1'), (4.0, 'executive memberships'), (4.0, 'broadline retailers'), (4.0, 'approximately 3'), (4.0, 'also available'), (1.0, 'u'), (1.0, 'taiwan'), (1.0, 'skus'), (1.0, 'respectively'), (1.0, 'mexico'), (1.0, 'korea'), (1.0, 'carry'), (1.0, 'average'), (1.0, '762'), (1.0, '2019'), (1.0, '2018'), (1.0, '2017')]","[(24.5, 'brand recognition could adversely affect'), (14.5, 'canadian operations could arise'), (8.5, 'maintain membership growth'), (8.0, 'comparable warehouse sales'), (5.0, 'comparable sales'), (4.5, 'slow growth'), (4.0, 'highly dependent'), (4.0, 'comprised 30'), (3.5, 'california operations'), (2.0, 'operations'), (2.0, 'operations'), (1.5, 'california'), (1.0, 'u'), (1.0, 'results'), (1.0, 'particularly'), (1.0, 'loyalty'), (1.0, 'failure'), (1.0, 'declines')]","[(9.0, 'unresolved staff comments'), (9.0, 'unresolve staff comments'), (4.0, 'status quo'), (3.857142857142857, 'item 2b'), (3.857142857142857, 'item 1e'), (3.857142857142857, 'item 1d'), (3.857142857142857, 'item 1c'), (3.857142857142857, 'item 1b'), (3.857142857142857, 'item 1a'), (3.333333333333333, 'make changes'), (1.8571428571428572, 'item'), (1.3333333333333333, 'make'), (1.3333333333333333, 'make'), (1.0, 'happy'), (1.0, 'going'), (1.0, 'decision'), (1.0, 'clarify'), (1.0, 'change')]","[(25.0, 'warehouses contained approximately 113 warehouses'), (23.5, 'following schedule shows warehouse openings'), (23.5, 'costco operated 782 membership warehouses'), (5.5, 'expected openings'), (5.5, 'costco owns'), (4.0, 'september 1'), (3.5, '162 leases'), (1.5, 'leases'), (1.0, 'relocations'), (1.0, 'net'), (1.0, 'land'), (1.0, 'end'), (1.0, 'closings'), (1.0, 'building'), (1.0, '2019'), (1.0, '2019'), (1.0, '2019'), (1.0, '114')]","[(14.0, 'consolidated financial statements included'), (13.5, 'legal proceedings see discussion'), (12.75, 'item 10 includes discussion'), (8.5, 'legal proceedings relating'), (6.0, 'financial statements'), (5.5, 'legal proceedings'), (5.5, 'legal proceedings'), (4.75, 'item 10'), (4.5, 'note 10'), (4.5, 'note 10'), (4.25, 'item 9'), (4.25, 'item 8'), (4.25, 'item 8'), (4.25, 'item 7'), (4.25, 'item 3'), (4.25, 'item 11'), (1.0, 'taxpayers'), (1.0, 'shareholders'), (1.0, 'share'), (1.0, 'report'), (1.0, 'non'), (1.0, 'interest'), (1.0, 'entitled'), (1.0, 'discussed'), (1.0, 'company'), (1.0, 'company')]","[(16.0, 'cumulative total shareholder return'), (14.5, 'sp 500 retail index'), (10.5, 'sp 500 index'), (9.0, 'stock price appreciation'), (9.0, 'following graph compares'), (9.0, 'costco common stock'), (9.0, '000 authorization approved'), (4.0, 'september 1'), (4.0, 'repurchase program'), (4.0, 'five years'), (4.0, 'august 31'), (4.0, 'april 2023'), (3.5, 'april 2019'), (1.5, '2019'), (1.0, 'reinvestment'), (1.0, 'investment'), (1.0, 'expires'), (1.0, 'dividends'), (1.0, 'directors'), (1.0, 'conducted'), (1.0, 'board'), (1.0, '4'), (1.0, '2014'), (1.0, '100')]","[(22.0, 'fiscal year contractual obligations 2021'), (15.5, 'new share repurchase program'), (9.5, '65 per share'), (9.0, 'cash flow provided'), (8.5, 'make future payments'), (8.0, 'net sales 10'), (7.0, 'contractual obligations'), (5.0, 'net sales'), (4.5, 'payments due'), (4.0, 'sga expenses'), (4.0, 'september 1'), (4.0, 'primarily derived'), (4.0, 'membership fees'), (4.0, '2024 2025'), (4.0, '2022 2023'), (1.0, 'thereafter'), (1.0, 'percentage'), (1.0, 'operations'), (1.0, 'follows'), (1.0, 'commitments'), (1.0, 'authorized'), (1.0, 'amount'), (1.0, '4'), (1.0, '2019'), (1.0, '000')]","[(16.0, 'known future expenditures denominated'), (4.0, 'particularly electricity'), (4.0, 'natural gas'), (4.0, 'manufacturing operations'), (4.0, 'functional foreign'), (4.0, 'forward foreign'), (4.0, 'exchange contracts'), (4.0, 'economically hedge'), (4.0, 'commodities used'), (1.0, 'use'), (1.0, 'seeking'), (1.0, 'retail'), (1.0, 'prices'), (1.0, 'part'), (1.0, 'non'), (1.0, 'manage'), (1.0, 'impact'), (1.0, 'fluctuations'), (1.0, 'fluctuations'), (1.0, 'fluctuations'), (1.0, 'exposed'), (1.0, 'energy'), (1.0, 'currency'), (1.0, 'company')]","[(8.0, 'effective internal control'), (5.0, 'internal control'), (4.0, 'transition option'), (4.0, 'september 1'), (4.0, 'material respects'), (4.0, 'integrated framework'), (4.0, 'fiscal 2020'), (4.0, 'first quarter'), (4.0, 'financial reporting'), (4.0, 'effect adjustment'), (4.0, 'criteria established'), (4.0, 'company plans'), (4.0, 'company maintained'), (1.0, 'utilize'), (1.0, 'guidance'), (1.0, 'cumulative'), (1.0, 'beginning'), (1.0, 'based'), (1.0, 'allows'), (1.0, 'adopt'), (1.0, '2019'), (1.0, '2013')]","[(15.0, 'maintaining adequate internal control'), (10.0, 'companys internal control'), (9.0, 'remediation plan discussed'), (4.0, 'rule 13a'), (4.0, 'reasonably likely'), (4.0, 'materially affected'), (4.0, 'materially affect'), (4.0, 'financial reporting'), (4.0, 'financial reporting'), (4.0, 'exchange act'), (1.0, 'responsible'), (1.0, 'management'), (1.0, 'made'), (1.0, 'implementation'), (1.0, 'f'), (1.0, 'establishing'), (1.0, 'defined'), (1.0, 'connection'), (1.0, 'changes'), (1.0, 'changes'), (1.0, '15')]"
Costco,2018,"[(25.0, 'net sales less merchandise costs'), (16.0, 'significantly lower gross margins'), (16.0, 'senior financial officers pursuant'), (9.0, '715 warehouses worldwide'), (8.0, 'costco operated 741'), (4.0, 'section 406'), (4.0, 'oxley act'), (4.0, 'operate profitably'), (2.0, 'costco'), (1.0, 'sarbanes'), (1.0, 'retailers'), (1.0, 'ethics'), (1.0, 'end'), (1.0, 'code'), (1.0, 'adopted'), (1.0, '2018')]","[(47.33333333333333, 'key senior management could negatively impact business'), (25.333333333333332, 'brand recognition could adversely affect'), (15.333333333333332, 'canadian operations could arise'), (9.0, 'comparable warehouse sales'), (8.5, 'maintain membership growth'), (4.5, 'slow growth'), (4.0, 'succession plan'), (4.0, 'highly dependent'), (4.0, 'comprised 30'), (3.5, 'california operations'), (2.0, 'operations'), (2.0, 'operations'), (1.5, 'california'), (1.0, 'u'), (1.0, 'results'), (1.0, 'particularly'), (1.0, 'loyalty'), (1.0, 'implement'), (1.0, 'identify'), (1.0, 'failure'), (1.0, 'failure'), (1.0, 'declines')]","[(9.0, 'unresolved staff comments'), (9.0, 'unresolve staff comments'), (4.0, 'status quo'), (3.857142857142857, 'item 2b'), (3.857142857142857, 'item 1e'), (3.857142857142857, 'item 1d'), (3.857142857142857, 'item 1c'), (3.857142857142857, 'item 1b'), (3.857142857142857, 'item 1a'), (3.333333333333333, 'make changes'), (1.8571428571428572, 'item'), (1.3333333333333333, 'make'), (1.3333333333333333, 'make'), (1.0, 'happy'), (1.0, 'going'), (1.0, 'decision'), (1.0, 'clarify'), (1.0, 'change')]","[(23.5, 'following schedule shows warehouse openings'), (14.5, 'warehouses contained approximately 110'), (13.666666666666666, '7 million square feet'), (10.0, '0million square feet'), (9.0, 'operating floor space'), (5.5, 'expected openings'), (4.666666666666666, '5 million'), (4.666666666666666, '3 million'), (4.0, 'merchandise shipments'), (4.0, 'december 31'), (3.5, 'fiscal 2018'), (2.5, 'warehouses'), (1.5, '2018'), (1.0, 'u'), (1.0, 'relocations'), (1.0, 'net'), (1.0, 'end'), (1.0, 'distribution'), (1.0, 'consolidation'), (1.0, 'closings'), (1.0, 'canada'), (1.0, '77'), (1.0, '19'), (1.0, '13')]","[(14.0, 'consolidated financial statements included'), (13.5, 'legal proceedings see discussion'), (12.75, 'item 10 includes discussion'), (8.5, 'legal proceedings relating'), (6.0, 'financial statements'), (5.5, 'legal proceedings'), (5.5, 'legal proceedings'), (4.75, 'item 10'), (4.5, 'note 10'), (4.5, 'note 10'), (4.25, 'item 9'), (4.25, 'item 8'), (4.25, 'item 8'), (4.25, 'item 7'), (4.25, 'item 3'), (4.25, 'item 11'), (1.0, 'taxpayers'), (1.0, 'shareholders'), (1.0, 'share'), (1.0, 'report'), (1.0, 'non'), (1.0, 'interest'), (1.0, 'entitled'), (1.0, 'discussed'), (1.0, 'company'), (1.0, 'company')]","[(16.0, 'total retail market performance'), (16.0, 'larger retail index provides'), (9.0, '000 authorization approved'), (4.0, 'september 2'), (4.0, 'september 1'), (4.0, 'repurchase program'), (4.0, 'information provided'), (4.0, 'better representation'), (4.0, 'april 2019'), (4.0, 'april 2015'), (1.0, 'transition'), (1.0, 'expires'), (1.0, 'directors'), (1.0, 'conducted'), (1.0, 'board'), (1.0, '4'), (1.0, '2018'), (1.0, '2013')]","[(9.0, 'cash flow provided'), (8.0, 'annual fee increase'), (4.0, 'workers compensation'), (4.0, 'vehicle liability'), (4.0, 'property damage'), (4.0, 'primarily due'), (4.0, 'primarily derived'), (4.0, 'predominantly self'), (4.0, 'officers liability'), (4.0, 'new warehouses'), (4.0, 'net sales'), (4.0, 'membership sign'), (4.0, 'membership fees'), (4.0, 'membership fees'), (4.0, 'inventory loss'), (4.0, 'general liability'), (4.0, 'employee health'), (4.0, 'care benefits'), (2.0, 'increase'), (1.0, 'ups'), (1.0, 'operations'), (1.0, 'insured'), (1.0, 'existing'), (1.0, 'directors'), (1.0, 'company')]","[(16.0, 'known future expenditures denominated'), (16.0, 'financial market risk results'), (11.166666666666666, 'foreign currency exchange rates'), (5.0, 'interest rates'), (5.0, 'exchange contracts'), (4.666666666666666, 'functional foreign'), (4.666666666666666, 'forward foreign'), (4.0, 'term investments'), (4.0, 'rate securities'), (4.0, 'fixed interest'), (4.0, 'economically hedge'), (2.5, 'currency'), (1.0, 'use'), (1.0, 'short'), (1.0, 'seeking'), (1.0, 'part'), (1.0, 'non'), (1.0, 'manage'), (1.0, 'majority'), (1.0, 'impact'), (1.0, 'fluctuations'), (1.0, 'fluctuations'), (1.0, 'fluctuations'), (1.0, 'exposure')]","[(25.0, 'accompanying condensed consolidated balance sheets'), (4.0, 'term investments'), (4.0, 'september 3'), (4.0, 'securities included'), (4.0, 'sale securities'), (4.0, 'insurance liabilities'), (4.0, '947 included'), (3.5, 'cash equivalents'), (1.5, 'cash'), (1.0, 'short'), (1.0, 'sales'), (1.0, 'respectively'), (1.0, 'respectively'), (1.0, 'proceeds'), (1.0, 'end'), (1.0, 'available'), (1.0, 'aggregate'), (1.0, '39'), (1.0, '291'), (1.0, '202'), (1.0, '2018'), (1.0, '2018'), (1.0, '2017'), (1.0, '2017'), (1.0, '2017'), (1.0, '2016'), (1.0, '148'), (1.0, '1'), (1.0, '1'), (1.0, '059')]","[(8.5, 'interim financial statements'), (4.5, 'financial reporting'), (4.0, 'timely basis'), (4.0, 'material weakness'), (4.0, 'material weakness'), (4.0, 'material misstatement'), (4.0, 'internal control'), (4.0, 'fiscal 2019'), (4.0, 'completed prior'), (1.0, 'remediation'), (1.0, 'prevented'), (1.0, 'end'), (1.0, 'detected'), (1.0, 'deficiency'), (1.0, 'deficiencies'), (1.0, 'combination'), (1.0, 'annual')]"
Costco,2017,"[(15.666666666666666, 'similar national brand products'), (15.666666666666666, 'believe kirkland signature products'), (9.666666666666666, 'high quality products'), (9.0, 'winter holiday season'), (9.0, 'senior financial officers'), (9.0, 'material seasonal impact'), (9.0, 'increased net sales'), (9.0, 'countries except korea'), (4.0, 'sell gasoline'), (4.0, 'generally lower'), (1.0, 'prices'), (1.0, 'operations'), (1.0, 'offered'), (1.0, 'members'), (1.0, 'france'), (1.0, 'ethics'), (1.0, 'earnings'), (1.0, 'costco'), (1.0, 'code'), (1.0, 'adopted')]","[(23.666666666666664, 'unauthorized party may obtain access'), (23.5, 'audits including grand jury investigations'), (9.666666666666666, 'security measures may'), (9.666666666666666, 'may become involved'), (9.0, 'unclaimed property laws'), (5.5, 'agency investigations'), (4.0, 'undermined due'), (4.0, 'personal information'), (4.0, 'outside parties'), (4.0, 'misappropriate business'), (4.0, 'legal proceedings'), (4.0, 'external malfeasance'), (4.0, 'employee error'), (4.0, 'data systems'), (1.0, 'tort'), (1.0, 'result'), (1.0, 'otherwise'), (1.0, 'number'), (1.0, 'litigation'), (1.0, 'internal'), (1.0, 'government'), (1.0, 'employment'), (1.0, 'consumer'), (1.0, 'actions')]","[(9.0, 'unresolved staff comments'), (9.0, 'unresolve staff comments'), (4.0, 'status quo'), (3.857142857142857, 'item 2b'), (3.857142857142857, 'item 1e'), (3.857142857142857, 'item 1d'), (3.857142857142857, 'item 1c'), (3.857142857142857, 'item 1b'), (3.857142857142857, 'item 1a'), (3.333333333333333, 'make changes'), (1.8571428571428572, 'item'), (1.3333333333333333, 'make'), (1.3333333333333333, 'make'), (1.0, 'happy'), (1.0, 'going'), (1.0, 'decision'), (1.0, 'clarify'), (1.0, 'change')]","[(23.5, 'following schedule shows warehouse openings'), (15.0, 'warehouses contained approximately 107'), (14.666666666666666, '3 million square feet'), (9.0, 'operating floor space'), (9.0, 'operate 24 depots'), (5.5, 'expected openings'), (5.0, 'approximately 11'), (4.666666666666666, '5 million'), (4.666666666666666, '18 million'), (4.0, 'international locations'), (4.0, 'december 31'), (3.5, 'fiscal 2017'), (1.5, '2017'), (1.0, 'relocations'), (1.0, 'net'), (1.0, 'end'), (1.0, 'consisting'), (1.0, 'closings'), (1.0, 'canada'), (1.0, '75')]","[(14.0, 'consolidated financial statements included'), (13.5, 'legal proceedings see discussion'), (12.75, 'item 10 includes discussion'), (8.5, 'legal proceedings relating'), (6.0, 'financial statements'), (5.5, 'legal proceedings'), (5.5, 'legal proceedings'), (4.75, 'item 10'), (4.5, 'note 10'), (4.5, 'note 10'), (4.25, 'item 9'), (4.25, 'item 8'), (4.25, 'item 8'), (4.25, 'item 7'), (4.25, 'item 3'), (4.25, 'item 11'), (1.0, 'taxpayers'), (1.0, 'shareholders'), (1.0, 'share'), (1.0, 'report'), (1.0, 'non'), (1.0, 'interest'), (1.0, 'entitled'), (1.0, 'discussed'), (1.0, 'company'), (1.0, 'company')]","[(9.0, '000 authorization approved'), (4.0, 'repurchase program'), (4.0, 'quarterly basis'), (4.0, 'pay dividends'), (4.0, 'october 10'), (4.0, 'company expects'), (4.0, 'april 2019'), (4.0, 'april 2015'), (4.0, '629 stockholders'), (1.0, 'record'), (1.0, 'expires'), (1.0, 'directors'), (1.0, 'continue'), (1.0, 'conducted'), (1.0, 'board'), (1.0, '8'), (1.0, '4'), (1.0, '2017')]","[(25.0, 'income taxes requires significant judgment'), (25.0, '2016 negatively impacted sga expenses'), (9.0, 'two basis points'), (9.0, 'complex tax laws'), (9.0, 'commerce business growth'), (4.0, 'regulatory matters'), (4.0, 'recurring legal'), (4.0, 'also increased'), (1.0, 'use'), (1.0, 'sales'), (1.0, 'provision'), (1.0, 'non'), (1.0, 'interpretation'), (1.0, 'internationally'), (1.0, 'estimates'), (1.0, 'e'), (1.0, 'domestically'), (1.0, 'determination'), (1.0, 'charges'), (1.0, 'application')]","[(16.0, 'manage counterparty risk associated'), (16.0, 'financial market risk results'), (15.0, 'foreign currency exchange rates'), (9.0, 'established banking relationships'), (5.0, 'interest rates'), (4.0, 'particularly electricity'), (4.0, 'partially mitigate'), (4.0, 'natural gas'), (4.0, 'limiting transactions'), (3.5, 'price contracts'), (1.5, 'contracts'), (1.0, 'warehouses'), (1.0, 'seek'), (1.0, 'seek'), (1.0, 'prices'), (1.0, 'fluctuations'), (1.0, 'fluctuations'), (1.0, 'fixed'), (1.0, 'facilities'), (1.0, 'exposure'), (1.0, 'exposed'), (1.0, 'energy'), (1.0, 'counterparties'), (1.0, 'consume'), (1.0, 'certain')]","[(25.0, 'public company accounting oversight board'), (25.0, 'independent registered public accounting firm'), (15.5, 'related financial information included'), (9.5, 'consolidated financial statements'), (4.0, 'united states'), (4.0, 'kpmg llp'), (4.0, 'form 10'), (4.0, 'costcos management'), (4.0, 'annual report'), (1.0, 'standards'), (1.0, 'responsible'), (1.0, 'preparation'), (1.0, 'k'), (1.0, 'conducted'), (1.0, 'audited'), (1.0, 'audit'), (1.0, 'accordance')]","[(16.0, 'provide reasonable assurance regarding'), (14.0, 'maintaining adequate internal control'), (13.166666666666666, 'financial reporting item 9acontrols'), (6.0, 'internal control'), (5.166666666666666, 'financial reporting'), (5.166666666666666, 'financial reporting'), (4.5, 'financial statements'), (4.0, 'rule 13a'), (4.0, 'external purposes'), (4.0, 'exchange act'), (1.0, 'u'), (1.0, 'responsible'), (1.0, 'reliability'), (1.0, 'procedures'), (1.0, 'preparation'), (1.0, 'management'), (1.0, 'gaap'), (1.0, 'f'), (1.0, 'establishing'), (1.0, 'designed'), (1.0, 'defined'), (1.0, 'continued'), (1.0, 'accordance'), (1.0, '15')]"
Pfizer,2021,"[(9.0, 'major products included'), (9.0, 'every person deserves'), (9.0, 'bringing together people'), (4.0, 'potential risks'), (4.0, 'mco formularies'), (4.0, 'generally successful'), (4.0, 'different backgrounds'), (1.0, 'work'), (1.0, 'time'), (1.0, 'seen'), (1.0, 'pfizer'), (1.0, 'perspectives'), (1.0, 'operations'), (1.0, 'material'), (1.0, 'heard'), (1.0, 'goal'), (1.0, 'experiences'), (1.0, 'cared'), (1.0, 'believe')]","[(16.0, 'respective consumer healthcare businesses'), (16.0, 'medicaid drug rebate program'), (15.0, 'gsk consumer healthcare name'), (5.0, 'gsk combined'), (4.0, 'state statutes'), (4.0, 'operates globally'), (4.0, 'marketing activities'), (4.0, 'extensive regulation'), (1.0, 'subject'), (1.0, 'sales'), (1.0, 'products'), (1.0, 'pricing'), (1.0, 'pfizer'), (1.0, 'jv'), (1.0, 'ffdca'), (1.0, 'federal'), (1.0, 'fcpa'), (1.0, '2019')]","[(9.0, 'individuals 5 years'), (9.0, 'every person deserves'), (9.0, 'bringing together people'), (8.0, 'work across developed'), (4.0, 'prevent covid'), (4.0, 'feared diseases'), (4.0, 'emerging markets'), (4.0, 'different backgrounds'), (4.0, 'advance wellness'), (2.0, 'work'), (1.0, 'vaccine'), (1.0, 'treatments'), (1.0, 'time'), (1.0, 'seen'), (1.0, 'prevention'), (1.0, 'pfizer'), (1.0, 'perspectives'), (1.0, 'older'), (1.0, 'heard'), (1.0, 'goal'), (1.0, 'fda'), (1.0, 'experiences'), (1.0, 'cures'), (1.0, 'challenge'), (1.0, 'cared'), (1.0, 'authorized'), (1.0, 'age'), (1.0, '19')]","[(25.0, 'approximately 41 million square feet'), (9.0, 'new york city'), (9.0, '39 plants around'), (4.0, 'leased properties'), (4.0, 'global headquarters'), (4.0, 'december 31'), (4.0, '327 owned'), (1.0, 'world'), (1.0, 'u'), (1.0, 'singapore'), (1.0, 'responsibility'), (1.0, 'pgs'), (1.0, 'located'), (1.0, 'japan'), (1.0, 'italy'), (1.0, 'ireland'), (1.0, 'india'), (1.0, 'including'), (1.0, 'germany'), (1.0, 'belgium'), (1.0, 'amounting'), (1.0, '2021')]","[(14.666666666666666, 'pfizer executive leadership team'), (8.5, '2022 annual meeting'), (4.666666666666666, 'executive officers'), (4.666666666666666, 'executive officers'), (4.5, 'regular meeting'), (4.0, 'set forth'), (4.0, 'offices indicated'), (1.0, 'table'), (1.0, 'successor'), (1.0, 'shareholders'), (1.0, 'qualified'), (1.0, 'office'), (1.0, 'member'), (1.0, 'holds'), (1.0, 'held'), (1.0, 'date'), (1.0, 'company'), (1.0, 'chosen'), (1.0, 'bod')]","[(9.0, 'sp 500 index'), (9.0, 'following graph assumes'), (9.0, 'composite peer group'), (8.0, 'companys common stock'), (8.0, 'based pharmaceutical companies'), (5.0, 'pharmaceutical companies'), (5.0, 'common stock'), (4.0, 'symbol pfe'), (4.0, 'principal market'), (4.0, 'major u'), (4.0, 'december 31'), (4.0, 'currently trades'), (4.0, '100 investment'), (3.75, 'pfizer inc'), (3.75, 'abbvie inc'), (3.25, 'amgen inc'), (1.75, 'inc'), (1.5, 'amgen'), (1.0, 'reinvestment'), (1.0, 'nyse'), (1.0, 'nyse'), (1.0, 'european'), (1.0, 'dividends'), (1.0, '2016')]","[(16.0, 'positive nsclc approved mar'), (16.0, 'include individuals ages 12'), (16.0, 'borne encephalitis approved aug'), (4.0, 'supplemental bla'), (4.0, 'remaining share'), (4.0, 'purchase authorization'), (4.0, 'prevent tick'), (4.0, 'line alk'), (4.0, 'foreign exchange'), (4.0, 'fda requesting'), (4.0, 'favorable impact'), (4.0, '2 billion'), (4.0, '15 years'), (4.0, '145 %,'), (3.5, 'december 31'), (3.5, 'december 2021'), (3.5, 'approximately 2'), (3.5, '3 billion'), (1.5, 'approximately'), (1.5, '31'), (1.5, '3'), (1.5, '2021'), (1.0, 'vaccine'), (1.0, 'ticovac'), (1.0, 'submitted'), (1.0, 'lorviqua'), (1.0, 'lorlatinib'), (1.0, 'lorbrena'), (1.0, 'immunization'), (1.0, 'first'), (1.0, 'expand'), (1.0, 'comirnaty'), (1.0, 'approval'), (1.0, '6'), (1.0, '5'), (1.0, '2019')]","[(22.0, 'market risk section within mda'), (9.0, '2021 form 10'), (8.0, 'pfizer announces qualified'), (7.0, 'market risk'), (4.5, 'qualified disclosures'), (4.5, 'pfizer inc'), (4.0, 'information required'), (4.0, 'financial condition'), (4.0, 'capital resources'), (1.0, 'reference'), (1.0, 'liquidity'), (1.0, 'k'), (1.0, 'item'), (1.0, 'incorporated'), (1.0, 'discussion'), (1.0, 'analysis')]","[(45.0, '2021 primarily include employee termination costs associated'), (25.0, 'grant date assuming continuous service'), (9.0, 'focused company program'), (4.0, 'units vest'), (4.0, 'total revenue'), (4.0, 'rsus granted'), (4.0, 'periods presented'), (4.0, 'fourth quarters'), (4.0, 'fourth quarter'), (4.0, 'financial results'), (4.0, 'discontinued operations'), (4.0, 'contributed 9'), (3.5, 'third anniversary'), (3.0, '2021'), (3.0, '2021'), (1.5, 'third'), (1.0, 'virtually'), (1.0, 'transforming'), (1.0, 'reflected'), (1.0, 'meridian'), (1.0, 'japan'), (1.0, 'japan'), (1.0, 'instances'), (1.0, 'beginning'), (1.0, '6'), (1.0, '2020'), (1.0, '2019')]","[(13.600000000000001, 'maintaining effective internal control'), (13.6, 'internal control integrated framework'), (8.1, 'companys internal control'), (5.6, 'internal control'), (4.5, 'companys management'), (4.0, 'subsidiary companies'), (4.0, 'reasonably likely'), (4.0, 'materially affected'), (4.0, 'materially affect'), (4.0, 'management assessed'), (4.0, 'financial reporting'), (4.0, 'financial reporting'), (4.0, 'financial reporting'), (4.0, 'december 31'), (4.0, 'criteria established'), (4.0, 'auditors report'), (3.5, 'pfizer inc'), (2.8, 'internal'), (2.8, 'control'), (1.5, 'pfizer'), (1.0, 'responsible'), (1.0, 'issued'), (1.0, 'effectiveness'), (1.0, 'company'), (1.0, 'company'), (1.0, 'company'), (1.0, 'change'), (1.0, 'based'), (1.0, '2021'), (1.0, '2013')]"
Pfizer,2020,"[(25.0, 'face significantly increased generic competition'), (9.0, 'major products included'), (9.0, 'expect certain products'), (9.0, 'every person deserves'), (9.0, 'bringing together people'), (4.0, 'mco formularies'), (4.0, 'different backgrounds'), (1.0, 'years'), (1.0, 'work'), (1.0, 'universally'), (1.0, 'successful'), (1.0, 'seen'), (1.0, 'pfizer'), (1.0, 'perspectives'), (1.0, 'next'), (1.0, 'heard'), (1.0, 'goal'), (1.0, 'generally'), (1.0, 'experiences'), (1.0, 'cared'), (1.0, 'although')]","[(16.0, 'respective consumer healthcare businesses'), (15.0, 'gsk consumer healthcare name'), (14.5, 'information security systems make'), (9.5, 'systems potentially vulnerable'), (5.0, 'information technology'), (5.0, 'gsk combined'), (4.0, 'service interruptions'), (4.0, 'operates globally'), (4.0, 'increasing levels'), (1.0, 'sophistication'), (1.0, 'size'), (1.0, 'pfizer'), (1.0, 'made'), (1.0, 'jv'), (1.0, 'individuals'), (1.0, 'groups'), (1.0, 'ever'), (1.0, 'cyber'), (1.0, 'complexity'), (1.0, 'attacks'), (1.0, '2019')]","[(25.0, 'face significantly increased generic competition'), (16.0, 'respective consumer healthcare businesses'), (15.0, 'gsk consumer healthcare name'), (9.0, 'expect certain products'), (9.0, 'every person deserves'), (9.0, 'bringing together people'), (5.0, 'gsk combined'), (4.0, 'operates globally'), (4.0, 'different backgrounds'), (1.0, 'work'), (1.0, 'seen'), (1.0, 'pfizer'), (1.0, 'perspectives'), (1.0, 'jv'), (1.0, 'heard'), (1.0, 'goal'), (1.0, 'experiences'), (1.0, 'cared')]","[(25.0, 'approximately 43 million square feet'), (9.0, 'next several years'), (4.0, 'pgs expects'), (4.0, 'operational efficiencies'), (4.0, 'many locations'), (4.0, 'leased properties'), (4.0, 'exit five'), (4.0, 'december 31'), (4.0, 'achieve synergy'), (4.0, '363 owned'), (1.0, 'sites'), (1.0, 'operations'), (1.0, 'located'), (1.0, 'co'), (1.0, 'business'), (1.0, 'amounting'), (1.0, '2020')]","[(15.0, 'pfizer executive leadership team'), (9.0, 'certain legal proceedings'), (8.5, '2021 annual meeting'), (5.0, 'executive officers'), (4.5, 'regular meeting'), (4.0, 'offices indicated'), (4.0, 'note 16a'), (4.0, 'holds office'), (1.0, 'successor'), (1.0, 'shareholders'), (1.0, 'qualified'), (1.0, 'member'), (1.0, 'involved'), (1.0, 'held'), (1.0, 'discussed'), (1.0, 'date'), (1.0, 'chosen'), (1.0, 'bod')]","[(8.0, 'myers squibb company'), (7.5, 'pfizer common stock'), (5.0, 'common stock'), (4.0, 'symbol pfe'), (4.0, 'principal market'), (4.0, 'pfizer inc'), (4.0, 'new yorkse'), (4.0, 'february 23'), (4.0, 'eli lilly'), (4.0, 'currently trades'), (4.0, 'astrazeneca plc'), (4.0, '582 holders'), (2.0, 'company'), (1.5, 'inc'), (1.0, 'record'), (1.0, 'nyse'), (1.0, 'glaxosmithkline'), (1.0, 'bristol'), (1.0, '2021'), (1.0, '139')]","[(49.0, 'international operational growth /( decline ): growth'), (9.0, 'hospital therapeutic area'), (8.666666666666666, 'increased royalty expenses'), (8.166666666666666, 'increased sales volumes'), (5.166666666666666, 'sales increased'), (4.0, 'unfavorable impact'), (4.0, 'primarily due'), (4.0, 'prevnar 13'), (4.0, 'prevenar 13'), (4.0, 'partially offset'), (4.0, 'intercompany inventory'), (4.0, 'hedging activity'), (4.0, 'foreign exchange'), (4.0, '441 million'), (1.0, 'xtandi'), (1.0, 'vyndaqel'), (1.0, 'vyndamax'), (1.0, 'inlyta'), (1.0, 'ibrance'), (1.0, 'eliquis'), (1.0, 'cost'), (1.0, 'chantix'), (1.0, 'champix'), (1.0, 'biosimilars')]","[(36.0, 'market risk section within mda section'), (9.0, '2020 form 10'), (8.5, 'provide certain information'), (4.0, 'pfizer inc'), (4.0, 'information required'), (4.0, 'financial condition'), (4.0, 'capital resources'), (1.5, 'required'), (1.0, 'reference'), (1.0, 'public'), (1.0, 'liquidity'), (1.0, 'k'), (1.0, 'item'), (1.0, 'incorporated'), (1.0, 'discussion'), (1.0, 'analysis')]","[(14.8, 'variable lease payments amounted'), (14.8, 'make lease payments arising'), (9.0, 'target pfizer inc'), (9.0, 'rou assets represent'), (8.8, 'lease liabilities represent'), (4.8, 'lease term'), (4.0, 'underlying asset'), (4.0, 'material impact'), (4.0, 'consolidated statement'), (4.0, '380 million'), (4.0, '327 million'), (2.8, 'lease'), (1.0, 'use'), (1.0, 'standard'), (1.0, 'right'), (1.0, 'obligation'), (1.0, 'income'), (1.0, 'adoption'), (1.0, '2020'), (1.0, '2019')]","[(23.5, 'management used criteria set forth'), (14.833333333333334, 'maintaining effective internal control'), (9.333333333333334, 'internal controlintegrated framework'), (9.333333333333334, 'companys internal control'), (6.0, 'companys management'), (4.0, 'treadway commission'), (4.0, 'sponsoring organizations'), (4.0, 'reasonably likely'), (4.0, 'reasonable basis'), (4.0, 'materially affected'), (4.0, 'materially affect'), (4.0, 'financial reporting'), (4.0, 'audit provides'), (1.0, 'responsible'), (1.0, 'opinion'), (1.0, 'committee'), (1.0, 'change'), (1.0, 'believe'), (1.0, '2013')]"
Pfizer,2019,"[(9.0, 'therachon holding ag'), (9.0, 'stage biotechnology company'), (8.333333333333334, 'effective new products'), (4.333333333333334, 'existing products'), (4.333333333333334, 'biopharmaceutical products'), (4.0, 'revenues come'), (4.0, 'remaining shares'), (4.0, 'held clinical'), (4.0, 'continued strength'), (4.0, 'additional uses'), (1.0, 'well'), (1.0, 'sale'), (1.0, 'safe'), (1.0, 'privately'), (1.0, 'necessary'), (1.0, 'manufacture'), (1.0, 'majority'), (1.0, 'discovery'), (1.0, 'development'), (1.0, 'development'), (1.0, 'businesses'), (1.0, 'acquired')]","[(9.0, 'two business operations'), (9.0, 'identifying new compounds'), (9.0, 'developing new products'), (6.666666666666667, 'synergies actually realized'), (4.0, 'time periods'), (4.0, 'synergies anticipated'), (4.0, 'joint venture'), (4.0, 'inherently uncertain'), (4.0, 'could differ'), (4.0, 'complex process'), (4.0, 'combined successfully'), (2.0, 'synergies'), (1.6666666666666667, 'realized'), (1.6666666666666667, 'realized'), (1.0, 'whether'), (1.0, 'regardless'), (1.0, 'policies'), (1.0, 'pfizer'), (1.0, 'outcome'), (1.0, 'management'), (1.0, 'lengthy'), (1.0, 'control'), (1.0, 'combination'), (1.0, 'amount')]","[(9.0, 'unresolved staff comments'), (4.0, 'please submit'), (3.5, 'item 1b'), (1.5, 'item'), (1.0, 'unresolvement'), (1.0, 'resolved'), (1.0, 'issues'), (1.0, 'issues'), (1.0, 'end'), (1.0, 'editor'), (1.0, 'comment'), (1.0, 'article'), (1.0, 'applicable'), (1.0, 'applicable'), (1.0, 'applicable')]","[(24.0, 'approximately 47 million square feet'), (15.0, 'pfizers properties extend internationally'), (10.0, 'approximately 90 countries'), (9.0, 'new york city'), (9.0, 'lease space around'), (9.0, 'administrative support functions'), (8.5, 'pfizer corporate headquarters'), (5.0, 'leased properties'), (4.5, 'pfizer continues'), (4.0, 'regulatory compliance'), (4.0, 'december 31'), (4.0, 'customer service'), (4.0, '453 owned'), (1.0, 'world'), (1.0, 'sales'), (1.0, 'rd'), (1.0, 'marketing'), (1.0, 'manufacturing'), (1.0, 'distribution'), (1.0, 'amounting'), (1.0, '2019')]","[(23.666666666666664, 'consolidated financial statements note 16'), (9.666666666666666, '2019 financial report'), (9.666666666666666, '2019 financial report'), (7.666666666666668, 'certain legal proceedings'), (4.666666666666667, 'legal proceedings'), (4.666666666666667, 'legal proceedings'), (4.0, 'item 3'), (1.0, 'reference'), (1.0, 'notes'), (1.0, 'involved'), (1.0, 'incorporated'), (1.0, 'discussed'), (1.0, 'discussed')]","[(25.0, 'peer group performance graph sections'), (25.0, 'average price paid per share'), (15.5, 'selected quarterly financial data'), (9.5, '2019 financial report'), (9.0, 'additional information required'), (4.0, 'principal market'), (4.0, 'february 25'), (4.0, 'common stock'), (4.0, 'common stock'), (4.0, '524 holders'), (1.0, 'unaudited'), (1.0, 'reference'), (1.0, 'record'), (1.0, 'pfizer'), (1.0, 'nyse'), (1.0, 'item'), (1.0, 'incorporated'), (1.0, '881'), (1.0, '709'), (1.0, '5'), (1.0, '292'), (1.0, '2020'), (1.0, '142')]","[(9.0, 'management management reports'), (9.0, 'heading financial review'), (9.0, 'financial business activities'), (9.0, '2019 financial review'), (9.0, '2019 financial report'), (4.0, 'information required'), (4.0, 'information required'), (1.0, 'reference'), (1.0, 'reference'), (1.0, 'incorporated'), (1.0, 'discussion'), (1.0, 'company'), (1.0, 'analyses')]","[(15.0, 'foreign exchange rate movements'), (14.75, 'financial risk management program'), (10.0, 'interest rate movements'), (9.0, 'fair value measurements'), (8.75, '2019 financial report'), (4.75, 'financial instruments'), (4.75, 'financial exposures'), (4.0, 'pfizer inc'), (4.0, 'party instruments'), (4.0, 'operational means'), (1.0, 'use'), (1.0, 'third'), (1.0, 'objective'), (1.0, 'minimize'), (1.0, 'manage'), (1.0, 'impact'), (1.0, 'earnings')]","[(23.666666666666668, 'independent registered public accounting firm'), (23.666666666666668, 'independent registered public accounting firm'), (8.75, '2019 financial reports'), (8.25, 'consolidated financial statements'), (7.416666666666667, '2019 financial report'), (5.25, 'financial statements'), (4.0, 'related data'), (4.0, 'information required'), (4.0, 'information required'), (3.6666666666666665, 'firm'), (1.6666666666666667, 'report'), (1.6666666666666667, 'report'), (1.0, 'reference'), (1.0, 'reference'), (1.0, 'item'), (1.0, 'incorporated'), (1.0, 'included')]","[(12.916666666666666, 'financial reporting managements report'), (9.25, '2019 financial report'), (9.0, 'recent fiscal quarter'), (7.5, 'companys internal control'), (5.416666666666666, 'financial reporting'), (5.416666666666666, 'financial reporting'), (4.5, 'internal control'), (4.5, 'internal control'), (4.5, 'internal control'), (4.0, 'reasonably likely'), (4.0, 'materially affected'), (4.0, 'materially affect'), (1.0, 'included'), (1.0, 'company'), (1.0, 'change')]"
Pfizer,2018,"[(22.5, 'pfizer recorded direct product revenues'), (10.0, 'one eh product'), (9.0, 'competitors promotional resources'), (8.5, 'major products included'), (5.5, 'revenues come'), (4.5, 'biopharmaceutical products'), (4.0, 'several factors'), (4.0, 'mco formularies'), (4.0, 'competitive position'), (4.0, '1 billion'), (1.0, 'universally'), (1.0, 'successful'), (1.0, 'sale'), (1.0, 'manufacture'), (1.0, 'majority'), (1.0, 'including'), (1.0, 'generally'), (1.0, 'effectiveness'), (1.0, 'amount'), (1.0, 'although'), (1.0, 'affected'), (1.0, '2017')]","[(9.0, 'identifying new compounds'), (9.0, 'encounter similar regulatory'), (9.0, 'developing new products'), (9.0, 'certain international markets'), (9.0, 'abbreviated legal pathways'), (4.0, 'uncertainties apply'), (4.0, 'provide something'), (4.0, 'legislative issues'), (4.0, 'inherently uncertain'), (4.0, 'healthcare provider'), (4.0, 'healthcare professional'), (4.0, 'government official'), (4.0, 'biosimilars exist'), (1.0, 'value'), (1.0, 'risks'), (1.0, 'outcome'), (1.0, 'countries'), (1.0, 'approval')]","[(9.0, 'unresolved staff comments'), (4.0, 'please submit'), (3.5, 'item 1b'), (1.5, 'item'), (1.0, 'unresolvement'), (1.0, 'resolved'), (1.0, 'issues'), (1.0, 'issues'), (1.0, 'end'), (1.0, 'editor'), (1.0, 'comment'), (1.0, 'article'), (1.0, 'applicable'), (1.0, 'applicable'), (1.0, 'applicable')]","[(25.0, 'approximately 53 million square feet'), (14.5, 'pfizers properties extend internationally'), (9.5, 'pfizers corporate headquarters'), (9.0, 'new york city'), (9.0, 'lease space around'), (9.0, 'administrative support functions'), (5.0, 'leased properties'), (4.0, 'regulatory compliance'), (4.0, 'december 31'), (4.0, 'customer service'), (4.0, '90 countries'), (4.0, '501 owned'), (3.5, 'pfizer continues'), (1.5, 'pfizer'), (1.0, 'world'), (1.0, 'sales'), (1.0, 'marketing'), (1.0, 'manufacturing'), (1.0, 'distribution'), (1.0, 'amounting'), (1.0, '2017')]","[(24.0, 'consolidated financial statements note 17a'), (10.0, '2017 financial report'), (7.666666666666668, 'certain legal proceedings'), (4.666666666666667, 'legal proceedings'), (4.666666666666667, 'legal proceedings'), (1.0, 'reference'), (1.0, 'reference'), (1.0, 'notes'), (1.0, 'involved'), (1.0, 'incorporated'), (1.0, 'discussed'), (1.0, 'discussed'), (1.0, 'contingencies'), (1.0, 'commitments')]","[(16.0, 'satisfy tax withholding obligations'), (9.0, 'term incentive programs'), (9.0, 'consolidated financial statements'), (7.5, 'common stock surrendered'), (4.5, 'common stock'), (4.0, 'principal market'), (4.0, 'february 20'), (4.0, 'additional information'), (4.0, '190 holders'), (4.0, '102 shares'), (2.0, 'stock'), (1.0, 'vesting'), (1.0, 'see'), (1.0, 'record'), (1.0, 'nyse'), (1.0, 'notes'), (1.0, 'long'), (1.0, 'connection'), (1.0, 'company'), (1.0, 'awards'), (1.0, '59'), (1.0, '2018'), (1.0, '158')]","[(9.0, 'management management reports'), (8.6, '2017 financial report'), (8.266666666666666, 'heading financial review'), (8.266666666666666, '2017 financial review'), (5.266666666666667, 'financial review'), (4.6, 'financial relationship'), (4.0, 'information required'), (4.0, 'information required'), (1.0, 'results'), (1.0, 'reference'), (1.0, 'reference'), (1.0, 'reference'), (1.0, 'operations'), (1.0, 'item'), (1.0, 'incorporated'), (1.0, 'included'), (1.0, 'examine'), (1.0, 'discussion'), (1.0, 'discussion'), (1.0, 'company')]","[(16.0, 'may affect future results'), (16.0, 'may affect future results'), (14.0, 'financial risk management section'), (12.0, 'forward looking information section'), (9.0, '2017 financial report'), (6.0, 'financial risk'), (5.5, 'looking information'), (4.5, 'information required'), (4.5, 'information required'), (2.5, 'forward'), (1.0, 'reference'), (1.0, 'reference'), (1.0, 'item'), (1.0, 'incorporated'), (1.0, 'factors'), (1.0, 'factors'), (1.0, 'discussion'), (1.0, 'discussion'), (1.0, 'discussion')]","[(25.0, 'independent registered public accounting firm'), (8.416666666666666, 'consolidated financial statements'), (8.416666666666666, 'consolidated financial statements'), (7.75, '2017 financial report'), (5.416666666666666, 'financial statements'), (4.0, 'supplementary data'), (4.0, 'supplementary data'), (4.0, 'related notes'), (4.0, 'item 8'), (4.0, 'information required'), (2.0, 'report'), (1.0, 'reference')]","[(12.916666666666666, 'financial reporting managements report'), (9.25, '2017 financial report'), (7.5, 'companys internal control'), (5.416666666666666, 'financial reporting'), (5.416666666666666, 'financial reporting'), (4.5, 'internal control'), (4.5, 'internal control'), (4.5, 'internal control'), (4.0, 'reasonably likely'), (4.0, 'materially affected'), (4.0, 'materially affect'), (1.0, 'included'), (1.0, 'company'), (1.0, 'change')]"
Pfizer,2017,"[(22.666666666666664, 'pfizer must report specific prices'), (16.0, 'exercise indirect price control'), (15.0, 'medicaid drug rebate program'), (9.0, 'social insurance administrations'), (9.0, 'setting reimbursement standards'), (9.0, 'medicare part b'), (5.0, 'drug manufacturers'), (4.666666666666666, 'pfizer patents'), (4.0, 'revenues come'), (4.0, 'negotiation mechanism'), (4.0, 'healthcare programs'), (4.0, 'government continues'), (4.0, 'government agencies'), (4.0, 'biopharmaceutical products'), (2.6666666666666665, 'pfizer'), (1.0, 'sale'), (1.0, 'ongoing'), (1.0, 'manufacture'), (1.0, 'majority'), (1.0, 'india'), (1.0, 'challenges')]","[(16.0, 'also seen significant competition'), (14.0, 'maintain competitive insurance markets'), (9.0, 'product development continue'), (9.0, 'many therapeutic areas'), (9.0, 'identifying new compounds'), (9.0, 'developing new products'), (6.0, 'insurance markets'), (4.0, 'regulatory requirements'), (4.0, 'rd portfolio'), (4.0, 'pfizer inc'), (4.0, 'may affect'), (4.0, 'inherently uncertain'), (4.0, 'high degree'), (4.0, 'complex process'), (4.0, 'candidates funded'), (4.0, 'average costs'), (1.0, 'well'), (1.0, 'sustainability'), (1.0, 'risk'), (1.0, 'rise'), (1.0, 'outcome'), (1.0, 'number'), (1.0, 'lengthy'), (1.0, 'involves'), (1.0, 'cost'), (1.0, 'continues')]","[(9.0, 'unresolved staff comments'), (4.0, 'please submit'), (3.5, 'item 1b'), (1.5, 'item'), (1.0, 'unresolvement'), (1.0, 'resolved'), (1.0, 'issues'), (1.0, 'issues'), (1.0, 'end'), (1.0, 'editor'), (1.0, 'comment'), (1.0, 'article'), (1.0, 'applicable'), (1.0, 'applicable'), (1.0, 'applicable')]","[(16.0, 'surplus real property assets'), (16.0, '3 million square feet'), (14.333333333333334, 'pfizers properties extend internationally'), (9.0, 'new york city'), (4.333333333333334, 'leased properties'), (4.0, 'operating space'), (4.0, 'december 31'), (4.0, 'corporate headquarters'), (4.0, '90 countries'), (4.0, '567 owned'), (4.0, '28 sites'), (3.5, 'pfizer inc'), (2.3333333333333335, 'properties'), (1.5, 'pfizer'), (1.0, 'regions'), (1.0, 'reductions'), (1.0, 'reduced'), (1.0, 'portfolio'), (1.0, 'number'), (1.0, 'disposal'), (1.0, '2016'), (1.0, '2')]","[(24.0, 'consolidated financial statements note 17a'), (10.0, '2016 financial report'), (7.666666666666668, 'certain legal proceedings'), (4.666666666666667, 'legal proceedings'), (4.666666666666667, 'legal proceedings'), (4.0, 'item 3'), (3.333333333333333, 'involved include'), (1.3333333333333333, 'involved'), (1.3333333333333333, 'involved'), (1.0, 'reference'), (1.0, 'notes'), (1.0, 'incorporated'), (1.0, 'discussed'), (1.0, 'contingencies'), (1.0, 'company'), (1.0, 'commitments')]","[(16.833333333333336, 'october 2014 stock purchase plan'), (15.333333333333334, 'accelerated share repurchase agreement'), (9.333333333333334, 'stock currently trades'), (9.333333333333334, '36 per share'), (8.5, '076 december 1'), (8.333333333333334, '11 billion share'), (7.0, 'purchase plan'), (5.5, 'october 23'), (5.333333333333334, 'common stock'), (4.5, 'december 31'), (4.0, 'symbol pfe'), (4.0, 'sachs co'), (4.0, 'march 8'), (4.0, 'february 21'), (4.0, '694 holders'), (3.0, '2014'), (2.0, '11'), (1.0, 'record'), (1.0, 'price'), (1.0, 'nyse'), (1.0, 'goldman'), (1.0, 'entered'), (1.0, 'directors'), (1.0, 'board'), (1.0, 'based'), (1.0, 'authorized'), (1.0, '862'), (1.0, '57'), (1.0, '355'), (1.0, '29'), (1.0, '2017'), (1.0, '2016'), (1.0, '2016'), (1.0, '2016'), (1.0, '166')]","[(8.666666666666666, 'year financial report'), (8.666666666666666, '2016 financial report'), (8.666666666666666, '2016 financial report'), (8.0, 'heading financial review'), (8.0, '2016 form 10'), (5.0, 'form 10'), (5.0, 'financial review'), (5.0, 'financial review'), (4.0, 'january 1'), (3.666666666666667, 'pfizer inc'), (3.666666666666667, 'pfizer filed'), (3.5, 'information required'), (3.5, 'discussion discussed'), (1.6666666666666667, 'pfizer'), (1.5, 'required'), (1.5, 'discussion'), (1.0, 'reference'), (1.0, 'reference'), (1.0, 'k'), (1.0, 'item'), (1.0, 'incorporated'), (1.0, '2017'), (1.0, '000')]","[(16.0, 'may affect future results'), (15.333333333333334, 'financial risk management section'), (9.333333333333334, '2016 financial report'), (9.333333333333334, '2016 financial report'), (3.666666666666667, 'looking information'), (3.666666666666667, 'information required'), (3.5, 'item includes'), (1.6666666666666667, 'information'), (1.5, 'item'), (1.0, 'summary'), (1.0, 'shareholders'), (1.0, 'reference'), (1.0, 'provide'), (1.0, 'investors'), (1.0, 'incorporated'), (1.0, 'happy'), (1.0, 'forward'), (1.0, 'factors'), (1.0, 'discussion'), (1.0, 'disclosure')]","[(25.0, 'independent registered public accounting firm'), (9.0, 'consolidated financial statements'), (9.0, 'consolidated financial statements'), (7.666666666666667, '2016 financial report'), (4.0, 'supplementary data'), (4.0, 'related notes'), (4.0, 'information required'), (4.0, 'information required'), (1.6666666666666667, 'report'), (1.6666666666666667, 'report'), (1.0, 'reference'), (1.0, 'reference'), (1.0, 'item'), (1.0, 'incorporated')]","[(12.916666666666666, 'financial reporting managements report'), (9.25, '2016 financial report'), (7.5, 'companys internal control'), (5.416666666666666, 'financial reporting'), (5.416666666666666, 'financial reporting'), (4.5, 'internal control'), (4.5, 'internal control'), (4.5, 'internal control'), (4.0, 'reasonably likely'), (4.0, 'materially affected'), (4.0, 'materially affect'), (1.0, 'included'), (1.0, 'company'), (1.0, 'change')]"
PepsiCo,2021,"[(25.0, 'convenient food brands including cheetos'), (24.0, 'various beverage brands including 7up'), (9.0, 'markets beverage concentrates'), (9.0, 'latin america makes'), (9.0, 'apac also makes'), (9.0, 'also important commodities'), (4.0, 'natural gas'), (4.0, 'marias gamesa'), (4.0, 'lubimy sad'), (4.0, 'fountain syrups'), (4.0, 'finished goods'), (3.666666666666667, 'pepsi max'), (3.666666666666667, 'diet pepsi'), (2.0, 'markets'), (1.6666666666666667, 'pepsi'), (1.0, 'tostitos'), (1.0, 'sells'), (1.0, 'saladitas'), (1.0, 'sabritas'), (1.0, 'ruffles'), (1.0, 'number'), (1.0, 'mirinda'), (1.0, 'mabel'), (1.0, 'lays'), (1.0, 'fuel'), (1.0, 'emperador'), (1.0, 'electricity'), (1.0, 'doritos'), (1.0, 'distributes'), (1.0, 'businesses')]","[(9.0, 'numerous evolving factors'), (9.0, 'business remains uncertain'), (4.0, 'new variants'), (4.0, 'effective treatments'), (3.5, '19 pandemic'), (1.5, 'pandemic'), (1.0, 'virus'), (1.0, 'virus'), (1.0, 'vaccines'), (1.0, 'vaccines'), (1.0, 'vaccines'), (1.0, 'spread'), (1.0, 'speed'), (1.0, 'scope'), (1.0, 'impact'), (1.0, 'extent'), (1.0, 'emergence'), (1.0, 'efficacy'), (1.0, 'duration'), (1.0, 'development'), (1.0, 'depend'), (1.0, 'covid'), (1.0, 'continue'), (1.0, 'availability'), (1.0, 'administered')]","[(9.0, 'written comments regarding'), (9.0, 'issued 180 days'), (8.333333333333334, 'unresolve staff comments'), (7.833333333333334, 'unresolved staff comments'), (4.5, 'remain unresolved'), (4.0, 'item 1b'), (4.0, 'current reports'), (4.0, '2021 year'), (2.3333333333333335, 'staff'), (1.0, 'sec'), (1.0, 'sec'), (1.0, 'received'), (1.0, 'preceding'), (1.0, 'periodic'), (1.0, 'end')]","[(15.0, 'principal executive office located'), (9.0, 'significant corporate properties'), (9.0, 'division utilizes manufacturing'), (5.0, 'facilities located'), (4.0, 'storage facilities'), (4.0, 'production plants'), (4.0, 'new york'), (4.0, 'distribution centers'), (4.0, 'development facilities'), (1.0, 'warehouses'), (1.0, 'texas'), (1.0, 'research'), (1.0, 'purchase'), (1.0, 'processing'), (1.0, 'plano'), (1.0, 'offices'), (1.0, 'bottling')]","[(15.0, 'see also item 1'), (9.0, 'material adverse effect'), (5.0, 'item 1a'), (4.0, 'regulatory proceedings'), (4.0, 'management believes'), (4.0, 'financial condition'), (4.0, 'final outcome'), (4.0, 'cash flows'), (1.0, 'variety'), (1.0, 'subsidiaries'), (1.0, 'results'), (1.0, 'party'), (1.0, 'operations'), (1.0, 'litigation'), (1.0, 'legal'), (1.0, 'investigations'), (1.0, 'inquiries'), (1.0, 'foregoing'), (1.0, 'claims')]","[(42.33333333333333, 'paid consecutive quarterly cash dividends since 1965'), (5.333333333333334, 'future dividends'), (4.0, 'usually declared'), (4.0, 'paid'), (3.5, '7 billion'), (3.3333333333333335, 'dividends'), (1.5, '7'), (1.0, 'total'), (1.0, 'shareholders'), (1.0, 'september'), (1.0, 'return'), (1.0, 'pepsico'), (1.0, 'payment'), (1.0, 'november'), (1.0, 'may'), (1.0, 'march'), (1.0, 'june'), (1.0, 'july'), (1.0, 'february'), (1.0, 'expect'), (1.0, 'end'), (1.0, 'discretion'), (1.0, 'directors'), (1.0, 'declaration'), (1.0, 'board'), (1.0, 'approximately'), (1.0, '2022')]","[(9.0, 'tax cash proceeds'), (9.0, 'notes due 2021'), (9.0, 'lived intangible assets'), (9.0, 'liquidity include cash'), (9.0, '1 %) indefinite'), (4.0, 'primary sources'), (4.0, 'least annually'), (4.0, '88 billion'), (3.5, '5 billion'), (1.5, '5'), (1.0, 'result'), (1.0, 'pre'), (1.0, 'operations'), (1.0, 'impairment'), (1.0, 'goodwill'), (1.0, 'b'), (1.0, 'assessed'), (1.0, 'approximately'), (1.0, 'amortized'), (1.0, '3'), (1.0, '26'), (1.0, '26'), (1.0, '2'), (1.0, '),')]","[(4.0, 'qualitative disclosures'), (4.0, 'qualitative disclosures'), (4.0, 'market risk'), (4.0, 'market risk'), (4.0, 'managements discussion'), (4.0, 'item 7b'), (4.0, 'item 7b'), (4.0, 'item 7b'), (4.0, 'item 7a'), (4.0, 'item 7a'), (4.0, 'item 7'), (4.0, 'financial condition'), (4.0, 'business risks'), (1.0, 'results'), (1.0, 'quantitative'), (1.0, 'quantitative'), (1.0, 'operations'), (1.0, 'included'), (1.0, 'analysis')]","[(8.266666666666666, 'see item 8'), (8.266666666666666, 'see item 8'), (8.1, 'see item 15'), (8.066666666666666, 'financial statement schedules'), (8.066666666666666, 'financial statement schedule'), (5.266666666666667, 'item 8'), (5.1, 'item 15'), (5.066666666666666, 'financial statement'), (4.4, 'financial statements'), (4.4, 'financial statements'), (4.0, 'supplementary data'), (1.0, 'exhibits'), (1.0, 'company'), (1.0, 'company'), (1.0, '1')]","[(25.0, 'ongoing global business transformation initiative'), (25.0, 'independent registered public accounting firm'), (15.5, 'consolidated financial statements included'), (9.0, 'financial processing systems'), (9.0, 'continued migrating certain'), (4.5, 'systems implementations'), (4.0, 'kpmg llp'), (4.0, 'fourth quarter'), (4.0, 'form 10'), (4.0, 'erp solution'), (4.0, 'annual report'), (1.0, 'part'), (1.0, 'k'), (1.0, 'audited'), (1.0, '2021')]"
PepsiCo,2020,"[(9.0, 'also important commodities'), (4.0, 'principal ingredients'), (4.0, 'pineapple juice'), (4.0, 'natural gas'), (4.0, 'juice concentrates'), (4.0, 'distribution network'), (4.0, 'compete effectively'), (4.0, 'businesses due'), (4.0, 'allows us'), (3.5, 'snack products'), (3.5, 'corn sweeteners'), (1.5, 'products'), (1.5, 'corn'), (1.0, 'use'), (1.0, 'use'), (1.0, 'strength'), (1.0, 'quality'), (1.0, 'orange'), (1.0, 'marketing'), (1.0, 'innovation'), (1.0, 'fuel'), (1.0, 'food'), (1.0, 'flexibility'), (1.0, 'flavorings'), (1.0, 'flavorings'), (1.0, 'electricity'), (1.0, 'coupled'), (1.0, 'brands'), (1.0, 'beverage'), (1.0, 'aspartame'), (1.0, 'apple')]","[(64.0, 'hard discounters take significant additional market share away'), (9.0, 'maintain adequate oversight'), (9.0, 'effective january 1'), (4.0, 'traditional retailers'), (4.0, 'sweetened beverages'), (4.0, 'product recalls'), (4.0, 'product quality'), (4.0, 'poland enacted'), (4.0, 'graduated tax'), (4.0, 'government investigations'), (4.0, 'commerce channels'), (4.0, 'adversely affected'), (1.0, 'safety'), (1.0, 'result'), (1.0, 'litigation'), (1.0, 'inquiries'), (1.0, 'failure'), (1.0, 'e'), (1.0, 'business'), (1.0, '2021')]","[(9.0, 'written comments regarding'), (9.0, 'issued 180 days'), (4.0, 'remain unresolved'), (4.0, 'current reports'), (4.0, '2020 year'), (1.0, 'staff'), (1.0, 'sec'), (1.0, 'sec'), (1.0, 'sec'), (1.0, 'resolved'), (1.0, 'received'), (1.0, 'prior'), (1.0, 'periodic'), (1.0, 'issues'), (1.0, 'end'), (1.0, 'comment')]","[(15.0, 'principal executive office located'), (9.0, 'significant corporate properties'), (9.0, 'division utilizes manufacturing'), (5.0, 'facilities located'), (4.0, 'storage facilities'), (4.0, 'production plants'), (4.0, 'new york'), (4.0, 'distribution centers'), (4.0, 'development facilities'), (1.0, 'warehouses'), (1.0, 'texas'), (1.0, 'research'), (1.0, 'purchase'), (1.0, 'processing'), (1.0, 'plano'), (1.0, 'offices'), (1.0, 'bottling')]","[(15.0, 'see also item 1'), (9.0, 'material adverse effect'), (5.0, 'item 1a'), (4.0, 'regulatory proceedings'), (4.0, 'management believes'), (4.0, 'financial condition'), (4.0, 'final outcome'), (4.0, 'cash flows'), (1.0, 'variety'), (1.0, 'subsidiaries'), (1.0, 'results'), (1.0, 'party'), (1.0, 'operations'), (1.0, 'litigation'), (1.0, 'legal'), (1.0, 'investigations'), (1.0, 'inquiries'), (1.0, 'foregoing'), (1.0, 'claims')]","[(46.5, 'paid consecutive quarterly cash dividends since 1965'), (15.0, 'nasdaq global select market'), (9.0, 'six swiss exchange'), (6.5, 'quarterly dividend'), (5.0, 'principal market'), (4.0, 'february 4'), (4.0, 'directors declared'), (4.0, 'common stock'), (4.0, 'also listed'), (4.0, '9 billion'), (1.0, 'total'), (1.0, 'shareholders'), (1.0, 'return'), (1.0, 'expect'), (1.0, 'board'), (1.0, 'approximately'), (1.0, '82'), (1.0, '5'), (1.0, '2021'), (1.0, '2021'), (1.0, '1')]","[(16.0, 'time mandatory transition tax'), (9.0, 'branded juice products'), (7.5, 'term debt obligations'), (5.0, 'debt obligations'), (4.5, 'term liabilities'), (4.0, 'tropicana brand'), (4.0, 'tcj act'), (4.0, 'strategic alliance'), (4.0, 'operating leases'), (4.0, 'operating leases'), (3.5, 'purchasing commitments'), (1.5, 'commitments'), (1.0, 'use'), (1.0, 'one'), (1.0, 'long'), (1.0, 'long'), (1.0, 'interest'), (1.0, 'connection'), (1.0, 'co'), (1.0, 'china')]","[(4.0, 'qualitative disclosures'), (4.0, 'qualitative disclosures'), (4.0, 'market risk'), (4.0, 'market risk'), (4.0, 'managements discussion'), (4.0, 'item 7b'), (4.0, 'item 7b'), (4.0, 'item 7b'), (4.0, 'item 7a'), (4.0, 'item 7a'), (4.0, 'item 7'), (4.0, 'financial condition'), (4.0, 'business risks'), (1.0, 'results'), (1.0, 'quantitative'), (1.0, 'quantitative'), (1.0, 'operations'), (1.0, 'included'), (1.0, 'analysis')]","[(15.0, 'consolidated financial statements included'), (14.5, '2020 excluded pioneer foods'), (5.0, 'financial reporting'), (4.0, 'managements assessment'), (4.0, 'kpmg llp'), (4.0, 'internal control'), (4.0, 'form 10'), (4.0, 'december 26'), (4.0, 'annual report'), (2.5, '2020'), (1.0, 'scope'), (1.0, 'k'), (1.0, 'effectiveness'), (1.0, 'cheery'), (1.0, 'audited'), (1.0, 'acquired')]","[(23.0, 'net revenue represented approximately 2'), (16.0, 'pioneer foods total assets'), (14.5, '2020 excluded pioneer foods'), (4.0, 'sec guidance'), (4.0, 'period covered'), (4.0, 'managements assessment'), (4.0, 'internal control'), (4.0, 'financial reporting'), (4.0, 'disclosure controls'), (4.0, 'december 26'), (3.0, '2'), (2.5, '2020'), (1.0, 'scope'), (1.0, 'report'), (1.0, 'procedures'), (1.0, 'permitted'), (1.0, 'pepsico'), (1.0, 'inc'), (1.0, 'end'), (1.0, 'effectiveness'), (1.0, 'effective'), (1.0, 'cheery'), (1.0, 'acquired'), (1.0, '4'), (1.0, '1')]"
PepsiCo,2019,"[(9.0, 'also important commodities'), (4.0, 'raw milk'), (4.0, 'principal ingredients'), (4.0, 'pineapple juice'), (4.0, 'natural gas'), (4.0, 'juice concentrates'), (4.0, 'essential oils'), (4.0, 'distribution network'), (4.0, 'allows us'), (3.5, 'snack products'), (3.5, 'corn sweeteners'), (1.5, 'products'), (1.5, 'corn'), (1.0, 'wheat'), (1.0, 'vegetable'), (1.0, 'use'), (1.0, 'sugar'), (1.0, 'sucralose'), (1.0, 'strength'), (1.0, 'seasonings'), (1.0, 'rice'), (1.0, 'quality'), (1.0, 'potatoes'), (1.0, 'oranges'), (1.0, 'orange'), (1.0, 'oats'), (1.0, 'marketing'), (1.0, 'innovation'), (1.0, 'grapefruit'), (1.0, 'fuel'), (1.0, 'fruits'), (1.0, 'food'), (1.0, 'flour'), (1.0, 'flexibility'), (1.0, 'flavorings'), (1.0, 'electricity'), (1.0, 'coupled'), (1.0, 'compete'), (1.0, 'businesses'), (1.0, 'brands'), (1.0, 'beverage'), (1.0, 'aspartame'), (1.0, 'apple')]","[(16.0, 'bottle deposit return system'), (9.0, 'business partners facilities'), (9.0, 'also important commodities'), (4.0, 'united states'), (4.0, 'reduced demand'), (4.0, 'product categories'), (4.0, 'natural gas'), (4.0, 'growing number'), (4.0, 'european countries'), (4.0, 'consumer demographics'), (4.0, 'businesses due'), (4.0, '10 states'), (1.0, 'well'), (1.0, 'use'), (1.0, 'result'), (1.0, 'products'), (1.0, 'fuel'), (1.0, 'electricity'), (1.0, 'effect'), (1.0, 'consumption'), (1.0, 'changes')]","[(17.833333333333336, 'unresolved staff comments remain unresolved'), (9.0, 'issued 180 days'), (8.833333333333334, 'written comments regarding'), (7.5, 'remain unresolved'), (5.833333333333334, 'written comments'), (4.0, 'item 1b'), (4.0, 'item 1a'), (4.0, 'current reports'), (4.0, '2019 year'), (3.0, 'staff'), (1.0, 'sec'), (1.0, 'sec'), (1.0, 'sec'), (1.0, 'received'), (1.0, 'received'), (1.0, 'prior'), (1.0, 'periodic'), (1.0, 'end')]","[(9.0, 'good operating condition'), (9.0, 'division utilizes manufacturing'), (4.0, 'sufficient capacity'), (4.0, 'properties generally'), (4.0, 'production plants'), (4.0, 'distribution centers'), (4.0, 'current operations'), (3.666666666666667, 'storage facilities'), (3.666666666666667, 'development facilities'), (1.6666666666666667, 'facilities'), (1.0, 'whole'), (1.0, 'warehouses'), (1.0, 'taken'), (1.0, 'suitable'), (1.0, 'selling'), (1.0, 'research'), (1.0, 'products'), (1.0, 'processing'), (1.0, 'offices'), (1.0, 'marketing'), (1.0, 'making'), (1.0, 'distributing'), (1.0, 'connection'), (1.0, 'bottling'), (1.0, 'believe'), (1.0, 'adequate')]","[(15.0, 'see also item 1'), (9.0, 'material adverse effect'), (5.0, 'item 1a'), (4.0, 'regulatory proceedings'), (4.0, 'management believes'), (4.0, 'financial condition'), (4.0, 'final outcome'), (4.0, 'cash flows'), (1.0, 'variety'), (1.0, 'subsidiaries'), (1.0, 'results'), (1.0, 'party'), (1.0, 'operations'), (1.0, 'litigation'), (1.0, 'legal'), (1.0, 'investigations'), (1.0, 'inquiries'), (1.0, 'foregoing'), (1.0, 'claims')]","[(15.0, 'nasdaq global select market'), (9.0, 'six swiss exchange'), (5.0, 'principal market'), (4.0, 'share repurchases'), (4.0, 'common stock'), (4.0, 'also listed'), (4.0, '5 billion'), (3.5, 'future dividends'), (1.5, 'dividends'), (1.0, 'total'), (1.0, 'shareholders'), (1.0, 'return'), (1.0, 'payment'), (1.0, 'expect'), (1.0, 'discretion'), (1.0, 'directors'), (1.0, 'declaration'), (1.0, 'board'), (1.0, 'approximately'), (1.0, '7'), (1.0, '2020')]","[(15.0, 'consolidated financial statements referred'), (5.0, 'financial position'), (4.0, 'similar programs'), (4.0, 'recognize revenue'), (4.0, 'present fairly'), (4.0, 'performance obligation'), (4.0, 'material respects'), (4.0, 'historical experience'), (4.0, 'december 29'), (4.0, 'december 28'), (4.0, 'contract terms'), (4.0, 'certain u'), (4.0, 'bonus extended'), (1.0, 'satisfied'), (1.0, 'opinion'), (1.0, 'company'), (1.0, 'companies'), (1.0, 'based'), (1.0, '2019'), (1.0, '2018')]","[(4.0, 'qualitative disclosures'), (4.0, 'qualitative disclosures'), (4.0, 'market risk'), (4.0, 'market risk'), (4.0, 'managements discussion'), (4.0, 'item 7b'), (4.0, 'item 7b'), (4.0, 'item 7b'), (4.0, 'item 7a'), (4.0, 'item 7a'), (4.0, 'item 7'), (4.0, 'financial condition'), (4.0, 'business risks'), (1.0, 'results'), (1.0, 'quantitative'), (1.0, 'quantitative'), (1.0, 'operations'), (1.0, 'included'), (1.0, 'analysis')]","[(8.266666666666666, 'see item 8'), (8.266666666666666, 'see item 8'), (8.1, 'see item 15'), (8.066666666666666, 'financial statement schedules'), (8.066666666666666, 'financial statement schedule'), (5.266666666666667, 'item 8'), (5.1, 'item 15'), (5.066666666666666, 'financial statement'), (4.4, 'financial statements'), (4.4, 'financial statements'), (4.0, 'supplementary data'), (1.0, 'exhibits'), (1.0, 'company'), (1.0, 'company'), (1.0, '1')]","[(15.0, 'consolidated financial statements included'), (9.0, 'wide systems solution'), (9.0, 'financial processing systems'), (9.0, 'continued migrating certain'), (5.0, 'financial reporting'), (4.0, 'materially affected'), (4.0, 'materially affect'), (4.0, 'kpmg llp'), (4.0, 'internal control'), (4.0, 'fourth quarter'), (4.0, 'form 10'), (4.0, 'annual report'), (1.0, 'transitions'), (1.0, 'k'), (1.0, 'expect'), (1.0, 'enterprise'), (1.0, 'audited'), (1.0, '2019')]"
PepsiCo,2018,"[(16.0, 'meet changing consumer demands'), (16.0, 'climate change may result'), (15.5, 'foreign corrupt practices act'), (9.5, 'export enhancement act'), (9.0, 'trade sanctions reform'), (8.5, 'also important commodities'), (4.5, 'also required'), (4.0, 'snack portfolio'), (4.0, 'regulatory requirements'), (4.0, 'natural gas'), (4.0, 'increased legal'), (1.0, 'refine'), (1.0, 'new'), (1.0, 'fuel'), (1.0, 'food'), (1.0, 'electricity'), (1.0, 'continued'), (1.0, 'concern'), (1.0, 'comply'), (1.0, 'businesses'), (1.0, 'beverage'), (1.0, '2018')]","[(36.0, 'warning requirements could reduce overall consumption'), (9.0, 'historical operating results'), (9.0, 'future operating results'), (9.0, 'existing tax laws'), (9.0, 'additional product labeling'), (9.0, 'actively considering changes'), (4.0, 'united states'), (4.0, 'trends may'), (4.0, 'reliable indicator'), (4.0, 'business performance'), (3.5, 'recently made'), (3.5, 'proposed imposition'), (1.5, 'made'), (1.5, 'imposition'), (1.0, 'sold'), (1.0, 'products'), (1.0, 'products'), (1.0, 'many'), (1.0, 'manufactured'), (1.0, 'financial'), (1.0, 'events'), (1.0, 'distributed'), (1.0, 'countries')]","[(17.5, 'unresolved staff comments remain unresolved'), (9.0, 'issued 180 days'), (9.0, '2018 fiscal year'), (8.333333333333334, 'written comments regarding'), (7.5, 'remain unresolved'), (5.833333333333334, 'written comments'), (5.166666666666666, 'staff regarding'), (4.0, 'item 1b'), (4.0, 'item 1a'), (4.0, 'current reports'), (3.5, 'quarterly reports'), (2.6666666666666665, 'staff'), (1.5, 'quarterly'), (1.0, 'sec'), (1.0, 'sec'), (1.0, 'sec'), (1.0, 'received'), (1.0, 'received'), (1.0, 'periodic'), (1.0, 'monthly'), (1.0, 'end')]","[(9.0, 'good operating condition'), (9.0, 'division utilizes plants'), (4.0, 'sufficient capacity'), (4.0, 'properties generally'), (4.0, 'either owned'), (4.0, 'distribution centers'), (4.0, 'current operations'), (3.5, 'storage facilities'), (1.5, 'facilities'), (1.0, 'whole'), (1.0, 'warehouses'), (1.0, 'taken'), (1.0, 'suitable'), (1.0, 'selling'), (1.0, 'products'), (1.0, 'offices'), (1.0, 'marketing'), (1.0, 'making'), (1.0, 'leased'), (1.0, 'distributing'), (1.0, 'connection'), (1.0, 'believe'), (1.0, 'adequate')]","[(13.833333333333334, 'environmental authority determines paz'), (9.5, 'authority may seek'), (9.0, 'impose monetary sanctions'), (9.0, 'alleged permitting violations'), (8.0, 'pepsico alimentos z'), (4.333333333333334, 'paz would'), (4.0, 'third party'), (4.0, 'submitted evidence'), (4.0, 'july 2018'), (4.0, '3 million'), (2.3333333333333335, 'paz'), (2.0, 'z'), (1.0, 'responsible'), (1.0, 'entitled'), (1.0, 'defense'), (1.0, 'appeal'), (1.0, 'allegations'), (1.0, '1')]","[(16.0, 'publicly announced repurchase programs'), (15.333333333333334, 'open market transactions pursuant'), (15.333333333333334, 'nasdaq global select market'), (14.5, '9275 payable march 29'), (9.0, 'six swiss exchange'), (5.333333333333334, 'principal market'), (4.0, 'usually declared'), (4.0, 'quarterly dividend'), (4.0, 'directors declared'), (4.0, 'common stock'), (4.0, 'also listed'), (3.5, 'february 13'), (2.5, 'march'), (1.5, 'february'), (1.0, 'shares'), (1.0, 'september'), (1.0, 'repurchased'), (1.0, 'paid'), (1.0, 'november'), (1.0, 'may'), (1.0, 'june'), (1.0, 'july'), (1.0, 'end'), (1.0, 'dividends'), (1.0, 'board'), (1.0, '2019'), (1.0, '2019'), (1.0, '0')]","[(9.0, 'operating profit excluding'), (9.0, 'constant currency basis'), (4.0, 'may 2035'), (4.0, 'certain u'), (4.0, 'bonus extended'), (4.0, '253 million'), (4.0, '191 million'), (3.5, 'tax charge'), (1.5, 'tax'), (1.0, 'transactions'), (1.0, 'result'), (1.0, 'recorded'), (1.0, 'pre'), (1.0, 'item'), (1.0, 'b'), (1.0, '847'), (1.0, '624'), (1.0, '500'), (1.0, '5'), (1.0, '4'), (1.0, '4'), (1.0, '044'), (1.0, '0'), (1.0, '0')]","[(4.0, 'qualitative disclosures'), (4.0, 'qualitative disclosures'), (4.0, 'market risk'), (4.0, 'market risk'), (4.0, 'managements discussion'), (4.0, 'item 7b'), (4.0, 'item 7b'), (4.0, 'item 7b'), (4.0, 'item 7a'), (4.0, 'item 7a'), (4.0, 'item 7'), (4.0, 'financial condition'), (4.0, 'business risks'), (1.0, 'results'), (1.0, 'quantitative'), (1.0, 'quantitative'), (1.0, 'operations'), (1.0, 'included'), (1.0, 'analysis')]","[(8.266666666666666, 'see item 8'), (8.266666666666666, 'see item 8'), (8.1, 'see item 15'), (8.066666666666666, 'financial statement schedules'), (8.066666666666666, 'financial statement schedule'), (5.266666666666667, 'item 8'), (5.1, 'item 15'), (5.066666666666666, 'financial statement'), (4.4, 'financial statements'), (4.4, 'financial statements'), (4.0, 'supplementary data'), (1.0, 'exhibits'), (1.0, 'company'), (1.0, 'company'), (1.0, '1')]","[(25.0, 'net revenue represented approximately 5'), (25.0, 'independent registered public accounting firm'), (9.0, 'sodastreams total assets'), (9.0, 'fourth fiscal quarter'), (9.0, 'consolidated total assets'), (8.5, 'consolidated financial statements'), (4.5, 'financial reporting'), (4.0, 'sodastream ),'), (4.0, 'kpmg llp'), (4.0, 'internal control'), (3.5, 'december 2018'), (1.5, '2018'), (1.0, 'subsidiaries'), (1.0, 'pepsico'), (1.0, 'inc'), (1.0, 'changes'), (1.0, 'audited'), (1.0, 'acquired'), (1.0, '1')]"
PepsiCo,2017,"[(16.0, 'climate change may result'), (9.0, 'could adversely affect'), (8.0, 'environmental compliance requirements'), (4.0, 'wide variety'), (4.0, 'regulatory requirements'), (4.0, 'potential effects'), (4.0, 'increased legal'), (4.0, 'greenhouse gases'), (4.0, 'financial performance'), (4.0, 'expenditures necessary'), (4.0, 'enjoyable beverages'), (4.0, 'continuing concern'), (2.0, 'requirements'), (1.0, 'u'), (1.0, 'snacks'), (1.0, 'sell'), (1.0, 'reduce'), (1.0, 'outside'), (1.0, 'new'), (1.0, 'mitigate'), (1.0, 'market'), (1.0, 'make'), (1.0, 'foods'), (1.0, 'distribute'), (1.0, 'convenient'), (1.0, 'comply'), (1.0, 'changes')]","[(31.5, 'take many forms including cyber extortion'), (9.0, 'existing tax laws'), (9.0, 'actively considering changes'), (6.0, 'cyber incidents'), (4.0, 'website defacement'), (4.0, 'social engineering'), (4.0, 'phishing emails'), (3.5, 'recently made'), (3.5, 'many'), (1.5, 'made'), (1.0, 'viruses'), (1.0, 'u'), (1.0, 'theft'), (1.0, 'sold'), (1.0, 'service'), (1.0, 'ransomware'), (1.0, 'products'), (1.0, 'passwords'), (1.0, 'manufactured'), (1.0, 'malware'), (1.0, 'introduction'), (1.0, 'distributed'), (1.0, 'denial'), (1.0, 'cyberattacks'), (1.0, 'credentials'), (1.0, 'countries')]","[(9.0, 'written comments regarding'), (9.0, 'issued 180 days'), (9.0, '2017 fiscal year'), (7.333333333333334, 'unresolved staff comments'), (4.333333333333334, 'remain unresolved'), (4.333333333333334, 'remain unresolved'), (4.0, 'item 1b'), (4.0, 'current reports'), (2.0, 'staff'), (1.0, 'sec'), (1.0, 'sec'), (1.0, 'received'), (1.0, 'preceding'), (1.0, 'periodic'), (1.0, 'end')]","[(9.0, 'nab latin america'), (8.0, 'division utilizes plants'), (4.0, 'either owned'), (4.0, 'distribution centers'), (4.0, 'approximate number'), (3.666666666666667, 'storage facilities'), (3.666666666666667, 'facilities utilized'), (3.5, 'essa amena'), (2.0, 'division'), (1.6666666666666667, 'facilities'), (1.5, 'amena'), (1.0, 'warehouses'), (1.0, 'selling'), (1.0, 'qfna'), (1.0, 'products'), (1.0, 'offices'), (1.0, 'marketing'), (1.0, 'making'), (1.0, 'leased'), (1.0, 'follows'), (1.0, 'flna'), (1.0, 'distributing'), (1.0, 'connection')]","[(16.0, 'supreme administrative court issued'), (9.0, 'material adverse effect'), (4.0, 'regulatory proceedings'), (4.0, 'penalty amount'), (4.0, 'october 2017'), (4.0, 'management believes'), (4.0, 'investigations cannot'), (4.0, 'invest funds'), (4.0, 'fully resolve'), (4.0, 'financial condition'), (4.0, 'cash flows'), (4.0, 'bottling plant'), (4.0, 'appealable decision'), (3.5, 'final outcome'), (1.5, 'final'), (1.0, 'results'), (1.0, 'results'), (1.0, 'rejecting'), (1.0, 'predicted'), (1.0, 'operations'), (1.0, 'non'), (1.0, 'matter'), (1.0, 'litigation'), (1.0, 'legal'), (1.0, 'inquiries'), (1.0, 'foregoing'), (1.0, 'claims'), (1.0, 'certainty'), (1.0, 'appeal'), (1.0, 'agreed')]","[(15.0, 'blank check preferred stock'), (9.0, 'new repurchase program'), (5.0, 'common stock'), (4.0, 'publicly announced'), (4.0, 'june 30'), (4.0, 'july 1'), (4.0, 'future dividends'), (4.0, 'february 13'), (4.0, '15 billion'), (1.0, 'unissued'), (1.0, 'payment'), (1.0, 'expire'), (1.0, 'discretion'), (1.0, 'directors'), (1.0, 'declaration'), (1.0, 'company'), (1.0, 'commence'), (1.0, 'board'), (1.0, 'authorized'), (1.0, '2021'), (1.0, '2018'), (1.0, '2018')]","[(45.0, 'higher commodity inflation reduced operating profit growth'), (14.5, 'see items affecting comparability'), (10.5, 'items affecting comparability'), (9.0, 'venezuelan businesses effective'), (9.0, '1 percentage point'), (7.5, 'net income attributable'), (5.0, 'net income'), (4.5, 'primarily attributable'), (4.0, 'venezuela deconsolidation'), (4.0, 'third quarter'), (4.0, 'negatively impacted'), (4.0, 'latin america'), (4.0, 'amena segments'), (3.0, 'inflation'), (3.0, 'inflation'), (1.0, 'pepsico'), (1.0, 'essa'), (1.0, 'end'), (1.0, '2015')]","[(4.0, 'qualitative disclosures'), (4.0, 'qualitative disclosures'), (4.0, 'market risk'), (4.0, 'market risk'), (4.0, 'managements discussion'), (4.0, 'item 7b'), (4.0, 'item 7b'), (4.0, 'item 7b'), (4.0, 'item 7a'), (4.0, 'item 7a'), (4.0, 'item 7'), (4.0, 'financial condition'), (4.0, 'business risks'), (1.0, 'results'), (1.0, 'quantitative'), (1.0, 'quantitative'), (1.0, 'operations'), (1.0, 'included'), (1.0, 'analysis')]","[(8.266666666666666, 'see item 8'), (8.266666666666666, 'see item 8'), (8.1, 'see item 15'), (8.066666666666666, 'financial statement schedules'), (8.066666666666666, 'financial statement schedule'), (5.266666666666667, 'item 8'), (5.1, 'item 15'), (5.066666666666666, 'financial statement'), (4.4, 'financial statements'), (4.4, 'financial statements'), (4.0, 'supplementary data'), (1.0, 'exhibits'), (1.0, 'company'), (1.0, 'company'), (1.0, '1')]","[(25.0, 'independent registered public accounting firm'), (16.0, 'consolidated financial statements included'), (9.0, 'time periods specified'), (8.5, 'exchange commission rules'), (4.5, 'exchange act'), (4.0, 'reported within'), (4.0, 'period covered'), (4.0, 'kpmg llp'), (4.0, 'information required'), (4.0, 'form 10'), (4.0, 'disclosure controls'), (3.5, 'annual report'), (1.5, 'report'), (1.0, 'us'), (1.0, 'summarized'), (1.0, 'submit'), (1.0, 'securities'), (1.0, 'reports'), (1.0, 'recorded'), (1.0, 'processed'), (1.0, 'procedures'), (1.0, 'k'), (1.0, 'forms'), (1.0, 'file'), (1.0, 'ensure'), (1.0, 'effective'), (1.0, 'disclosed'), (1.0, 'audited')]"
AbbVie,2021,"[(25.0, 'single global business segment dedicated'), (4.0, 'markets worldwide'), (4.0, 'intended use'), (4.0, 'innovative medicines'), (4.0, 'including japan'), (4.0, 'fda reviews'), (4.0, 'determine whether'), (4.0, 'abbvie operates'), (1.0, 'therapies'), (1.0, 'sold'), (1.0, 'sale'), (1.0, 'safe'), (1.0, 'research'), (1.0, 'product'), (1.0, 'numerous'), (1.0, 'nda'), (1.0, 'manufacturing'), (1.0, 'humira'), (1.0, 'effective'), (1.0, 'development'), (1.0, 'commercialization'), (1.0, 'china'), (1.0, 'brazil'), (1.0, 'bla'), (1.0, 'australia')]","[(16.0, 'abbvie product infringes upon'), (15.5, 'third parties may claim'), (9.5, 'development may fail'), (9.0, 'major markets outside'), (4.0, 'united states'), (4.0, 'superior safety'), (4.0, 'safety concerns'), (4.0, 'patent protection'), (4.0, 'numerous reasons'), (4.0, 'intellectual property'), (4.0, 'including failure'), (4.0, 'demonstrate effectiveness'), (4.0, 'competing therapies'), (4.0, 'appear promising'), (3.5, 'pharmaceutical products'), (1.5, 'products'), (1.0, 'u'), (1.0, 'reach'), (1.0, 'marketing'), (1.0, 'market'), (1.0, 'important'), (1.0, 'efficacy')]","[(14.5, 'unresolved staff comments none'), (4.0, 'item 1b'), (2.5, 'none'), (1.0, 'unresolvement'), (1.0, 'resolved'), (1.0, 'resolved'), (1.0, 'issues'), (1.0, 'issues'), (1.0, 'issue'), (1.0, 'happy'), (1.0, 'end'), (1.0, 'clarify'), (1.0, 'case'), (1.0, 'article')]","[(25.0, 'approximately 20 million square feet'), (23.5, 'leases approximately 645 facilities worldwide'), (14.5, 'two central distribution centers'), (9.0, 'including puerto rico'), (9.0, 'floor space dedicated'), (5.5, 'development facilities'), (4.0, 'united states'), (4.0, 'new york'), (4.0, 'new jersey'), (4.0, 'december 31'), (4.0, 'company also'), (4.0, 'abbvie owns'), (4.0, 'abbott park'), (2.5, 'distribution'), (1.0, 'u'), (1.0, 'research'), (1.0, 'production'), (1.0, 'pleasanton'), (1.0, 'massachusetts'), (1.0, 'madison'), (1.0, 'located'), (1.0, 'irvine'), (1.0, 'illinois'), (1.0, 'containing'), (1.0, 'cambridge'), (1.0, 'california'), (1.0, 'california'), (1.0, 'branchburg'), (1.0, 'aggregate'), (1.0, 'administration'), (1.0, 'abvie'), (1.0, '2021')]","[(14.0, 'consolidated financial statements included'), (9.0, 'supplementary data ,""'), (6.0, 'financial statements'), (4.0, 'reference herein'), (4.0, 'note 15'), (4.0, 'note 15'), (4.0, 'legal proceedings'), (4.0, 'legal proceedings'), (4.0, 'legal proceedings'), (4.0, 'item 8'), (4.0, 'information pertaining'), (1.0, 'provided'), (1.0, 'provided'), (1.0, 'incorporated'), (1.0, 'contingencies')]","[(16.0, 'depend upon many factors'), (15.0, 'new york stock exchange'), (9.0, 'including financial condition'), (5.0, 'common stock'), (4.0, 'principal market'), (4.0, 'operating subsidiaries'), (4.0, 'capital requirements'), (1.0, 'within'), (1.0, 'timing'), (1.0, 'symbol'), (1.0, 'payment'), (1.0, 'future'), (1.0, 'earnings'), (1.0, 'dividends'), (1.0, 'discretion'), (1.0, 'directors'), (1.0, 'declaration'), (1.0, 'board'), (1.0, 'amount'), (1.0, 'abbvie'), (1.0, 'abbvie'), (1.0, 'abbv')]","[(23.0, 'pipeline includes approximately 90 compounds'), (16.0, 'actual results may differ'), (4.0, 'license agreements'), (4.0, 'eye care'), (4.0, 'development individually'), (3.0, 'pipeline'), (1.0, 'oncology'), (1.0, 'neuroscience'), (1.0, 'neuroscience'), (1.0, 'indications'), (1.0, 'immunology'), (1.0, 'focused'), (1.0, 'estimates'), (1.0, 'devices'), (1.0, 'company'), (1.0, 'collaboration'), (1.0, 'aesthetics'), (1.0, 'abbvie')]","[(34.0, '100 basis points would adversely impact'), (24.0, 'primary net foreign currency exposures'), (14.666666666666666, 'interest rate swap contracts'), (9.333333333333334, 'foreign exchange rates'), (6.0, 'adversely impacted'), (5.0, 'interest rates'), (5.0, 'interest rates'), (4.0, 'japanese yen'), (4.0, 'fair value'), (4.0, 'equity could'), (4.0, 'december 31'), (4.0, 'chinese yuan'), (4.0, 'cash flows'), (4.0, 'canadian dollar'), (4.0, 'british pound'), (4.0, '244 million'), (3.5, 'company estimates'), (1.5, 'company'), (1.0, 'risk'), (1.0, 'increase'), (1.0, 'exposed'), (1.0, 'euro'), (1.0, 'earnings'), (1.0, 'changes'), (1.0, 'approximately'), (1.0, 'abbvie'), (1.0, '2021')]","[(16.0, 'stemcentrx impairment related expenses'), (16.0, 'effective income tax rates'), (10.666666666666666, 'december 2011 pharmacyclics entered'), (9.0, 'term loan covenants'), (9.0, 'senior note covenants'), (9.0, 'cadila healthcare limited'), (9.0, '2019 also included'), (8.0, 'restated license agreement'), (5.666666666666666, 'december 2011'), (5.0, 'license agreement'), (4.666666666666666, 'december 31'), (4.0, 'worldwide collaboration'), (4.0, 'owned subsidiary'), (4.0, 'janssen biotech'), (2.5, 'pharmacyclics'), (2.5, 'entered'), (1.0, 'wholly'), (1.0, 'inc'), (1.0, 'effects'), (1.0, 'compliance'), (1.0, 'company'), (1.0, 'amended'), (1.0, 'abbvie'), (1.0, '2021')]","[(25.0, 'independent registered public accounting firm'), (14.5, 'ernst young llp expressed'), (10.5, 'ernst young llp'), (9.0, 'chief executive officer'), (4.0, 'unqualified opinion'), (4.0, 'internal control'), (4.0, 'internal control'), (4.0, 'financial reporting'), (4.0, 'december 31'), (4.0, 'attestation report'), (1.0, 'stated'), (1.0, 'richard'), (1.0, 'michael'), (1.0, 'evaluated'), (1.0, 'effectiveness'), (1.0, 'effectiveness'), (1.0, 'effectiveness'), (1.0, 'audited'), (1.0, 'abbvie'), (1.0, '2021')]"
AbbVie,2020,"[(45.0, 'european governments also regulate pharmaceutical product prices'), (16.0, 'national health care systems'), (16.0, 'applicable supervising regulatory authorities'), (16.0, 'abbvie must obtain approval'), (9.0, 'commence clinical trials'), (9.0, 'clinical trial application'), (4.0, 'target markets'), (4.0, 'large part'), (3.0, 'product'), (3.0, 'product'), (1.0, 'products'), (1.0, 'marketing'), (1.0, 'fund'), (1.0, 'cost'), (1.0, 'control')]","[(16.0, 'third parties may claim'), (16.0, 'abbvie product infringes upon'), (9.0, 'major markets outside'), (4.0, 'united states'), (4.0, 'successfully developed'), (4.0, 'pharmaceutical products'), (4.0, 'patent protection'), (4.0, 'intellectual property'), (3.5, 'marketing products'), (1.5, 'marketing'), (1.0, 'u'), (1.0, 'started'), (1.0, 'positioned'), (1.0, 'particular'), (1.0, 'number'), (1.0, 'important'), (1.0, 'develop'), (1.0, 'competitors'), (1.0, 'companies'), (1.0, 'botox'), (1.0, 'aggregate')]","[(14.5, 'unresolved staff comments none'), (4.0, 'item 1b'), (2.5, 'none'), (1.0, 'unresolvement'), (1.0, 'resolved'), (1.0, 'resolved'), (1.0, 'issues'), (1.0, 'issues'), (1.0, 'issue'), (1.0, 'happy'), (1.0, 'end'), (1.0, 'clarify'), (1.0, 'case'), (1.0, 'article')]","[(16.0, 'two central distribution centers'), (15.0, '1 north waukegan road'), (9.0, 'including puerto rico'), (5.0, 'north chicago'), (4.0, 'united states'), (4.0, 'owned properties'), (4.0, 'material encumbrances'), (4.0, 'illinois 60064'), (4.0, 'development facilities'), (4.0, 'corporate offices'), (4.0, 'company also'), (1.0, 'u'), (1.0, 'research'), (1.0, 'located'), (1.0, 'abroad'), (1.0, 'abbvie'), (1.0, 'abbvie'), (1.0, '6400')]","[(14.0, 'consolidated financial statements included'), (9.0, 'supplementary data ,""'), (6.0, 'financial statements'), (4.0, 'reference herein'), (4.0, 'note 15'), (4.0, 'note 15'), (4.0, 'legal proceedings'), (4.0, 'legal proceedings'), (4.0, 'legal proceedings'), (4.0, 'item 8'), (4.0, 'information pertaining'), (1.0, 'provided'), (1.0, 'provided'), (1.0, 'incorporated'), (1.0, 'contingencies')]","[(15.5, 'depend upon many factors'), (13.5, 'future stock market performance'), (10.0, 'stock price performance'), (9.5, 'factors deemed relevant'), (9.0, 'including financial condition'), (4.0, 'operating subsidiaries'), (4.0, 'necessarily indicative'), (4.0, 'following graph'), (4.0, 'capital requirements'), (2.5, 'future'), (1.0, 'within'), (1.0, 'timing'), (1.0, 'payment'), (1.0, 'earnings'), (1.0, 'dividends'), (1.0, 'discretion'), (1.0, 'directors'), (1.0, 'directors'), (1.0, 'declaration'), (1.0, 'board'), (1.0, 'amount'), (1.0, 'abbvie')]","[(25.0, 'commercialize investigational bispecific antibody therapeutics'), (9.0, 'acquired iprd expense'), (4.0, 'pipeline includes'), (4.0, 'license agreements'), (4.0, 'development individually'), (4.0, '90 compounds'), (4.0, '750 million'), (4.0, '2020 included'), (3.5, 'collaboration agreement'), (1.5, 'collaboration'), (1.0, 'treatment'), (1.0, 'result'), (1.0, 'research'), (1.0, 'indications'), (1.0, 'genmab'), (1.0, 'genmab'), (1.0, 'entering'), (1.0, 'devices'), (1.0, 'develop'), (1.0, 'charge'), (1.0, 'cancer')]","[(24.0, 'primary net foreign currency exposures'), (15.5, 'foreign exchange forward contracts'), (10.0, 'foreign exchange rates'), (8.5, 'dollar would decrease'), (4.5, 'interest rates'), (4.5, 'canadian dollar'), (4.0, 'underlying currencies'), (4.0, 'japanese yen'), (4.0, 'fair value'), (4.0, 'equity could'), (4.0, 'cash flows'), (4.0, 'british pound'), (4.0, 'adversely impacted'), (3.5, 'company estimates'), (1.5, 'company'), (1.0, 'u'), (1.0, 'risk'), (1.0, 'levels'), (1.0, 'hedged'), (1.0, 'exposed'), (1.0, 'euro'), (1.0, 'earnings'), (1.0, 'changes'), (1.0, 'appreciation'), (1.0, 'abbvie'), (1.0, '10'), (1.0, '1'), (1.0, '1')]","[(9.0, 'total net revenues'), (9.0, 'term loan covenants'), (9.0, 'single largest product'), (9.0, 'senior note covenants'), (4.0, 'december 31'), (4.0, 'approximately 43'), (1.0, 'humira'), (1.0, 'compliance'), (1.0, 'company'), (1.0, 'adalimumab'), (1.0, 'accounted'), (1.0, 'abbvie'), (1.0, 'abbvie'), (1.0, '61'), (1.0, '58'), (1.0, '2020'), (1.0, '2020'), (1.0, '2019'), (1.0, '2018')]","[(23.5, 'provide reasonable assurance regarding reliability'), (16.0, 'generally accepted accounting principles'), (8.0, 'internal control systems'), (5.5, 'reasonable basis'), (5.0, 'internal control'), (4.0, 'inherent limitations'), (4.0, 'financial statements'), (4.0, 'financial reporting'), (4.0, 'financial reporting'), (4.0, 'external purposes'), (4.0, 'audit provides'), (4.0, 'abbvie inc'), (3.5, 'well designed'), (1.5, 'designed'), (1.0, 'preparation'), (1.0, 'opinion'), (1.0, 'matter'), (1.0, 'company'), (1.0, 'believes'), (1.0, 'accordance')]"
AbbVie,2019,"[(47.5, 'government generally introduces price cut rounds every'), (47.5, 'european governments also regulate pharmaceutical product prices'), (19.0, 'also mandates price decreases'), (16.0, 'national health care systems'), (9.0, 'markets advanced therapies'), (4.0, 'specific products'), (4.0, 'serious diseases'), (4.0, 'abbvie develops'), (1.0, 'year'), (1.0, 'world'), (1.0, 'control'), (1.0, 'complex'), (1.0, 'address')]","[(16.0, 'abbvie product infringes upon'), (14.333333333333334, 'third parties may claim'), (9.0, 'currently contemplated timeline'), (9.0, 'access capital markets'), (4.333333333333334, 'allergan may'), (4.0, 'pending acquisition'), (4.0, 'pay dividends'), (4.0, 'intended benefits'), (4.0, 'intellectual property'), (4.0, 'generate cash'), (3.5, 'ongoing ability'), (2.3333333333333335, 'may'), (1.5, 'ability'), (1.0, 'terms'), (1.0, 'operations'), (1.0, 'depend'), (1.0, 'completed'), (1.0, 'achieve')]","[(4.0, 'first time'), (4.0, 'december 11'), (1.0, 'u'), (1.0, 'senate'), (1.0, 'senate'), (1.0, 'resolved'), (1.0, 'resolve'), (1.0, 'resolution'), (1.0, 'resolution'), (1.0, 'resolution'), (1.0, 'none'), (1.0, 'issues'), (1.0, 'issues'), (1.0, 'issue'), (1.0, 'hold'), (1.0, 'hearing'), (1.0, 'government'), (1.0, 'consider'), (1.0, 'attempted'), (1.0, 'article'), (1.0, 'article'), (1.0, 'article'), (1.0, '2015')]","[(15.0, '1 north waukegan road'), (9.0, 'one distribution center'), (9.0, 'including puerto rico'), (5.0, 'north chicago'), (4.0, 'united states'), (4.0, 'owned properties'), (4.0, 'material encumbrances'), (4.0, 'illinois 60064'), (4.0, 'corporate offices'), (1.0, 'located'), (1.0, 'company'), (1.0, 'company'), (1.0, 'abbvie'), (1.0, '6400')]","[(14.0, 'consolidated financial statements included'), (9.0, 'supplementary data ,""'), (6.0, 'financial statements'), (4.0, 'reference herein'), (4.0, 'note 15'), (4.0, 'note 15'), (4.0, 'legal proceedings'), (4.0, 'legal proceedings'), (4.0, 'legal proceedings'), (4.0, 'item 8'), (4.0, 'information pertaining'), (1.0, 'provided'), (1.0, 'provided'), (1.0, 'incorporated'), (1.0, 'contingencies')]","[(9.0, 'securities exchange act'), (4.0, 'section 18'), (4.0, 'performance graph'), (1.0, 'within'), (1.0, 'timing'), (1.0, 'subject'), (1.0, 'shall'), (1.0, 'sec'), (1.0, 'payment'), (1.0, 'future'), (1.0, 'furnished'), (1.0, 'filed'), (1.0, 'dividends'), (1.0, 'discretion'), (1.0, 'directors'), (1.0, 'deemed'), (1.0, 'declaration'), (1.0, 'board'), (1.0, 'amount'), (1.0, 'abbvie'), (1.0, '1934')]","[(16.0, 'supplemental new drug application'), (15.0, 'april 2019 regulatory approvals'), (9.0, 'success primarily resulted'), (9.0, 'severe plaque psoriasis'), (5.0, 'november 2019'), (4.0, 'younger patients'), (4.0, 'higher probabilities'), (4.0, 'abbvie submitted'), (3.5, 'line treatment'), (1.5, 'treatment'), (1.0, 'snda'), (1.0, 'sll'), (1.0, 'skyrizi'), (1.0, 'rituximab'), (1.0, 'moderate'), (1.0, 'imbruvica'), (1.0, 'first'), (1.0, 'fda'), (1.0, 'combination'), (1.0, 'cll')]","[(24.0, 'primary net foreign currency exposures'), (15.5, 'foreign exchange forward contracts'), (10.0, 'foreign exchange rates'), (8.5, 'dollar would decrease'), (4.5, 'interest rates'), (4.5, 'canadian dollar'), (4.0, 'underlying currencies'), (4.0, 'japanese yen'), (4.0, 'fair value'), (4.0, 'equity could'), (4.0, 'cash flows'), (4.0, 'british pound'), (4.0, 'adversely impacted'), (3.5, 'company estimates'), (1.5, 'company'), (1.0, 'u'), (1.0, 'risk'), (1.0, 'levels'), (1.0, 'hedged'), (1.0, 'exposed'), (1.0, 'euro'), (1.0, 'earnings'), (1.0, 'changes'), (1.0, 'appreciation'), (1.0, 'abbvie'), (1.0, '10')]","[(16.0, 'actual results may differ'), (9.0, 'treat alzheimers disease'), (9.0, 'tax sharing agreement'), (9.0, 'tax credit carryforwards'), (9.0, 'restated license agreement'), (9.0, 'income tax liabilities'), (8.0, 'company issued 1'), (4.0, 'third quarter'), (4.0, 'periods prior'), (4.0, 'neurodegenerative disorders'), (4.0, 'commercialize medicines'), (4.0, '188 million'), (4.0, '0 billion'), (3.5, 'indemnified abbvie'), (3.0, 'abbott entered'), (2.0, 'company'), (1.5, 'entered'), (1.5, 'abbvie'), (1.5, 'abbott'), (1.0, 'separation'), (1.0, 'separation'), (1.0, 'reata'), (1.0, 'reata'), (1.0, 'provides'), (1.0, 'liable'), (1.0, 'estimates'), (1.0, 'effective'), (1.0, 'develop'), (1.0, 'date'), (1.0, 'amended'), (1.0, 'alector'), (1.0, '2019')]","[(9.0, 'chief executive officer'), (7.5, 'internal control systems'), (4.5, 'internal control'), (4.0, 'well designed'), (4.0, 'reasonably likely'), (4.0, 'materially affected'), (4.0, 'materially affect'), (4.0, 'management assessed'), (4.0, 'inherent limitations'), (4.0, 'financial reporting'), (4.0, 'financial reporting'), (4.0, 'december 31'), (2.0, 'control'), (1.0, 'said'), (1.0, 'richard'), (1.0, 'michael'), (1.0, 'matter'), (1.0, 'effectiveness'), (1.0, 'company'), (1.0, 'changes'), (1.0, 'abbvie'), (1.0, '2019')]"
AbbVie,2018,"[(47.5, 'government generally introduces price cut rounds every'), (17.5, 'also mandates price decreases'), (9.0, 'markets advanced therapies'), (4.0, 'specific products'), (4.0, 'serious diseases'), (4.0, 'intended use'), (4.0, 'fda reviews'), (4.0, 'determine whether'), (4.0, 'abbvie develops'), (1.0, 'year'), (1.0, 'world'), (1.0, 'safe'), (1.0, 'product'), (1.0, 'nda'), (1.0, 'effective'), (1.0, 'complex'), (1.0, 'bla'), (1.0, 'address')]","[(14.5, 'could cause actual results'), (9.0, 'access capital markets'), (4.0, 'pay dividends'), (4.0, 'matters described'), (4.0, 'item 7'), (4.0, 'item 1a'), (4.0, 'generate cash'), (4.0, 'financial condition'), (4.0, 'anticipated include'), (3.5, 'risk factors'), (3.5, 'ongoing ability'), (2.5, 'results'), (1.5, 'factors'), (1.5, 'ability'), (1.0, 'operations'), (1.0, 'operations'), (1.0, 'management'), (1.0, 'events'), (1.0, 'discussion'), (1.0, 'differ'), (1.0, 'depend'), (1.0, 'analysis'), (1.0, 'abbvie')]","[(4.0, 'first time'), (4.0, 'december 11'), (1.0, 'u'), (1.0, 'senate'), (1.0, 'senate'), (1.0, 'resolved'), (1.0, 'resolve'), (1.0, 'resolution'), (1.0, 'resolution'), (1.0, 'resolution'), (1.0, 'none'), (1.0, 'issues'), (1.0, 'issues'), (1.0, 'issue'), (1.0, 'hold'), (1.0, 'hearing'), (1.0, 'government'), (1.0, 'consider'), (1.0, 'attempted'), (1.0, 'article'), (1.0, 'article'), (1.0, 'article'), (1.0, '2015')]","[(15.0, '1 north waukegan road'), (9.0, 'one distribution center'), (9.0, 'manufacturing facilities worldwide'), (9.0, 'including puerto rico'), (5.0, 'north chicago'), (4.0, 'united states'), (4.0, 'owned properties'), (4.0, 'material encumbrances'), (4.0, 'illinois 60064'), (4.0, 'corporate offices'), (1.0, 'located'), (1.0, 'company'), (1.0, 'abbvie'), (1.0, '6400')]","[(14.0, 'consolidated financial statements included'), (9.0, 'supplementary data ,""'), (6.0, 'financial statements'), (4.0, 'reference herein'), (4.0, 'note 14'), (4.0, 'note 14'), (4.0, 'legal proceedings'), (4.0, 'legal proceedings'), (4.0, 'legal proceedings'), (4.0, 'item 8'), (4.0, 'information pertaining'), (1.0, 'provided'), (1.0, 'provided'), (1.0, 'incorporated'), (1.0, 'contingencies')]","[(16.0, 'depend upon many factors'), (9.0, 'securities exchange act'), (9.0, 'including financial condition'), (4.0, 'section 18'), (4.0, 'performance graph'), (4.0, 'operating subsidiaries'), (4.0, 'capital requirements'), (1.0, 'within'), (1.0, 'timing'), (1.0, 'subject'), (1.0, 'shall'), (1.0, 'sec'), (1.0, 'payment'), (1.0, 'future'), (1.0, 'furnished'), (1.0, 'filed'), (1.0, 'earnings'), (1.0, 'earnings'), (1.0, 'dividends'), (1.0, 'discretion'), (1.0, 'directors'), (1.0, 'deemed'), (1.0, 'declaration'), (1.0, 'board'), (1.0, 'amount'), (1.0, 'abbvie'), (1.0, '1934')]","[(16.0, 'worldwide net revenues grew'), (16.0, 'humira sales increased 11'), (9.0, 'revenue growth related'), (9.0, 'constant currency basis'), (4.0, 'united states'), (4.0, 'driven primarily'), (1.0, 'venclexta'), (1.0, 'mavyret'), (1.0, 'imbruvica'), (1.0, '2018'), (1.0, '2017'), (1.0, '18'), (1.0, '16'), (1.0, '15')]","[(34.0, '100 basis points would adversely impact'), (14.666666666666666, 'interest rate swap contracts'), (8.333333333333334, 'foreign exchange rates'), (6.0, 'adversely impacted'), (5.0, 'interest rates'), (5.0, 'interest rates'), (4.0, 'fair value'), (4.0, 'equity could'), (4.0, 'december 31'), (4.0, 'cash flows'), (4.0, '403 million'), (3.5, 'company estimates'), (1.5, 'company'), (1.0, 'risk'), (1.0, 'increase'), (1.0, 'exposed'), (1.0, 'earnings'), (1.0, 'changes'), (1.0, 'approximately'), (1.0, 'abbvie'), (1.0, '2018')]","[(25.0, 'testosterone replacement therapy products liability'), (15.5, 'various tax positions pertaining'), (15.0, 'united states district court'), (9.5, 'net tax benefit'), (5.0, 'northern district'), (4.0, 'trial purposes'), (4.0, 'prior years'), (4.0, 'mdl rules'), (4.0, 'company recognized'), (4.0, 'approximately 4'), (4.0, '91 million'), (4.0, '2017 related'), (4.0, '131 million'), (4.0, '000 claims'), (1.0, 'resolution'), (1.0, 'pre'), (1.0, 'illinois'), (1.0, 'consolidated'), (1.0, '2018')]","[(23.0, 'provide reasonable assurance regarding reliability'), (16.0, 'generally accepted accounting principles'), (8.0, 'internal control systems'), (5.0, 'internal control'), (4.0, 'inherent limitations'), (4.0, 'financial statements'), (4.0, 'financial reporting'), (4.0, 'financial reporting'), (4.0, 'external purposes'), (4.0, 'certain assumptions'), (3.5, 'well designed'), (3.0, 'assurance'), (1.5, 'designed'), (1.0, 'system'), (1.0, 'succeed'), (1.0, 'preparation'), (1.0, 'part'), (1.0, 'matter'), (1.0, 'likelihood'), (1.0, 'events'), (1.0, 'design'), (1.0, 'design'), (1.0, 'controls'), (1.0, 'based'), (1.0, 'accordance'), (1.0, 'abbvie')]"
AbbVie,2017,"[(47.5, 'government generally introduces price cut rounds every'), (17.5, 'also mandates price decreases'), (15.0, 'including hepatitis c virus'), (9.5, 'including blood cancers'), (9.5, 'human immunodeficiency virus'), (9.0, 'chronic autoimmune diseases'), (4.0, 'treating conditions'), (3.5, 'specific products'), (1.5, 'products'), (1.0, 'year'), (1.0, 'virology'), (1.0, 'rheumatology'), (1.0, 'oncology'), (1.0, 'hiv'), (1.0, 'hcv'), (1.0, 'gastroenterology'), (1.0, 'focused'), (1.0, 'dermatology'), (1.0, 'abbvie')]","[(16.0, 'third parties may claim'), (14.666666666666666, 'lower priced generic products'), (9.0, 'product infringes upon'), (9.0, 'major markets outside'), (9.0, 'could face competition'), (9.0, 'access capital markets'), (4.666666666666666, 'products expire'), (4.666666666666666, 'pharmaceutical products'), (4.0, 'united states'), (4.0, 'pay dividends'), (4.0, 'patent protection'), (4.0, 'intellectual property'), (4.0, 'generate cash'), (3.5, 'ongoing ability'), (1.5, 'ability'), (1.0, 'u'), (1.0, 'patents'), (1.0, 'operations'), (1.0, 'marketing'), (1.0, 'important'), (1.0, 'depend'), (1.0, 'certain'), (1.0, 'abbvie'), (1.0, 'abbvie')]","[(4.0, 'first time'), (4.0, 'december 11'), (1.0, 'u'), (1.0, 'senate'), (1.0, 'senate'), (1.0, 'resolved'), (1.0, 'resolve'), (1.0, 'resolution'), (1.0, 'resolution'), (1.0, 'resolution'), (1.0, 'none'), (1.0, 'issues'), (1.0, 'issues'), (1.0, 'issue'), (1.0, 'hold'), (1.0, 'hearing'), (1.0, 'government'), (1.0, 'consider'), (1.0, 'attempted'), (1.0, 'article'), (1.0, 'article'), (1.0, 'article'), (1.0, '2015')]","[(15.0, '1 north waukegan road'), (9.0, 'one distribution center'), (9.0, 'including puerto rico'), (5.0, 'north chicago'), (4.0, 'united states'), (4.0, 'owned properties'), (4.0, 'material encumbrances'), (4.0, 'manufacturing facilities'), (4.0, 'illinois 60064'), (4.0, 'corporate offices'), (1.0, 'u'), (1.0, 'located'), (1.0, 'company'), (1.0, 'company'), (1.0, 'abbvie'), (1.0, '6400')]","[(14.0, 'consolidated financial statements included'), (9.0, 'supplementary data ,""'), (6.0, 'financial statements'), (4.0, 'reference herein'), (4.0, 'note 14'), (4.0, 'note 14'), (4.0, 'legal proceedings'), (4.0, 'legal proceedings'), (4.0, 'legal proceedings'), (4.0, 'item 8'), (4.0, 'information pertaining'), (1.0, 'provided'), (1.0, 'provided'), (1.0, 'incorporated'), (1.0, 'contingencies')]","[(15.5, 'depend upon many factors'), (9.5, 'factors deemed relevant'), (9.0, 'including financial condition'), (9.0, 'debt service obligations'), (8.5, 'access capital markets'), (4.5, 'capital requirements'), (4.0, 'regulatory constraints'), (4.0, 'operating subsidiaries'), (4.0, 'legal requirements'), (4.0, 'industry practice'), (4.0, 'covenants associated'), (1.0, 'within'), (1.0, 'timing'), (1.0, 'payment'), (1.0, 'future'), (1.0, 'earnings'), (1.0, 'dividends'), (1.0, 'discretion'), (1.0, 'directors'), (1.0, 'directors'), (1.0, 'declaration'), (1.0, 'certain'), (1.0, 'board'), (1.0, 'amount'), (1.0, 'ability'), (1.0, 'abbvie'), (1.0, 'abbvie')]","[(16.0, 'intangible asset impairment charge'), (15.5, 'hcv genotype 1 infection'), (9.5, 'hcv ns5a inhibitor'), (9.0, 'commercial paper outstanding'), (9.0, '4a protease inhibitor'), (9.0, '2016 primarily due'), (4.0, 'regimen containing'), (4.0, 'net revenues'), (4.0, 'gross margin'), (4.0, 'december 31'), (4.0, 'adult patients'), (4.0, '400 million'), (4.0, '354 million'), (3.5, 'treatment approved'), (3.5, 'treated patients'), (3.333333333333333, '2017 decreased'), (1.5, 'treatment'), (1.5, 'treated'), (1.3333333333333333, '2017'), (1.3333333333333333, '2017'), (1.0, 'wm'), (1.0, 'previously'), (1.0, 'previously'), (1.0, 'percentage'), (1.0, 'ns3'), (1.0, 'newly'), (1.0, 'mavyret'), (1.0, 'indicated'), (1.0, 'first'), (1.0, 'balance'), (1.0, 'abbvie')]","[(24.5, 'primary net foreign currency exposures'), (16.5, 'foreign exchange forward contracts'), (9.0, 'variables held constant'), (4.0, 'would decrease'), (4.0, 'underlying currencies'), (4.0, 'japanese yen'), (4.0, 'fair value'), (4.0, 'company estimates'), (4.0, 'british pound'), (1.0, 'u'), (1.0, 'levels'), (1.0, 'hedged'), (1.0, 'euro'), (1.0, 'dollar'), (1.0, 'appreciation'), (1.0, 'abbvie'), (1.0, '10'), (1.0, '1')]","[(9.0, 'performance shares vested'), (8.5, 'fair market value'), (8.5, 'business combination using'), (4.5, 'market participant'), (4.5, 'business plans'), (4.0, 'similar companies'), (4.0, 'assumptions used'), (4.0, '362 million'), (4.0, '348 million'), (4.0, '335 million'), (3.5, 'acquisition method'), (1.5, 'acquisition'), (1.0, 'views'), (1.0, 'rsus'), (1.0, 'rsas'), (1.0, 'pharmacyclics'), (1.0, 'estimates'), (1.0, 'consistent'), (1.0, 'company'), (1.0, 'company'), (1.0, 'accounting'), (1.0, 'accounted'), (1.0, '2017'), (1.0, '2016'), (1.0, '2015')]","[(24.5, 'independent registered public accounting firm'), (16.5, 'generally accepted accounting principles'), (16.0, 'provide reasonable assurance regarding'), (9.0, 'ernst young llp'), (4.0, 'unqualified opinion'), (4.0, 'internal control'), (4.0, 'financial statements'), (4.0, 'financial reporting'), (4.0, 'financial reporting'), (4.0, 'external purposes'), (1.0, 'reliability'), (1.0, 'preparation'), (1.0, 'expressed'), (1.0, 'designed'), (1.0, 'accordance'), (1.0, 'abbvie')]"
Coca-Cola,2021,"[(64.0, 'worlds top six nonalcoholic sparkling soft drink brands'), (25.0, 'united states represented 83 percent'), (23.5, 'companys worldwide unit case volume'), (17.5, 'unit case volume outside'), (4.0, 'market five'), (4.0, 'diet coke'), (4.0, 'diet coke'), (4.0, 'development goals'), (1.0, 'variety'), (1.0, 'training'), (1.0, 'sprite'), (1.0, 'programs'), (1.0, 'offer'), (1.0, 'leadership'), (1.0, 'fanta'), (1.0, 'contribute'), (1.0, 'cola'), (1.0, 'coca'), (1.0, '2021')]","[(8.0, 'evolved products depends'), (4.0, 'weather conditions'), (4.0, 'successful development'), (4.0, 'including timely'), (4.0, 'highly uncertain'), (4.0, 'future developments'), (4.0, 'financial condition'), (4.0, 'consumer acceptance'), (4.0, 'cash flows'), (4.0, '19 pandemic'), (3.5, 'full extent'), (2.0, 'products'), (1.5, 'extent'), (1.0, 'thecovid'), (1.0, 'success'), (1.0, 'sales'), (1.0, 'results'), (1.0, 'predicted'), (1.0, 'operations'), (1.0, 'operate'), (1.0, 'number'), (1.0, 'new'), (1.0, 'markets'), (1.0, 'influenced'), (1.0, 'factors'), (1.0, 'depend'), (1.0, 'cannot'), (1.0, 'affect')]","[(9.0, 'unresolved staff comments'), (4.0, 'please submit'), (3.5, 'item 1b'), (1.5, 'item'), (1.0, 'unresolvement'), (1.0, 'resolved'), (1.0, 'issues'), (1.0, 'issues'), (1.0, 'end'), (1.0, 'editor'), (1.0, 'comment'), (1.0, 'article'), (1.0, 'applicable'), (1.0, 'applicable'), (1.0, 'applicable')]","[(42.25, 'production facilities varies based upon seasonal demand'), (6.5, 'additional production'), (4.75, 'existing facilities'), (4.0, 'worldwide headquarters'), (4.0, 'management believes'), (4.0, 'capital equipment'), (4.0, 'adding shifts'), (4.0, 'acre complex'), (3.5, 'adding personnel'), (2.75, 'facilities'), (2.75, 'facilities'), (1.5, 'personnel'), (1.0, 'utilization'), (1.0, 'products'), (1.0, 'located'), (1.0, 'georgia'), (1.0, 'extent'), (1.0, 'expanding'), (1.0, 'atlanta'), (1.0, 'achieved'), (1.0, '35')]","[(23.0, 'companys income taxes going forward'), (15.4, 'upon tax calculation methodology'), (15.4, 'relevant federal tax law'), (10.0, 'reallocating income earned'), (10.0, 'companys foreign licensees'), (9.4, 'tax years 2007'), (9.4, 'tax court misinterpreted'), (9.4, '1995 tax years'), (9.0, 'significant additional liabilities'), (9.0, 'closing agreement provided'), (7.666666666666666, 'company would likely'), (6.333333333333334, 'irs agreed would'), (4.666666666666666, 'company would'), (4.0, 'material facts'), (4.0, 'company believes'), (4.0, 'assessed penalties'), (4.0, 'applicable regulations'), (2.0, 'company'), (2.0, 'agreed'), (1.6666666666666667, 'irs'), (1.6666666666666667, 'irs'), (1.0, 'using'), (1.0, 'used'), (1.0, 'subject'), (1.0, 'misapplied'), (1.0, 'event'), (1.0, 'circumstances'), (1.0, 'change'), (1.0, 'calculating'), (1.0, 'absent'), (1.0, '2009'), (1.0, '1987')]","[(9.0, 'total shareowner return'), (9.0, 'dow jones food'), (9.0, 'constructed peer group'), (8.0, 'pecker group index'), (5.0, 'pecker index'), (4.0, 'securities act'), (4.0, 'equity securities'), (4.0, 'december 31'), (4.0, '100 investment'), (1.0, 'sold'), (1.0, 'self'), (1.0, 'reinvested'), (1.0, 'registered'), (1.0, 'issuance'), (1.0, 'included'), (1.0, 'dividends'), (1.0, 'day'), (1.0, 'company'), (1.0, 'company'), (1.0, 'companies'), (1.0, 'based'), (1.0, 'assumes'), (1.0, 'amended'), (1.0, '2016'), (1.0, '1933')]","[(49.0, 'top six nonalcoholic sparkling soft drink brands'), (25.0, 'accurately predict future cash flows'), (16.0, 'defined benefit pension plans'), (16.0, 'companys total income related'), (4.0, 'may impact'), (4.0, 'market five'), (4.0, 'fair value'), (4.0, 'diet coke'), (4.0, 'diet coke'), (4.0, 'developing markets'), (4.0, '61 million'), (1.0, 'world'), (1.0, 'sprite'), (1.0, 'fanta'), (1.0, 'especially'), (1.0, 'emerging'), (1.0, 'determination'), (1.0, 'cola'), (1.0, 'coca'), (1.0, 'ability'), (1.0, '2021')]","[(22.666666666666664, 'company uses derivative financial instruments'), (16.0, 'forecasted cash flows denominated'), (15.333333333333334, 'purchases foreign currency options'), (13.833333333333334, 'foreign currency exchange rates'), (9.5, 'forward exchange contracts'), (9.0, 'hedge certain portions'), (8.5, 'interest rate volatility'), (5.5, 'interest rates'), (5.333333333333334, 'foreign currencies'), (4.666666666666666, 'company enters'), (4.0, 'reduce exposure'), (4.0, 'market risks'), (4.0, 'future issuances'), (4.0, 'commodity prices'), (4.0, 'adverse fluctuations'), (2.6666666666666665, 'company'), (1.0, 'subject'), (1.0, 'regard'), (1.0, 'existing'), (1.0, 'debt'), (1.0, 'collars')]","[(33.5, 'equally weighted among net operating revenues'), (22.333333333333336, 'performance share unit awards granted'), (10.0, 'earnings per share'), (9.333333333333334, 'predefined performance period'), (9.0, 'free cash flow'), (5.333333333333334, 'performance criteria'), (4.0, 'three years'), (4.0, 'service cost'), (4.0, 'line item'), (4.0, 'consolidated statements'), (3.5, 'net'), (1.0, 'table'), (1.0, 'recorded'), (1.0, 'loss'), (1.0, 'income'), (1.0, 'income'), (1.0, 'amounts'), (1.0, '2021'), (1.0, '2018')]","[(25.0, 'independent registered public accounting firm'), (9.0, 'companys disclosure controls'), (4.0, 'set forth'), (4.0, 'rule 13a'), (4.0, 'part ii'), (4.0, 'item 8'), (4.0, 'internal control'), (4.0, 'internal control'), (4.0, 'financial reporting'), (4.0, 'exchange act'), (4.0, 'december 31'), (4.0, 'company evaluated'), (3.5, 'attestation report'), (1.5, 'report'), (1.0, 'procedures'), (1.0, 'operation'), (1.0, 'management'), (1.0, 'effectiveness'), (1.0, 'e'), (1.0, 'design'), (1.0, 'defined'), (1.0, '2021'), (1.0, '15')]"
Coca-Cola,2020,"[(16.0, 'branded beverage products available'), (9.0, 'united states generally'), (9.0, 'cola believes people'), (9.0, 'authorized bottlers outside'), (8.5, 'independent bottling partners'), (4.5, 'consolidated bottling'), (4.0, 'stated duration'), (4.0, 'possible extensions'), (4.0, 'performing talent'), (4.0, 'important asset'), (4.0, 'distribution operations'), (4.0, 'attract high'), (1.0, 'wholesalers'), (1.0, 'well'), (1.0, 'us'), (1.0, 'subject'), (1.0, 'strive'), (1.0, 'retailers'), (1.0, 'renewals'), (1.0, 'network'), (1.0, 'make'), (1.0, 'distributors'), (1.0, 'consumers'), (1.0, 'coca'), (1.0, 'cases'), (1.0, 'bottler'), (1.0, 'agreements')]","[(14.0, 'risk legal compliance environments'), (8.0, 'evolved products depends'), (5.0, 'reputational risk'), (5.0, 'increased legal'), (4.0, 'weather conditions'), (4.0, 'successful development'), (4.0, 'including timely'), (4.0, 'exposes us'), (4.0, 'consumer acceptance'), (4.0, 'conduct business'), (2.0, 'products'), (1.0, 'success'), (1.0, 'sales'), (1.0, 'operate'), (1.0, 'number'), (1.0, 'new'), (1.0, 'markets'), (1.0, 'markets'), (1.0, 'influenced'), (1.0, 'high'), (1.0, 'factors'), (1.0, 'extent')]","[(9.0, 'unresolved staff comments'), (4.0, 'please submit'), (3.5, 'item 1b'), (1.5, 'item'), (1.0, 'unresolvement'), (1.0, 'resolved'), (1.0, 'issues'), (1.0, 'issues'), (1.0, 'end'), (1.0, 'editor'), (1.0, 'comment'), (1.0, 'article'), (1.0, 'applicable'), (1.0, 'applicable'), (1.0, 'applicable')]","[(44.0, 'production facilities varies based upon seasonal demand'), (9.0, 'north america group'), (9.0, 'acre office complex'), (6.5, 'existing facilities'), (6.5, 'additional production'), (4.0, 'worldwide headquarters'), (4.0, 'management believes'), (4.0, 'main offices'), (4.0, 'capital equipment'), (4.0, 'adding personnel'), (1.0, 'utilization'), (1.0, 'properties'), (1.0, 'products'), (1.0, 'located'), (1.0, 'included'), (1.0, 'georgia'), (1.0, 'extent'), (1.0, 'except'), (1.0, 'corporate'), (1.0, 'atlanta'), (1.0, 'achieved'), (1.0, '35')]","[(14.5, 'wisconsin insurance coverage litigation'), (9.5, 'obtain coverage agreements'), (9.0, 'transfer pricing adjustment'), (9.0, 'brazilian legal restrictions'), (8.666666666666666, 'additional tax adjustment'), (8.666666666666666, '2009 tax years'), (5.0, 'insurance companies'), (4.666666666666666, 'tax court'), (4.0, 'opinion regarding'), (4.0, 'irs increased'), (4.0, 'chem continued'), (4.0, 'amount would'), (4.0, '385 million'), (4.0, '135 million'), (1.0, 'settle'), (1.0, 'royalties'), (1.0, 'resulting'), (1.0, 'refunded'), (1.0, 'pursue'), (1.0, 'prevail'), (1.0, 'payment'), (1.0, 'licensee'), (1.0, 'know'), (1.0, 'issue'), (1.0, 'effect'), (1.0, 'company'), (1.0, 'company'), (1.0, 'company'), (1.0, 'company'), (1.0, 'brazil'), (1.0, 'aqua'), (1.0, 'appeal'), (1.0, '2007')]","[(16.0, 'principal united states market'), (14.666666666666666, 'new york stock exchange'), (9.0, 'substantially greater number'), (4.666666666666666, 'common stock'), (4.666666666666666, 'common stock'), (4.0, 'whose shares'), (4.0, 'street name'), (4.0, 'securities act'), (4.0, 'financial institutions'), (4.0, 'equity securities'), (3.5, 'beneficial holders'), (1.5, 'holders'), (1.0, 'traded'), (1.0, 'sold'), (1.0, 'registered'), (1.0, 'record'), (1.0, 'listed'), (1.0, 'include'), (1.0, 'held'), (1.0, 'figure'), (1.0, 'company'), (1.0, 'company'), (1.0, 'company'), (1.0, 'brokers'), (1.0, 'banks'), (1.0, 'amended'), (1.0, '1933')]","[(564.5, '2 latin america 29 1 north america 379 62 asia pacific 31 42 global ventures 4 bottling investments 34 100 corporate 303 251 total'), (12.5, 'corporate'), (9.0, 'millions ): europe'), (8.0, 'middle east africa'), (7.833333333333334, 'operating charges incurred'), (4.833333333333334, 'operating charges'), (4.333333333333334, 'operating segment'), (4.0, 'company recorded'), (3.5, '853 million'), (2.0, 'africa'), (1.5, '853'), (1.0, 'follows'), (1.0, '73'), (1.0, '458'), (1.0, '2020')]","[(23.0, 'company uses derivative financial instruments'), (16.0, 'used 70 functional currencies'), (13.5, 'foreign currency exchange rates'), (9.5, 'forward exchange contracts'), (8.5, 'net unrealized gain'), (8.5, 'interest rate volatility'), (5.5, 'interest rates'), (5.0, 'foreign operations'), (4.5, 'net investments'), (4.0, 'market risks'), (4.0, 'future issuances'), (4.0, 'dollar would'), (4.0, 'commodity prices'), (4.0, 'adverse fluctuations'), (4.0, '140 million'), (3.0, 'company'), (1.0, 'u'), (1.0, 'subject'), (1.0, 'regard'), (1.0, 'reduce'), (1.0, 'increased'), (1.0, 'hedges'), (1.0, 'exposure'), (1.0, 'existing'), (1.0, 'enter'), (1.0, 'debt'), (1.0, 'addition'), (1.0, '2020')]","[(16.0, 'fair value disclosures related'), (9.0, 'unrecognized tax benefits'), (9.0, 'stock options exercised'), (9.0, 'pension plan assets'), (9.0, 'next 12 months'), (4.0, 'total number'), (4.0, 'note 16'), (4.0, '47 million'), (4.0, '34 million'), (4.0, '23 million'), (1.0, 'respectively'), (1.0, 'included'), (1.0, 'expected'), (1.0, 'change'), (1.0, 'amount'), (1.0, '2020'), (1.0, '2019'), (1.0, '2018')]","[(16.0, 'quarter ended december 31'), (4.0, 'reasonably likely'), (4.0, 'period covered'), (4.0, 'materially affected'), (4.0, 'materially affect'), (4.0, 'internal control'), (4.0, 'internal control'), (4.0, 'financial reporting'), (4.0, 'disclosure controls'), (3.333333333333333, 'company evaluated'), (1.3333333333333333, 'company'), (1.3333333333333333, 'company'), (1.0, 'report'), (1.0, 'procedures'), (1.0, 'operation'), (1.0, 'end'), (1.0, 'effectiveness'), (1.0, 'design'), (1.0, 'changes'), (1.0, '2020')]"
Coca-Cola,2019,"[(16.0, 'worldwide unit case volume'), (9.0, 'united states generally'), (9.0, 'sales promotion programs'), (9.0, 'competitive factors impacting'), (9.0, 'business include pricing'), (9.0, 'authorized bottlers outside'), (4.0, 'store displays'), (4.0, 'stated duration'), (4.0, 'sale marketing'), (4.0, 'possible extensions'), (4.0, 'india accounted'), (4.0, '31 percent'), (1.0, 'us'), (1.0, 'subject'), (1.0, 'renewals'), (1.0, 'point'), (1.0, 'mexico'), (1.0, 'china'), (1.0, 'cases'), (1.0, 'brazil'), (1.0, 'bottler'), (1.0, 'agreements'), (1.0, 'advertising')]","[(14.0, 'risk legal compliance environments'), (5.0, 'reputational risk'), (5.0, 'increased legal'), (4.0, 'weather conditions'), (4.0, 'highly skilled'), (4.0, 'exposing us'), (4.0, 'diverse workforce'), (4.0, 'conduct business'), (4.0, 'business depends'), (1.0, 'success'), (1.0, 'sales'), (1.0, 'retain'), (1.0, 'products'), (1.0, 'operate'), (1.0, 'motivate'), (1.0, 'markets'), (1.0, 'markets'), (1.0, 'influenced'), (1.0, 'high'), (1.0, 'extent'), (1.0, 'develop'), (1.0, 'attract'), (1.0, 'ability')]","[(9.0, 'unresolved staff comments'), (4.0, 'please submit'), (3.5, 'item 1b'), (1.5, 'item'), (1.0, 'unresolvement'), (1.0, 'resolved'), (1.0, 'issues'), (1.0, 'issues'), (1.0, 'end'), (1.0, 'editor'), (1.0, 'comment'), (1.0, 'article'), (1.0, 'applicable'), (1.0, 'applicable'), (1.0, 'applicable')]","[(34.5, 'facilities varies based upon seasonal demand'), (15.0, 'north america operating segment'), (10.5, 'lease additional facilities'), (10.0, 'north america group'), (9.0, 'office space throughout'), (9.0, 'acre office complex'), (4.0, 'worldwide headquarters'), (4.0, 'real estate'), (4.0, 'main offices'), (4.0, 'distribution operations'), (1.0, 'world'), (1.0, 'utilization'), (1.0, 'use'), (1.0, 'storage'), (1.0, 'storage'), (1.0, 'products'), (1.0, 'processing'), (1.0, 'packaging'), (1.0, 'manufacturing'), (1.0, 'located'), (1.0, 'included'), (1.0, 'georgia'), (1.0, 'extent'), (1.0, 'atlanta'), (1.0, 'administrative'), (1.0, '35')]","[(15.0, 'certain related foreign licensees'), (14.5, 'transfer pricing matter involving'), (9.0, 'lyonnaise american holding'), (9.0, 'disputed amounts relate'), (8.0, 'company sold aqua'), (5.0, 'adjustments related'), (4.0, 'united states'), (4.0, 'taxable income'), (4.0, 'summary judgment'), (4.0, 'october 15'), (4.0, 'intangible property'), (4.0, 'company filed'), (4.0, 'appropriate amount'), (3.5, 'irs designated'), (2.5, 'matter'), (2.0, 'company'), (1.5, 'irs'), (1.0, 'report'), (1.0, 'portion'), (1.0, 'motion'), (1.0, 'mexico'), (1.0, 'litigation'), (1.0, 'licensing'), (1.0, 'licensee'), (1.0, 'inc'), (1.0, 'connection'), (1.0, 'chem'), (1.0, '2015')]","[(87.5, 'sp 500 index total return stock price plus reinvested dividends'), (30.0, 'year cumulative total return among'), (12.5, 'peer group index'), (9.0, 'substantially greater number'), (9.0, 'performance graph comparison'), (8.0, 'include bg foods'), (8.0, 'common stock'), (4.0, 'whose shares'), (4.0, 'street name'), (4.0, 'seaboard corporation'), (4.0, 'financial institutions'), (4.0, 'cola company'), (3.5, 'beneficial holders'), (2.0, 'include'), (1.5, 'holders'), (1.0, 'record'), (1.0, 'j'), (1.0, 'indices'), (1.0, 'inc'), (1.0, 'held'), (1.0, 'five'), (1.0, 'figure'), (1.0, 'coca'), (1.0, 'brokers'), (1.0, 'banks'), (1.0, '2019')]","[(19.0, 'sports drinks grew 1 percent'), (10.0, '7 percent growth'), (9.0, 'unit case volume'), (9.0, 'trading debt securities'), (9.0, 'past 12 months'), (9.0, 'nonmarketable securities totaled'), (9.0, 'equity method investments'), (7.0, 'sports drinks'), (4.0, 'unrealized gains'), (4.0, 'net income'), (4.0, 'brands acquired'), (4.0, 'acquired brands'), (4.0, '263 million'), (3.5, 'enhanced water'), (3.0, '1'), (1.5, 'water'), (1.0, 'refers'), (1.0, 'realized'), (1.0, 'losses'), (1.0, 'included'), (1.0, 'driven'), (1.0, 'company'), (1.0, 'businesses'), (1.0, 'acquisitions'), (1.0, '2018')]","[(64.0, 'financial market risks using several objective measurement systems'), (34.0, 'derivative instruments expire within 24 months'), (25.0, 'company generally hedges anticipated exposures'), (9.0, 'total notional values'), (9.0, 'foreign currency derivatives'), (6.0, '48 months'), (4.0, 'sensitivity analysis'), (4.0, 'december 31'), (4.0, '276 million'), (4.0, '142 million'), (1.0, 'monitor'), (1.0, 'majority'), (1.0, 'less'), (1.0, 'including'), (1.0, 'however'), (1.0, 'exposure'), (1.0, 'advance'), (1.0, '2019'), (1.0, '2018'), (1.0, '17'), (1.0, '14')]","[(25.0, 'accurately predict future cash flows'), (9.0, 'unrecognized tax benefits'), (9.0, 'next 12 months'), (9.0, 'grant date using'), (8.5, 'stock option grants'), (4.5, 'merton option'), (4.0, 'pricing model'), (4.0, 'may impact'), (4.0, 'fair value'), (4.0, 'fair value'), (4.0, 'developing markets'), (1.0, 'scholes'), (1.0, 'expected'), (1.0, 'estimated'), (1.0, 'especially'), (1.0, 'emerging'), (1.0, 'determination'), (1.0, 'change'), (1.0, 'black'), (1.0, 'amount'), (1.0, 'ability')]","[(14.0, 'quarter ended december 31'), (14.0, 'chief financial officer concluded'), (10.0, 'chief executive officer'), (6.0, 'december 31'), (5.0, 'financial reporting'), (4.0, 'internal control'), (4.0, 'disclosure controls'), (4.0, 'disclosure controls'), (3.333333333333333, 'company evaluated'), (1.3333333333333333, 'company'), (1.3333333333333333, 'company'), (1.0, 'procedures'), (1.0, 'operation'), (1.0, 'effectiveness'), (1.0, 'effective'), (1.0, 'design'), (1.0, 'changes'), (1.0, '2019'), (1.0, '2019')]"
Coca-Cola,2018,"[(25.0, 'cola may periodically consider options'), (9.0, 'united states generally'), (9.0, 'authorized bottlers outside'), (4.0, 'steviol glycosides'), (4.0, 'stated duration'), (4.0, 'principal non'), (4.0, 'possible extensions'), (4.0, 'ownership interest'), (4.0, 'nutritive sweeteners'), (4.0, 'acesulfame potassium'), (3.5, 'controlled bottler'), (1.5, 'bottler'), (1.0, 'use'), (1.0, 'us'), (1.0, 'sucralose'), (1.0, 'subject'), (1.0, 'saccharin'), (1.0, 'renewals'), (1.0, 'reducing'), (1.0, 'owned'), (1.0, 'divesting'), (1.0, 'cyclamate'), (1.0, 'company'), (1.0, 'coca'), (1.0, 'cases'), (1.0, 'business'), (1.0, 'aspartame'), (1.0, 'agreements')]","[(31.0, 'independent bottling partners operate could increase'), (16.0, 'thus indirectly negatively impact'), (14.0, 'risk legal compliance environments'), (5.0, 'reputational risk'), (5.0, 'increased legal'), (4.0, 'weather conditions'), (4.0, 'operating costs'), (4.0, 'exposes us'), (4.0, 'energy sources'), (4.0, 'conduct business'), (3.5, 'operate'), (3.5, 'increase'), (3.333333333333333, 'major markets'), (1.3333333333333333, 'markets'), (1.3333333333333333, 'markets'), (1.0, 'supply'), (1.0, 'shortage'), (1.0, 'sales'), (1.0, 'results'), (1.0, 'products'), (1.0, 'price'), (1.0, 'operations'), (1.0, 'influenced'), (1.0, 'high'), (1.0, 'fuel'), (1.0, 'extent'), (1.0, 'disruption')]","[(9.0, 'unresolved staff comments'), (4.0, 'please submit'), (3.5, 'item 1b'), (1.5, 'item'), (1.0, 'unresolvement'), (1.0, 'resolved'), (1.0, 'issues'), (1.0, 'issues'), (1.0, 'end'), (1.0, 'editor'), (1.0, 'comment'), (1.0, 'article'), (1.0, 'applicable'), (1.0, 'applicable'), (1.0, 'applicable')]","[(33.333333333333336, 'facilities varies based upon seasonal demand'), (9.333333333333334, 'lease additional facilities'), (9.0, 'office space throughout'), (9.0, 'acre office complex'), (4.0, 'worldwide headquarters'), (4.0, 'real estate'), (4.0, 'management believes'), (3.3333333333333335, 'facilities'), (1.0, 'world'), (1.0, 'utilization'), (1.0, 'suitable'), (1.0, 'products'), (1.0, 'products'), (1.0, 'production'), (1.0, 'located'), (1.0, 'georgia'), (1.0, 'extent'), (1.0, 'company'), (1.0, 'atlanta'), (1.0, 'adequate'), (1.0, '35')]","[(16.0, '000 active claims pending'), (9.0, 'tax court issued'), (9.0, 'summary judgment motion'), (4.0, 'management believes'), (4.0, 'first named'), (4.0, 'asbestos lawsuits'), (4.0, 'around 1985'), (4.0, 'approximately 40'), (3.5, 'company filed'), (1.5, 'company'), (1.0, 'u'), (1.0, 'u'), (1.0, 'petition'), (1.0, 'favor'), (1.0, 'except'), (1.0, 'end'), (1.0, 'disclosed'), (1.0, 'defendant'), (1.0, 'decision'), (1.0, 'currently'), (1.0, 'chem'), (1.0, 'aqua')]","[(23.0, 'plan ("" 2012 plan "")'), (16.0, 'year ended december 31'), (9.0, 'substantially greater number'), (8.5, '500 million shares'), (7.4, 'company publicly announced'), (4.5, 'whose shares'), (4.0, 'street name'), (4.0, 'securities act'), (4.0, 'october 18'), (4.0, 'financial institutions'), (4.0, 'equity securities'), (4.0, 'common stock'), (4.0, 'common stock'), (3.5, 'beneficial holders'), (3.0, '2012'), (1.5, 'holders'), (1.4, 'company'), (1.4, 'company'), (1.4, 'company'), (1.4, 'company'), (1.0, 'sold'), (1.0, 'registered'), (1.0, 'record'), (1.0, 'purchase'), (1.0, 'include'), (1.0, 'held'), (1.0, 'figure'), (1.0, 'directors'), (1.0, 'brokers'), (1.0, 'board'), (1.0, 'banks'), (1.0, 'authorized'), (1.0, '2018'), (1.0, '1933')]","[(16.0, 'two local franchise bottlers'), (13.5, 'company maintains debt levels'), (9.0, 'offset dilution resulting'), (9.0, 'interest coverage ratio'), (9.0, 'consider prudent based'), (9.0, 'based compensation plans'), (5.0, 'company refranchised'), (4.0, 'repurchase shares'), (4.0, 'employee stock'), (4.0, 'cash flows'), (4.0, 'bottling operations'), (2.5, 'debt'), (1.0, 'percentage'), (1.0, 'expect'), (1.0, 'china'), (1.0, 'capital'), (1.0, '2019'), (1.0, '2017')]","[(23.5, 'company uses derivative financial instruments'), (16.0, 'forecasted cash flows denominated'), (14.916666666666666, 'purchases foreign currency options'), (13.416666666666666, 'foreign currency exchange rates'), (9.916666666666666, 'foreign currency derivatives'), (9.5, 'forward exchange contracts'), (9.0, 'total notional values'), (9.0, 'hedge certain portions'), (5.5, 'company enters'), (5.25, 'foreign currencies'), (5.0, 'interest rates'), (4.0, 'market risks'), (4.0, 'december 31'), (4.0, 'commodity prices'), (4.0, 'adverse fluctuations'), (4.0, '142 million'), (4.0, '057 million'), (1.0, 'reduce'), (1.0, 'exposure'), (1.0, '2018'), (1.0, '2017'), (1.0, '17'), (1.0, '13')]","[(25.0, 'accurately predict future cash flows'), (16.0, 'one less day compared'), (14.0, 'first quarter 2018 results'), (9.0, 'trading debt securities'), (9.0, 'majority voting interest'), (6.0, 'first quarter'), (4.0, 'unrealized gains'), (4.0, 'net income'), (4.0, 'may impact'), (4.0, 'fair value'), (4.0, 'developing markets'), (3.5, 'company consolidates'), (1.5, 'company'), (1.0, 'realized'), (1.0, 'ownership'), (1.0, 'losses'), (1.0, 'included'), (1.0, 'impacted'), (1.0, 'especially'), (1.0, 'entities'), (1.0, 'emerging'), (1.0, 'determination'), (1.0, 'control'), (1.0, 'ability'), (1.0, '2017')]","[(16.0, 'quarter ended december 31'), (4.0, 'period covered'), (4.0, 'internal control'), (4.0, 'financial reporting'), (4.0, 'disclosure controls'), (3.5, 'company evaluated'), (1.5, 'company'), (1.0, 'report'), (1.0, 'procedures'), (1.0, 'operation'), (1.0, 'end'), (1.0, 'effectiveness'), (1.0, 'design'), (1.0, 'changes'), (1.0, '2018')]"
Coca-Cola,2017,"[(9.0, 'excluding seasonal hires'), (9.0, 'collective bargaining agreements'), (8.5, 'manufacture fountain syrups'), (4.5, 'fountain retailers'), (4.0, 'united states'), (4.0, 'steviol glycosides'), (4.0, 'principal non'), (4.0, 'nutritive sweeteners'), (4.0, 'north america'), (4.0, 'december 31'), (4.0, 'certain countries'), (4.0, 'approximately 3'), (4.0, 'acesulfame potassium'), (4.0, '700 employees'), (1.0, 'use'), (1.0, 'sucralose'), (1.0, 'sell'), (1.0, 'schweppes'), (1.0, 'saccharin'), (1.0, 'owned'), (1.0, 'cyclamate'), (1.0, 'covered'), (1.0, 'company'), (1.0, 'business'), (1.0, 'aspartame'), (1.0, '2017')]","[(22.0, 'future restructuring activities may result'), (7.0, 'restructuring activities'), (4.0, 'safety requirements'), (4.0, 'privacy laws'), (4.0, 'insecurity among'), (4.0, 'human rights'), (4.0, 'company associates'), (1.0, 'u'), (1.0, 'success'), (1.0, 'regulations'), (1.0, 'plans'), (1.0, 'n'), (1.0, 'increase'), (1.0, 'health'), (1.0, 'failure'), (1.0, 'essential'), (1.0, 'environmental'), (1.0, 'employees'), (1.0, 'comply'), (1.0, 'business'), (1.0, 'announcement')]","[(9.0, 'unresolved staff comments'), (4.0, 'please submit'), (3.5, 'item 1b'), (1.5, 'item'), (1.0, 'unresolvement'), (1.0, 'resolved'), (1.0, 'issues'), (1.0, 'issues'), (1.0, 'end'), (1.0, 'editor'), (1.0, 'comment'), (1.0, 'article'), (1.0, 'applicable'), (1.0, 'applicable'), (1.0, 'applicable')]","[(33.5, 'facilities varies based upon seasonal demand'), (15.0, 'north america operating segment'), (10.0, 'north america group'), (9.0, 'present intended purposes'), (8.0, 'sufficient production capacity'), (4.0, 'past experience'), (4.0, 'management believes'), (4.0, 'main offices'), (4.0, 'appropriately utilized'), (3.5, 'facilities'), (2.0, 'production'), (1.0, 'utilization'), (1.0, 'suitable'), (1.0, 'products'), (1.0, 'products'), (1.0, 'line'), (1.0, 'included'), (1.0, 'extent'), (1.0, 'company'), (1.0, 'adequate')]","[(15.0, 'wisconsin trial court entered'), (15.0, '15 million policy limit'), (14.5, 'final declaratory judgment regarding'), (8.5, 'insurance policies issued'), (8.0, 'remaining defendant insurers'), (8.0, 'company owned aqua'), (5.0, 'trial date'), (5.0, '400 million'), (4.5, 'insurance coverage'), (4.0, 'vigorously defend'), (4.0, 'march 5'), (4.0, 'july 24'), (4.0, 'company purchased'), (4.0, 'company intends'), (4.0, 'asserted cross'), (2.5, 'judgment'), (2.0, 'insurers'), (2.0, 'company'), (1.0, 'two'), (1.0, 'time'), (1.0, 'set'), (1.0, 'rights'), (1.0, 'prevail'), (1.0, 'position'), (1.0, 'parties'), (1.0, 'one'), (1.0, 'obligations'), (1.0, 'merits'), (1.0, 'confident'), (1.0, 'claims'), (1.0, 'chem'), (1.0, 'appealed'), (1.0, 'ability'), (1.0, '2018'), (1.0, '2007'), (1.0, '1981'), (1.0, '1970')]","[(23.0, 'plan ("" 2012 plan "")'), (23.0, 'dow jones food beverage index'), (17.0, 'dow jones tobacco index'), (10.0, 'peer group index'), (9.0, 'substantially greater number'), (9.0, 'constructed peer group'), (8.5, '500 million shares'), (7.5, 'company publicly announced'), (4.5, 'whose shares'), (4.0, 'street name'), (4.0, 'october 18'), (4.0, 'financial institutions'), (4.0, 'common stock'), (4.0, 'common stock'), (3.5, 'beneficial holders'), (3.0, '2012'), (1.5, 'holders'), (1.5, 'company'), (1.5, 'company'), (1.5, 'company'), (1.0, 'self'), (1.0, 'record'), (1.0, 'purchase'), (1.0, 'included'), (1.0, 'include'), (1.0, 'held'), (1.0, 'figure'), (1.0, 'excluded'), (1.0, 'directors'), (1.0, 'companies'), (1.0, 'brokers'), (1.0, 'board'), (1.0, 'banks'), (1.0, 'authorized')]","[(25.0, 'deferred income taxes decreased due'), (16.0, 'two local franchise bottlers'), (16.0, 'tax reform act signed'), (9.0, 'past 12 months'), (4.0, 'liabilities increased'), (4.0, 'december 22'), (4.0, 'company refranchised'), (4.0, 'brands acquired'), (4.0, 'bottling operations'), (4.0, 'acquired brands'), (1.0, 'refers'), (1.0, 'law'), (1.0, 'china'), (1.0, '2017')]","[(33.0, 'derivative instruments expire within 24 months'), (24.666666666666664, 'company uses derivative financial instruments'), (23.666666666666664, 'company generally hedges anticipated exposures'), (15.0, 'interest rate risk related'), (15.0, 'foreign currency exchange rates'), (9.0, 'highly liquid securities'), (6.0, 'interest rates'), (6.0, '36 months'), (4.0, 'reduce exposure'), (4.0, 'market risks'), (4.0, 'commodity prices'), (4.0, 'adverse fluctuations'), (3.6666666666666665, 'company'), (1.0, 'subject'), (1.0, 'majority'), (1.0, 'less'), (1.0, 'investments'), (1.0, 'however'), (1.0, 'advance')]","[(24.5, 'total unrecognized compensation cost related'), (15.5, 'based compensation awards granted'), (8.0, 'upon sale price'), (7.833333333333334, 'fair value less'), (5.0, 'sell based'), (4.833333333333334, 'fair value'), (4.333333333333334, 'carrying value'), (4.0, 'record assets'), (4.0, 'nonvested stock'), (4.0, 'nonrecurring basis'), (4.0, 'december 31'), (4.0, 'assets measured'), (4.0, '286 million'), (2.0, 'sale'), (1.0, 'table'), (1.0, 'summarized'), (1.0, 'required'), (1.0, 'plans'), (1.0, 'lower'), (1.0, 'losses'), (1.0, 'liabilities'), (1.0, 'held'), (1.0, 'gains'), (1.0, 'costs'), (1.0, 'company'), (1.0, 'agreed'), (1.0, '2017')]","[(25.0, 'cola beverages africa proprietary limited'), (16.0, 'quarter ended december 31'), (7.666666666666667, 'company began consolidating'), (4.0, 'related assets'), (4.0, 'reasonably likely'), (4.0, 'materially affected'), (4.0, 'materially affect'), (4.0, 'internal control'), (4.0, 'internal control'), (4.0, 'financial reporting'), (4.0, 'financial reporting'), (4.0, 'financial reporting'), (3.5, 'october 2017'), (1.6666666666666667, 'company'), (1.6666666666666667, 'company'), (1.5, '2017'), (1.0, 'scope'), (1.0, 'operations'), (1.0, 'operations'), (1.0, 'management'), (1.0, 'excluded'), (1.0, 'coca'), (1.0, 'changes'), (1.0, 'ccba'), (1.0, 'assessment'), (1.0, 'assessment')]"
Mastercard,2021,"[(4.0, 'internal controls'), (4.0, 'data assets'), (4.0, 'comprehensive aml'), (4.0, 'compliance officer'), (4.0, 'cft program'), (1.0, 'use'), (1.0, 'transaction'), (1.0, 'services'), (1.0, 'range'), (1.0, 'products'), (1.0, 'procedures'), (1.0, 'policies'), (1.0, 'platforms'), (1.0, 'peer'), (1.0, 'peer'), (1.0, 'network'), (1.0, 'needs'), (1.0, 'mastercard'), (1.0, 'infrastructure'), (1.0, 'including'), (1.0, 'implemented'), (1.0, 'enables'), (1.0, 'distributed'), (1.0, 'designation'), (1.0, 'customers'), (1.0, 'create'), (1.0, 'comprised'), (1.0, 'based'), (1.0, 'architecture'), (1.0, 'adapt')]","[(25.0, 'risk management activities provide protection'), (24.5, 'foregoing competitive threats could materially'), (15.0, 'litigation settlements could impact'), (4.0, 'limited number'), (4.0, 'including reducing'), (4.0, 'future limitations'), (4.0, 'compete effectively'), (4.0, 'adversely affect'), (4.0, 'adverse changes'), (3.666666666666667, 'overall business'), (3.666666666666667, 'business resulting'), (2.5, 'litigation'), (1.6666666666666667, 'business'), (1.0, 'volume'), (1.0, 'value'), (1.0, 'results'), (1.0, 'respect'), (1.0, 'relationships'), (1.0, 'operations'), (1.0, 'failure'), (1.0, 'customers'), (1.0, 'currencies')]","[(9.0, 'unresolved staff comments'), (9.0, 'unresolve staff comments'), (9.0, 'unrelaxed staff comments'), (4.0, 'item 1d'), (4.0, 'item 1c'), (4.0, 'item 1b'), (4.0, 'item 1a'), (1.0, 'respond'), (1.0, 'required'), (1.0, 'issues'), (1.0, 'applicable'), (1.0, 'applicable'), (1.0, 'applicable')]","[(16.0, 'leased commercial properties throughout'), (8.5, 'lease new space'), (4.5, 'space requirements'), (4.0, 'subsidiaries owned'), (4.0, 'related impacts'), (4.0, 'periodically review'), (4.0, 'may acquire'), (4.0, 'december 31'), (4.0, 'currently conduct'), (4.0, 'address climate'), (1.0, 'u'), (1.0, 'suitable'), (1.0, 'needs'), (1.0, 'meet'), (1.0, 'mastercard'), (1.0, 'however'), (1.0, 'facilities'), (1.0, 'countries'), (1.0, 'business'), (1.0, 'business'), (1.0, 'believe'), (1.0, 'adequate'), (1.0, '2021')]","[(16.0, 'consolidated financial statements included'), (7.0, 'legal proceedings refer'), (4.333333333333334, 'regulatory proceedings'), (4.333333333333334, 'regulatory proceedings'), (4.0, 'part ii'), (4.0, 'note 21'), (4.0, 'note 13'), (4.0, 'item 8'), (4.0, 'item 3'), (4.0, 'item 3'), (4.0, 'accrued litigation'), (4.0, 'accrued expenses'), (1.6666666666666667, 'legal'), (1.6666666666666667, 'legal')]","[(16.0, '49 per share paid'), (12.5, 'class b common stock'), (9.0, 'quarterly cash dividend'), (8.0, 'exchange quotation system'), (6.0, 'common stock'), (4.0, 'publicly listed'), (4.0, 'graph assumes'), (4.0, 'february 9'), (4.0, 'february 8'), (4.0, 'directors declared'), (4.0, '100 investment'), (2.5, 'class'), (2.0, 'exchange'), (1.0, 'reinvestment'), (1.0, 'indices'), (1.0, 'holders'), (1.0, 'dividends'), (1.0, 'board'), (1.0, '2022'), (1.0, '2022'), (1.0, '0')]","[(16.0, 'lower effective tax rates'), (9.0, 'favorable geographic mix'), (9.0, 'data services solutions'), (4.0, 'total consideration'), (4.0, 'significant portion'), (4.0, 'remaining growth'), (4.0, 'net income'), (4.0, 'largest customers'), (4.0, 'driven primarily'), (4.0, 'december 31'), (4.0, 'cyber intelligence'), (4.0, 'concentrated among'), (4.0, '3 billion'), (3.5, '2021 contributed'), (1.5, '2021'), (1.0, 'respectively'), (1.0, 'earnings'), (1.0, 'completed'), (1.0, 'businesses'), (1.0, 'acquisitions'), (1.0, '4'), (1.0, '2020')]","[(21.166666666666664, 'market risk sensitive instruments arising'), (15.666666666666666, 'management monitors risk exposures'), (15.0, 'foreign currency exchange rates'), (10.0, 'derivative financial instruments'), (7.166666666666666, 'market risk'), (5.0, 'interest rates'), (4.0, 'policies governing'), (4.0, 'ongoing basis'), (4.0, 'economic losses'), (4.0, 'adverse changes'), (1.0, 'use'), (1.0, 'risks'), (1.0, 'potential'), (1.0, 'oversees'), (1.0, 'manage'), (1.0, 'investments'), (1.0, 'incurred'), (1.0, 'implementation'), (1.0, 'funding'), (1.0, 'factors'), (1.0, 'establishes')]","[(22.5, 'purported merchant class plaintiffs filed'), (16.5, 'certain purported agreements entered'), (16.0, 'mastercards initial public offering'), (9.0, 'supplemental complaint alleging'), (9.0, 'monte carlo technique'), (8.5, 'underlying net equity'), (8.5, 'income approach based'), (4.5, 'liabilities based'), (4.5, 'equity method'), (4.0, 'violate u'), (4.0, 'subsequent periods'), (4.0, 'may 2006'), (4.0, 'july 2006'), (4.0, 'investments accounted'), (4.0, 'intangible assets'), (4.0, 'identifiable tangible'), (4.0, 'financial institutions'), (4.0, 'fair values'), (4.0, 'fair value'), (4.0, 'determined utilizing'), (4.0, 'contingent consideration'), (4.0, 'common stock'), (3.5, 'european merchants'), (3.0, 'class'), (3.0, 'acquisition date'), (1.5, 'merchants'), (1.5, 'date'), (1.5, 'acquisition'), (1.0, 'well'), (1.0, 'settlements'), (1.0, 'pan'), (1.0, 'number'), (1.0, 'mastercard'), (1.0, 'ipo'), (1.0, 'ipo'), (1.0, 'group'), (1.0, 'excess'), (1.0, 'cost'), (1.0, 'connection'), (1.0, 'allocated'), (1.0, '1')]","[(25.0, 'independent registered public accounting firm'), (15.5, 'consolidated financial statements included'), (9.5, 'chief financial officer'), (9.0, 'chief executive officer'), (4.0, 'pricewaterhousecoopers llp'), (4.0, 'form 10'), (4.0, 'disclosure controls'), (4.0, 'december 31'), (4.0, 'annual report'), (1.0, 'reviewed'), (1.0, 'procedures'), (1.0, 'president'), (1.0, 'members'), (1.0, 'management'), (1.0, 'k'), (1.0, 'effectiveness'), (1.0, 'audited'), (1.0, 'assistance'), (1.0, '2021')]"
Mastercard,2020,"[(16.0, 'mastercard makes payments easier'), (16.0, 'cyber risk assessment capabilities'), (9.0, 'help financial institutions'), (9.0, 'customers one partner'), (4.0, 'wide range'), (4.0, 'services using'), (4.0, 'receive revenue'), (4.0, 'rail network'), (4.0, 'payment solutions'), (4.0, 'known brands'), (4.0, 'issue cards'), (4.0, 'interest rates'), (4.0, 'governments secure'), (4.0, 'fees charged'), (4.0, 'extend credit'), (4.0, 'digital assets'), (4.0, 'data analytics'), (4.0, 'border needs'), (4.0, 'account holders'), (1.0, 'well'), (1.0, 'use'), (1.0, 'turn'), (1.0, 'providing'), (1.0, 'operate'), (1.0, 'offers'), (1.0, 'multi'), (1.0, 'merchants'), (1.0, 'family'), (1.0, 'efficient'), (1.0, 'domestic'), (1.0, 'determine'), (1.0, 'cross'), (1.0, 'corporations'), (1.0, 'along'), (1.0, 'ai')]","[(25.0, 'risk management activities provide protection'), (9.0, 'similar health epidemic'), (8.0, 'global covid pandemic'), (4.0, 'ultimate impact'), (4.0, 'threats due'), (4.0, 'significant rise'), (4.0, 'significant portion'), (4.0, 'limited number'), (4.0, 'highly uncertain'), (4.0, 'adverse changes'), (2.0, 'covid'), (1.0, 'working'), (1.0, 'workforce'), (1.0, 'value'), (1.0, 'types'), (1.0, 'subject'), (1.0, 'resulted'), (1.0, 'respect'), (1.0, 'home'), (1.0, 'currencies'), (1.0, 'change'), (1.0, 'advent'), (1.0, '19')]","[(9.0, 'unresolved staff comments'), (9.0, 'unresolve staff comments'), (9.0, 'unrelaxed staff comments'), (4.0, 'item 1d'), (4.0, 'item 1c'), (4.0, 'item 1b'), (4.0, 'item 1a'), (1.0, 'respond'), (1.0, 'required'), (1.0, 'issues'), (1.0, 'applicable'), (1.0, 'applicable'), (1.0, 'applicable')]","[(16.0, 'leased commercial properties throughout'), (4.0, 'subsidiaries owned'), (4.0, 'principal technology'), (4.0, 'operations center'), (4.0, 'new york'), (4.0, 'december 31'), (4.0, 'currently conduct'), (4.0, 'corporate headquarters'), (1.0, 'u'), (1.0, 'suitable'), (1.0, 'purchase'), (1.0, 'mastercard'), (1.0, 'located'), (1.0, 'facilities'), (1.0, 'countries'), (1.0, 'business'), (1.0, 'believe'), (1.0, 'adequate'), (1.0, '2020')]","[(16.0, 'consolidated financial statements included'), (7.0, 'legal proceedings refer'), (4.333333333333334, 'regulatory proceedings'), (4.333333333333334, 'regulatory proceedings'), (4.0, 'part ii'), (4.0, 'note 21'), (4.0, 'note 13'), (4.0, 'item 8'), (4.0, 'item 3'), (4.0, 'item 3'), (4.0, 'accrued litigation'), (4.0, 'accrued expenses'), (1.6666666666666667, 'legal'), (1.6666666666666667, 'legal')]","[(16.0, 'cumulative total stockholder return'), (9.0, 'quarterly cash dividend'), (9.0, '96 136 136'), (4.0, 'directors declared'), (4.0, 'common stock'), (4.0, 'average price'), (4.0, '100 investment'), (4.0, '03 billion'), (3.5, 'graph assumes'), (1.5, 'graph'), (1.0, 'table'), (1.0, 'reinvestment'), (1.0, 'mastercards'), (1.0, 'indices'), (1.0, 'dividends'), (1.0, 'compare'), (1.0, 'class'), (1.0, 'board'), (1.0, '91'), (1.0, '330'), (1.0, '0')]","[(9.0, 'spread rapidly across'), (9.0, 'significant negative effects'), (8.0, 'transactional currency represents'), (4.0, 'measures taken'), (4.0, 'global economy'), (4.0, 'future developments'), (4.0, 'functional currency'), (4.0, 'full extent'), (4.0, 'financial condition'), (4.0, 'expense transactions'), (4.0, 'converting revenue'), (2.0, 'currency'), (1.0, 'results'), (1.0, 'response'), (1.0, 'pandemic'), (1.0, 'pandemic'), (1.0, 'operations'), (1.0, 'impact'), (1.0, 'globe'), (1.0, 'effect'), (1.0, 'depend'), (1.0, 'covid'), (1.0, 'coronavirus'), (1.0, 'business'), (1.0, 'affect'), (1.0, '19')]","[(20.333333333333336, 'market risk sensitive instruments arising'), (13.0, 'foreign currency exchange rates'), (9.333333333333334, 'risk management activities'), (9.0, 'consolidated financial statements'), (8.5, 'interest rate exposures'), (6.833333333333334, 'market risk'), (6.0, 'foreign currency'), (5.5, 'interest rates'), (5.5, 'hedging instruments'), (4.0, 'note 23'), (4.0, 'economic losses'), (4.0, 'adverse changes'), (1.0, 'potential'), (1.0, 'managed'), (1.0, 'incurred'), (1.0, 'factors'), (1.0, 'discussed'), (1.0, 'derivative')]","[(34.0, 'company declared total per share dividends'), (18.0, 'except per share data'), (16.0, 'years ended december 31'), (14.5, 'class b common stock'), (9.0, 'monte carlo technique'), (9.0, 'income approach based'), (9.0, 'corporate services business'), (8.5, '2020 2019 2018'), (4.5, 'august 2019'), (4.0, 'subsequent periods'), (4.0, 'nets denmark'), (4.0, 'mastercard entered'), (4.0, 'fair value'), (4.0, 'determined utilizing'), (4.0, 'definitive agreement'), (4.0, 'contingent consideration'), (4.0, 'acquisition date'), (2.5, 'class'), (1.0, 'summarized'), (1.0, 'millions'), (1.0, 'majority'), (1.0, 'acquire')]","[(25.0, 'independent registered public accounting firm'), (15.0, 'consolidated financial statements included'), (5.0, 'financial reporting'), (4.0, 'pricewaterhousecoopers llp'), (4.0, 'mastercard incorporated'), (4.0, 'management assessed'), (4.0, 'internal control'), (4.0, 'form 10'), (4.0, 'december 31'), (4.0, 'annual report'), (1.0, 'k'), (1.0, 'effectiveness'), (1.0, 'audited'), (1.0, '2020')]"
Mastercard,2019,"[(4.0, 'item 5'), (4.0, 'item 4'), (4.0, 'item 3'), (4.0, 'item 2'), (4.0, 'item 1'), (4.0, 'item 1'), (4.0, 'item 1'), (3.333333333333333, 'new company'), (3.333333333333333, 'new business'), (3.25, 'new ceo'), (2.833333333333333, 'business needs'), (1.5, 'needs'), (1.3333333333333333, 'company'), (1.3333333333333333, 'company'), (1.3333333333333333, 'business'), (1.3333333333333333, 'business'), (1.3333333333333333, 'business'), (1.3333333333333333, 'business'), (1.25, 'ceo'), (1.25, 'ceo'), (1.25, 'ceo'), (1.0, 'top'), (1.0, 'responsible'), (1.0, 'makes'), (1.0, 'make'), (1.0, 'loss'), (1.0, 'list')]","[(12.1, 'risk factors risk factors'), (9.05, 'risk factors include'), (9.0, 'infantile disease may'), (6.05, 'risk factors'), (4.0, 'item 1a'), (4.0, 'adverse effect'), (3.5, 'adverse history'), (2.8, 'risk'), (1.5, 'history'), (1.0, 'pregnant'), (1.0, 'person'), (1.0, 'person'), (1.0, 'person'), (1.0, 'life'), (1.0, 'health'), (1.0, 'future')]","[(9.0, 'confidential support call'), (8.5, 'unresolved staff comments'), (8.5, 'unresolved staff comments'), (8.5, 'unresolve staff comments'), (7.666666666666667, 'local samaritans branch'), (4.0, 'see www'), (4.0, 'please submit'), (4.0, 'item 1b'), (4.0, 'item 1b'), (4.0, 'item 1a'), (4.0, '08457 909090'), (2.5, 'comments'), (1.6666666666666667, 'samaritans'), (1.6666666666666667, 'samaritans'), (1.0, 'visit'), (1.0, 'uk'), (1.0, 'org'), (1.0, 'mailonline'), (1.0, 'comment'), (1.0, 'co')]","[(4.625, 'property property properties'), (4.0, 'item 8'), (4.0, 'item 7'), (4.0, 'item 6'), (4.0, 'item 5'), (4.0, 'item 5'), (4.0, 'item 4'), (4.0, 'item 3'), (4.0, 'item 2'), (4.0, 'item 2'), (4.0, 'item 10'), (3.0, 'property properties'), (1.625, 'property'), (1.625, 'property'), (1.625, 'property'), (1.625, 'property'), (1.625, 'property'), (1.375, 'properties'), (1.375, 'properties'), (1.375, 'properties'), (1.375, 'properties'), (1.375, 'properties'), (1.375, 'properties'), (1.0, 'maintenance'), (1.0, 'construction'), (1.0, 'building'), (1.0, 'building')]","[(9.0, 'next two weeks'), (4.0, 'legal proceedings'), (4.0, 'legal proceedings'), (4.0, 'item 6'), (4.0, 'item 5'), (4.0, 'item 4'), (4.0, 'item 3'), (4.0, 'first time'), (1.0, 'whether'), (1.0, 'judge'), (1.0, 'judge'), (1.0, 'judge'), (1.0, 'hearing'), (1.0, 'heard'), (1.0, 'hear'), (1.0, 'entitled'), (1.0, 'court'), (1.0, 'court'), (1.0, 'case'), (1.0, 'case'), (1.0, 'case'), (1.0, 'brought')]","[(15.5, 'new york stock exchange'), (9.5, 'common stock trades'), (9.0, 'account various factors'), (8.5, 'anticipated cash needs'), (4.5, 'available cash'), (4.0, 'sole discretion'), (4.0, 'operating results'), (4.0, 'future dividends'), (4.0, 'financial condition'), (4.0, 'dividend declaration'), (1.0, 'taking'), (1.0, 'symbol'), (1.0, 'payment'), (1.0, 'including'), (1.0, 'directors'), (1.0, 'current'), (1.0, 'class'), (1.0, 'board')]","[(25.0, 'local currency basis increased 13'), (16.0, 'repurchased 26 million shares'), (4.0, 'united states'), (4.0, 'prior year'), (4.0, 'net revenue'), (4.0, 'individual country'), (4.0, 'common stock'), (4.0, '2019 versus'), (4.0, '0 billion'), (1.0, 'period'), (1.0, 'generated'), (1.0, 'gdv'), (1.0, '8'), (1.0, '6'), (1.0, '10')]","[(23.666666666666664, 'foreign exchange rates could result'), (23.666666666666664, 'foreign exchange derivative contracts outstanding'), (11.666666666666666, 'foreign exchange risk'), (9.0, 'future cash flows'), (9.0, 'fair value loss'), (9.0, 'daily settlement activities'), (4.0, 'maximum length'), (4.0, 'hypothetical 10'), (4.0, 'december 31'), (4.0, 'also subject'), (4.0, 'adverse change'), (4.0, '30 years'), (4.0, '144 million'), (4.0, '113 million'), (1.0, 'variability'), (1.0, 'time'), (1.0, 'part'), (1.0, 'hedged'), (1.0, 'exposure'), (1.0, 'effect'), (1.0, 'approximately'), (1.0, '2019'), (1.0, '2018')]","[(9.0, 'monte carlo technique'), (8.5, 'underlying net equity'), (8.5, 'income approach based'), (4.5, 'liabilities based'), (4.5, 'equity method'), (4.0, 'subsequent periods'), (4.0, 'realized gains'), (4.0, 'investments accounted'), (4.0, 'intangible assets'), (4.0, 'identifiable tangible'), (4.0, 'fair values'), (4.0, 'fair value'), (4.0, 'determined utilizing'), (4.0, 'contingent consideration'), (3.5, 'sale securities'), (3.0, 'acquisition date'), (1.5, 'sale'), (1.5, 'date'), (1.5, 'acquisition'), (1.0, 'significant'), (1.0, 'losses'), (1.0, 'excess'), (1.0, 'cost'), (1.0, 'available'), (1.0, 'allocated'), (1.0, '2019'), (1.0, '2018'), (1.0, '2017')]","[(25.0, 'independent registered public accounting firm'), (15.5, 'consolidated financial statements included'), (9.5, 'chief financial officer'), (9.0, 'chief executive officer'), (4.0, 'pricewaterhousecoopers llp'), (4.0, 'form 10'), (4.0, 'disclosure controls'), (4.0, 'december 31'), (4.0, 'annual report'), (1.0, 'reviewed'), (1.0, 'procedures'), (1.0, 'president'), (1.0, 'members'), (1.0, 'management'), (1.0, 'k'), (1.0, 'effectiveness'), (1.0, 'audited'), (1.0, 'assistance'), (1.0, '2019')]"
Mastercard,2018,"[(9.0, 'based payment capabilities'), (8.5, 'rapidly evolving legal'), (8.333333333333334, 'local regulatory schemes'), (4.5, 'legal challenges'), (4.333333333333334, 'regulatory environment'), (4.333333333333334, 'heightened regulatory'), (4.0, 'time account'), (4.0, 'offer real'), (4.0, 'legislative scrutiny'), (4.0, 'internal controls'), (4.0, 'ctf program'), (4.0, 'comprehensive aml'), (4.0, 'compliance officer'), (1.0, 'vocalink'), (1.0, 'procedures'), (1.0, 'policies'), (1.0, 'operate'), (1.0, 'mastercard'), (1.0, 'including'), (1.0, 'implemented'), (1.0, 'expansion'), (1.0, 'dynamic'), (1.0, 'designation'), (1.0, 'comprised'), (1.0, 'acquisition')]","[(9.0, 'one new law'), (9.0, 'material adverse impact'), (9.0, 'establish interchange rates'), (9.0, 'devoting substantial resources'), (4.0, 'regulatory proceedings'), (4.0, 'overall business'), (4.0, 'legislative activity'), (4.0, 'business created'), (3.5, 'risks described'), (1.5, 'risks'), (1.0, 'right'), (1.0, 'results'), (1.0, 'replicated'), (1.0, 'regulation'), (1.0, 'potential'), (1.0, 'operations'), (1.0, 'magnified'), (1.0, 'litigation'), (1.0, 'jurisdictions'), (1.0, 'defending'), (1.0, 'could')]","[(9.0, 'unresolved staff comments'), (4.0, 'please submit'), (3.5, 'item 1b'), (1.5, 'item'), (1.0, 'unresolvement'), (1.0, 'resolved'), (1.0, 'issues'), (1.0, 'issues'), (1.0, 'end'), (1.0, 'editor'), (1.0, 'comment'), (1.0, 'article'), (1.0, 'applicable'), (1.0, 'applicable'), (1.0, 'applicable')]","[(16.0, 'leased 169 commercial properties'), (9.0, 'lease new space'), (8.0, 'facilities primarily consist'), (4.0, 'subsidiaries owned'), (4.0, 'regional offices'), (4.0, 'operations centers'), (4.0, 'may acquire'), (4.0, 'december 31'), (4.0, 'currently conduct'), (2.0, 'facilities'), (1.0, 'well'), (1.0, 'suitable'), (1.0, 'needs'), (1.0, 'meet'), (1.0, 'mastercard'), (1.0, 'corporate'), (1.0, 'business'), (1.0, 'business'), (1.0, 'believe'), (1.0, 'adequate')]","[(15.0, 'consolidated financial statements included'), (10.0, 'annual financial statements'), (7.666666666666667, 'item 8 refers'), (4.666666666666667, 'item 8'), (4.666666666666667, 'item 8'), (4.0, 'regulatory proceedings'), (4.0, 'part ii'), (4.0, 'part ii'), (4.0, 'note 20'), (4.0, 'note 12'), (4.0, 'accrued litigation'), (4.0, 'accrued expenses'), (1.0, 'refer'), (1.0, 'legal'), (1.0, 'company')]","[(16.0, 'cumulative total stockholder return'), (12.333333333333334, 'class b common stock'), (9.0, 'mastercard repurchased 4'), (9.0, '25 per share'), (9.0, '20 per share'), (8.5, 'quarterly cash dividend'), (8.5, '4 million shares'), (6.0, 'common stock'), (4.5, 'dividend declaration'), (4.5, '888 million'), (4.333333333333334, 'mastercards class'), (4.0, 'years presented'), (4.0, 'sole discretion'), (4.0, 'future dividends'), (4.0, 'february 5'), (4.0, 'average price'), (3.5, 'directors declared'), (2.3333333333333335, 'class'), (1.5, 'directors'), (1.0, 'table'), (1.0, 'stockholders'), (1.0, 'payment'), (1.0, 'graph'), (1.0, 'follows'), (1.0, 'compare'), (1.0, 'company'), (1.0, 'board'), (1.0, 'board'), (1.0, '2019'), (1.0, '201'), (1.0, '0')]","[(16.0, 'net revenue increased 20'), (9.0, 'provide pricing rebates'), (9.0, '219 million accrual'), (8.5, 'future cash payments'), (8.0, 'contingent consideration attributable'), (7.5, '2018 versus 2017'), (4.5, 'future performance'), (4.5, '2018 related'), (4.0, 'transaction volumes'), (4.0, 'standard fees'), (4.0, 'neutral basis'), (4.0, 'december 31'), (4.0, 'become due'), (4.0, 'amounts due'), (4.0, 'acquisitions made'), (3.5, 'table also'), (2.0, 'contingent'), (2.0, '2017'), (1.5, 'table'), (1.0, 'reported'), (1.0, 'included'), (1.0, 'include'), (1.0, 'incentives'), (1.0, 'exchange'), (1.0, 'customers'), (1.0, 'currency'), (1.0, 'agreements')]","[(30.0, 'also use foreign currency denominated debt'), (9.0, 'scheduled annual maturities'), (9.0, 'fixed income securities'), (8.5, 'effective interest rates'), (8.0, 'denominated debt'), (6.0, 'foreign operations'), (4.5, 'exchange rates'), (4.0, 'sale investments'), (4.0, 'net investment'), (4.0, 'maturity distribution'), (4.0, 'fair value'), (4.0, 'december 31'), (4.0, 'adverse movements'), (3.5, 'principal amounts'), (1.5, 'principal'), (1.0, 'well'), (1.0, 'portion'), (1.0, 'included'), (1.0, 'hedge'), (1.0, 'follows'), (1.0, 'euro'), (1.0, 'available')]","[(9.0, 'exercise significant influence'), (9.0, 'consolidated balance sheet'), (8.0, 'substance common stock'), (5.0, 'common stock'), (4.0, 'penalties payable'), (4.0, 'equity method'), (4.0, 'december 31'), (3.5, 'company accounts'), (1.5, 'company'), (1.0, 'recognized'), (1.0, 'ownership'), (1.0, 'material'), (1.0, 'investments'), (1.0, 'investee'), (1.0, 'holds'), (1.0, 'generally'), (1.0, 'amounts'), (1.0, 'accounting'), (1.0, 'ability'), (1.0, '50'), (1.0, '2018'), (1.0, '2017'), (1.0, '20')]","[(25.0, 'independent registered public accounting firm'), (15.0, 'consolidated financial statements included'), (5.0, 'financial reporting'), (4.0, 'pricewaterhousecoopers llp'), (4.0, 'mastercard incorporated'), (4.0, 'management assessed'), (4.0, 'internal control'), (4.0, 'form 10'), (4.0, 'december 31'), (4.0, 'annual report'), (1.0, 'k'), (1.0, 'effectiveness'), (1.0, 'audited'), (1.0, '2018')]"
Mastercard,2017,"[(16.0, 'central acquiring rules within'), (9.0, 'rapidly evolving legal'), (9.0, 'interregional interchange rates'), (9.0, 'european union issued'), (9.0, 'european economic area'), (4.0, 'regulatory environment'), (4.0, 'objections related'), (4.0, 'legislative scrutiny'), (4.0, 'internal controls'), (4.0, 'heightened regulatory'), (4.0, 'ctf program'), (4.0, 'comprehensive aml'), (4.0, 'compliance officer'), (1.0, 'statement'), (1.0, 'set'), (1.0, 'procedures'), (1.0, 'policies'), (1.0, 'operate'), (1.0, 'mastercard'), (1.0, 'including'), (1.0, 'implemented'), (1.0, 'eea'), (1.0, 'dynamic'), (1.0, 'designation'), (1.0, 'comprised')]","[(23.333333333333336, 'existing tax laws may impact'), (13.75, 'developed alternative payments systems'), (9.333333333333334, 'effective tax rate'), (8.75, 'commerce payments systems'), (6.083333333333334, 'tax payments'), (5.75, 'payments systems'), (4.0, 'potential changes'), (4.0, 'new entrants'), (4.0, 'mobile devices'), (4.0, 'internal controls'), (4.0, 'ctf program'), (4.0, 'comprehensive aml'), (4.0, 'compliance officer'), (4.0, 'also compete'), (1.0, 'procedures'), (1.0, 'policies'), (1.0, 'including'), (1.0, 'implemented'), (1.0, 'e'), (1.0, 'designation'), (1.0, 'comprised')]","[(9.0, 'unresolved staff comments'), (4.0, 'please submit'), (3.5, 'item 1b'), (1.5, 'item'), (1.0, 'unresolvement'), (1.0, 'resolved'), (1.0, 'issues'), (1.0, 'issues'), (1.0, 'end'), (1.0, 'editor'), (1.0, 'comment'), (1.0, 'article'), (1.0, 'applicable'), (1.0, 'applicable'), (1.0, 'applicable')]","[(13.333333333333334, 'leased 167 commercial properties'), (5.333333333333334, 'leased properties'), (4.0, 'united states'), (4.0, 'subsidiaries owned'), (4.0, 'december 31'), (4.0, 'currently conduct'), (4.0, 'also lease'), (4.0, '10 states'), (2.3333333333333335, 'properties'), (1.0, 'suitable'), (1.0, 'mastercard'), (1.0, 'located'), (1.0, 'facilities'), (1.0, 'district'), (1.0, 'countries'), (1.0, 'columbia'), (1.0, 'business'), (1.0, 'believe'), (1.0, 'adequate'), (1.0, '69')]","[(16.0, 'consolidated financial statements included'), (4.0, 'regulatory proceedings'), (4.0, 'regulatory proceedings'), (4.0, 'part ii'), (4.0, 'part ii'), (4.0, 'notes 10'), (4.0, 'item 8'), (4.0, 'item 8'), (4.0, 'item 8'), (4.0, 'item 8'), (4.0, 'item 3'), (4.0, 'accrued litigation'), (4.0, 'accrued expenses'), (1.0, 'refer'), (1.0, 'refer'), (1.0, 'legal'), (1.0, 'legal'), (1.0, '18')]","[(21.0, 'voting class b common stock'), (16.0, 'new york stock exchange'), (11.0, 'common stock trades'), (9.0, 'approximately 307 holders'), (9.0, 'account various factors'), (4.0, 'sole discretion'), (4.0, 'operating results'), (4.0, 'future dividends'), (4.0, 'financial condition'), (4.0, 'february 9'), (4.0, 'available cash'), (3.0, 'class'), (1.0, 'taking'), (1.0, 'symbol'), (1.0, 'record'), (1.0, 'payment'), (1.0, 'non'), (1.0, 'including'), (1.0, 'directors'), (1.0, 'declaration'), (1.0, 'board'), (1.0, '2018')]","[(25.0, 'adjusted operating expenses increased 16'), (9.0, 'provide pricing rebates'), (9.0, '2017 versus 2016'), (8.5, 'future cash payments'), (4.5, 'future performance'), (4.0, 'transaction volumes'), (4.0, 'standard fees'), (4.0, 'special items'), (4.0, 'financial statements'), (4.0, 'become due'), (4.0, 'assumptions discussed'), (4.0, 'amounts due'), (4.0, 'accounting estimates'), (1.0, 'table'), (1.0, 'section'), (1.0, 'included'), (1.0, 'incentives'), (1.0, 'impact'), (1.0, 'excluding'), (1.0, 'exchange'), (1.0, 'customers'), (1.0, 'critical'), (1.0, 'contingent'), (1.0, 'consider'), (1.0, 'agreements')]","[(9.0, 'european foreign operations'), (9.0, 'commercial paper program'), (9.0, 'approximates fair value'), (8.0, 'net investment hedge'), (5.0, 'net investment'), (4.0, 'term held'), (4.0, 'maturity securities'), (4.0, 'denominated debt'), (4.0, 'december 31'), (4.0, 'credit facility'), (4.0, '700 million'), (4.0, '452 million'), (1.0, 'short'), (1.0, 'respectively'), (1.0, 'portion'), (1.0, 'euro'), (1.0, 'designated'), (1.0, 'cost'), (1.0, 'borrowings'), (1.0, '2017'), (1.0, '2016')]","[(9.0, 'measuring fair value'), (9.0, 'level 3 due'), (9.0, 'gross realized gains'), (8.0, 'substance common stock'), (5.0, 'common stock'), (4.0, 'sale securities'), (4.0, 'observable inputs'), (4.0, 'equity method'), (4.0, 'company accounts'), (4.0, 'backed securities'), (1.0, 'significant'), (1.0, 'sales'), (1.0, 'losses'), (1.0, 'lack'), (1.0, 'investments'), (1.0, 'classified'), (1.0, 'available'), (1.0, 'asset'), (1.0, 'accounting'), (1.0, '2017'), (1.0, '2016'), (1.0, '2015')]","[(25.0, 'independent registered public accounting firm'), (16.0, 'consolidated financial statements included'), (15.0, 'chief financial officer reviewed'), (10.0, 'chief executive officer'), (4.0, 'pricewaterhousecoopers llp'), (4.0, 'form 10'), (4.0, 'disclosure controls'), (4.0, 'december 31'), (4.0, 'annual report'), (1.0, 'procedures'), (1.0, 'president'), (1.0, 'k'), (1.0, 'effectiveness'), (1.0, 'audited'), (1.0, '2017')]"
